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ABSTRACT
There have been many studies aimed at the determination of the 
molecular pathologies responsible for genetic disease. Many strategies 
have been used for detection of base changes in genes which lead to 
disease and in this study several mutation detection protocols were 
compared and optimised in order to determine a suitable strategy for the 
detection of molecular pathologies in large multi-exonic genes. The HGPRT 
gene was used as a model gene and a panel of 10 known mutations present 
in this gene was used to optimise and compare SSCP, heteroduplex 
detection on hydrolink gels (HDHG) and chemical cleavage of mismatches 
(CCM) as a first line screening strategy for pin-pointing the mutation 
containing exon. Any suspicious exons were then sequenced using 
automated fluorescent sequencing.
These protocols were then applied to the identification of unknown 
pathologies in the HGPRT\ DAtfDand BRCA1 genes. HDHG was the most 
successful strategy for detecting changes in larger amplification products 
where there were fewer exons, while SSCP was most effective when the 
PCR products were around 200bp in size and where there were a large 
number of samples to be analysed. Three mutations were identified in the 
HGPRT gene of index cases from Lesch-Nyhan families and the mutation 
detection strategies coupled with linkage analysis using a tetranucleotide 
repeat within the HGPRT gene, were used to pin-point carriers of the 
mutations in these families. Four different mutations were found in seven of 
the breast/ovarian cancer families, including a 2bp deletion which was 
identified in four unrelated families, indicating the presence of a common 
Scottish mutation. No mutations were identified in the DMD/BMD gene of 
the individuals who showed no large exon deletion and it may be that the 
optimum strategy for the detection of mutations in this gene has not yet been 
identified.
SUMMARY
The overall aim of this study was to optimise and compare several 
PCR based mutation detection strategies , using the multi-exonic 
Hypoxanthine guanine phosphoribosyltransferase(HGPRT),Duchenne 
muscular dystrophy (DMD ) and hereditary breast/ovarian cancer (BRCA1) 
genes as model genes. Scanning strategies were compared using a panel 
of 10 different HGPRT mutations which were present in seven different 
exons of the gene. These included a 1bp insertion, a 2 bp deletion and eight 
single nucleotide substitutions. Amplification of the individual exons of the 
HGPRT gene was problematic but after extensive modification of reaction 
components, in particular the PCR buffer and dNTP concentration and 
alteration of the annealing temperatures, all exons with the exception of 
exon 1 were successfully amplified. However the PCR was not particularly 
robust for a number of exons and the yield and success rate of the 
amplifications was improved by high level purification of the PCR primers.
Protocols for heteroduplex detection using hydrolink gels (HDHG) 
and single strand conformation polymorphism analysis (SSCP) were 
optimised and compared to determine which would be the most effective as 
a first scanning strategy to indicate the mutation-containing exon. The HDHG 
protocol had previously only been used for analysis of autosomal genes and 
primarily for length mutations. The detection efficiency of the hydrolink matrix 
had also not been evaluated to any great degree. The hydrolink protocol 
was optimised and developed in this study for an X-linked condition and with 
the optimised protocol all 10 HGPRT mutations were detected with a low 
false positive rate. In contrast, despite extensive modifications to the gel 
running conditions, SSCP yielded confusing results and clearly detected 
only 2 of the original panel of 10 mutations which were present in the 
smaller sized amplification fragments. This finding was consistent with the 
reports that SSCP detects mutations at a higher efficiency in small 
amplification fragments. Further, the HDHG protocol did not require 
radioactive labelling of the PCR products, negating the need for 
autoradiography, hence rendering the protocol faster, safer and simpler for 
analysis of this gene, with the small number of families to be analysed and 
the small number of exons in the gene.
Heteroduplex detection using hydrolink gels was then utilised as the 
first scanning stage after multiplex PCR analysis to exclude large length 
mutations in 13 families with an index case with Lesch-Nyhan syndrome 
with unknown molecular pathologies. After the mutation containing exon 
was identified, further information was obtained by an optimised chemical 
cleavage of mismatch (CCM) protocol and attempted direct sequencing of 
the amplified mutation containing fragment. Four novel pathological 
mutations were detected with sequence information being available for three 
of the mutations. The first mutation involved a base substitution of a guanine 
for an adenine at base 134 in exon 2 in the index case HGPRT GLA7292 
which resulted in an amino acid change of a lysine for an arginine at amino 
acid 45. This mutation occured in the last bases of exon 2 and is predicted 
to interfere with RNA splicing. No RNA was available however from this 
family to confirm this prediction. Another mutation resulted from a 1bp 
deletion of thymidine at nucleotide 462 in exon 6 of the index case HGPRT 
GLA7291, which resulted in premature chain termination of the protein 11 
amino-acids from the deletion site. In the pedigree HGPRT GLA7294 a 
large insertion in exon 4 was present which is expected to disrupt the 
folded conformation of the protein. This exon could not be sequenced due to 
the exon sequence and no further information could be gathered about this 
mutation. In a further pedigree HGPRT 10427, a 60 bp insertion was 
identified in the cDNA from the index case and after sequencing this was 
identified as the insertion of an ALU element between exons 6 and 7. As the 
DNA from this index case could not be PCR amplified from this region, the 
exact site of the insertion was uncertain. The mutation detection strategies 
coupled with linkage analysis using a tetranucleotide repeat located within 
the HGPRT gene, were subsequently succesfully applied to the designation 
of carrier status to female relatives of affected index cases in severalfamilies.
An identical strategy was used to screen 21 exon/promoter regions of 
the DMD gene from 14 boys who appeared to have no large gene 
alterations. The PCR had previously been optimised for some of the exons 
and was easily optimised for the amplification of the remainder. Despite 
identification of possible base changes using the screening stategies, no 
conclusive sequence information could be obtained for any of the suspected 
changes.
Due to the large size of the BRCA1 gene, the large number of 
samples to be analysed and the small size of the amplification products 
designed to amplify the individual exons, it was decided to use SSCP 
analysis to scan the gene for mutations. Any band shifts identified were 
sequenced using automated sequencing strategies, and any mutations 
found were screened for in the remaining samples by allele specific 
oligonucleotide hybridisation ( ASO). 90 family samples were analysed and 
seven different mutations were found, four of which were pathological in 
seven families. A 2bp deletion in exon 2 was found in one family(185 del 
AG>ter 39). This mutation results in a premature termination of the protein at 
codon 39. This mutation is one of the most common mutations described in 
the BRCA1 gene so far in families around the world. A a 1bp insertion in 
exon 20 (5382 ins C>ter 1892) was found in one family. This mutation 
results in the production of a truncated protein and has been described in 
several other unrelated families. A 2 bp deletion in exon 11(2800 del AA>ter 
901), was found primarily in one of the BRCA1 families. This mutation 
results in premature termination of the protein and was described previously 
in one American family. After further screening this 2bp deletion was found 
in four Scottish families who appear unrelated and could indicate the 
presence of a common Scottish mutation. The remaining fourth probable 
pathological mutation found was an A>G substitution at base 180. This 
results in an lie to Val amino acid substitution in the second amino acid of th e ^  
RING Finger motif and is suspected to have pathological significance but 
cannot be confirmed as such in the absence of functional studies on the 
protein. 50 assumed sporadic ovarian and 100 assumed sporadic breast 
tumours were also screened for the mutations found and none were 
identified. Three polymorphisms were also detected which had not 
previously been described; a G>A substitution in intron 16 which was not 
thought to interfere with splicing, axJ>C substitution at position 4427 in exon 
13 which resulted in no amino acid alteration in the protein and a C>T 
nucleotide substitution at position 2731 in exon 11 resulting in a Pro to Leu 
amino acid substitution. These changes were presumed to be 
polymorphisms as the alternate allele was present at high frequencies in 
both the affected individuals being screened for BRCA1 mutations and in 
control DNA and DNA from the DMD and Lesch-Nyhan pedigrees. There 
was no increasein the frequency of the altered allele in individu als with 
breast/ovarian cancer compared to other DNA samples indicatingthat these 
polymorphisms were probablynot significant or exclusive to the BRCA 1
pathologies.
The mutation detection strategies employed in the analysis of these 
genes, appeared to be very gene and exon dependent. Different strategies 
appeared to be better for different genes depending on the exon structure 
and size and on the number of samples to be analysed. The quality of DNA 
and hence the success of the PCR amplification in providing good quality 
amplified DNA as a starting material was also important. No universally 
appropriate strategy was found for the analysis of all three genes, but the 
automated sequencing strategy appears the best approach for obtaining 
good quality sequence.
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CHAPTER 1
INTRODUCTION
1.1 Genetic Disease.
Genetic disease has become increasingly important in recent years 
as more infections are becoming controllable . Therefore, research is 
being aimed towards the elucidation of molecular pathways and how their 
breakdown can contribute and cause disease. From the knowledge of the 
central dogma that DNA encodes for RNA which encodes for a particular 
protein it is obvious that any change to the DNA sequence will have an 
effect on the encoded protein. It is on this basis that genetic disease must be 
examined, to understand and to be able to deal with genetic disease on a 
clinical basis.
Many genetic diseases are a result of small alterations involving 
single genes or parts of genes and the effects of these changes are often 
difficult to spot and to understand. There are many human genes which 
have been mapped and their role in the biological pathways and their 
breakdown understood, however there are still many diseases thought to 
have a genetic component where no specific gene has been attributed . 
With such a wide variety and high prevalence of genetic disease, and with 
the lack of medical tools available in their treatment , it has become 
necessary to be able to assign carrier status, to prenatally diagnose affected 
pregnancies and to identify carriers of cancer predisposing genes to aid 
disease management.
Many diseases involving enzyme defects can be diagnosed 
biochemically although the enzyme levels for affected individuals, carriers 
and the normal population often overlap rendering the results difficult to 
interpret. Other traditional methods of prenatal diagnosis and carrier 
detection involve linkage analysis using polymorphic markers, but these 
methods are not always suitable or the results informative. It is partly 
because of this and because information is being sought about the exact 
molecular nature of these conditions at the protein and DNA levels that there 
is an increasing demand for information about the exact nature of the DNA 
and protein alterations in genetic diseases.
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There are many strategies for investigation of the molecular 
pathologies of genetic diseases and this study is aimed to compare several 
different mutation detection techniques in three multiexonic hereditary 
diseases, Lesch-Nyhan syndrome, Duchenne /Becker muscular dystrophy 
and inherited early onset breast / ovarian cancer.
1.2 Lesch-Nvhan Syndrome.
Lesch-Nyhan syndrome is an X-Linked recessive disease, with a birth 
incidence of 1 in 100,000 male births, (Kelley et al., 1983) which is caused 
by deficiency of an enzyme hypoxanth ine-guanine phospho- 
ribosyltransferase (HGPRT) . The genetic features of the disease make it 
highly amenable to study because of its position on the X chromosome as 
is shown in figure 1.1, rendering the mutant alleles hemizygotic in male cells 
and functionally hemizygotic in female cells as a consequence of X- 
inactivation. The hereditary pattern of the condition is therefore simpler to 
follow in pedigree analysis as one in two male progeny are affected and 
one in two female progeny are on average, carriers. The gene known to be 
defective in this condition, the HGPRT gene, is well characterised as since 
itsjnitial description in the late 1960's (Lesch and Nyhan, 1964), HGPRT 
deficiency has been the subject of intensive investigation.
1.2.1 The Clinical Features of Lesch-Nvhan Syndrome.
There are two distinct clinical syndromes associated with deficiency of 
the human HGPRT enzyme. Complete deficiency of enzyme activity is 
associated with an X-linked recessive condition , Lesch-Nyhan syndrome 
(Lesch and Nyhan, 1964), while partial deficiency of enzyme activity results 
in hyperuricemia and a form of gouty arthritis (Kelley and Wyngaarden, 
1983). However a complete spectrum of HGPRT activity levels from zero to 
30% have been reported.
Lesch-Nyhan syndrome was first described as a familial disorder of 
uric acid metabolism and central nervous system dysfunction and the 
specific enzyme defect was subsequently reported by Seegmiller in 1967. 
The symptoms include spastic paralysis, mental retardation and 
choreoathetosis which becomes increasingly marked with age (Lieber et al., 
1973) and bizarre , aggressive behaviour , particularly in the form of
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Figure 1.1. Location of the HGPRT and DMD genes on 
the X-chromosome.
biting,scratching and self-mutilation (Letts et al., 1975, Francke et al., 1976). 
In affected boys developmental delay and all the symptoms of gouty arthritis 
may develop. The symptoms generally manifest themselves in the first year 
of life and the aggressive tendencies become apparent usually in the third 
year of life with patients not usually surviving beyond five years.
1.2.2 Carrier Detection and Prenatal Diagnosis of Lesch-Nvhan Syndrome.
Initial diagnosis is made by measurement of the HGPRT levels in 
erythrocytes and co-measurement of the activity levels of other enzymes 
such as phosphoribosyl-1-pyrophosphate (PRPP) synthase which has 
raised activity in samples from Lesch-Nyhan patients, (Kelley et al., 1978). 
Treatment is limited , gouty symptoms can be treated with drugs , but there 
is little treatment for the cerebral defects as the damage is thought to have 
occured initially during prenatal development. Children are often restrained 
to prevent automutilation and many patients are institutionalised. Due to the 
lack of treatment currently available for Lesch-Nyhan syndrome there is a 
demand for carrier and prenatal detection of the mutant allele, coupled with 
genetic counselling in families where there has been a previous affected 
child.
Due to Lyonisation (Lyon, 1961), biochemical analysis of carrier 
status depends on the ability to distinguish between the two populations of 
cells from a cell culture, from a skin biopsy or by measurement of HGPRT 
activity in a single hair root ( Gartler et al., 1971 ;Halley and Heukels-Dully, 
1977; Watts et al., 1982). These methods have given some results, however 
the measurements must be interpreted on the basis of the individual families 
and often interpretation is very difficult and time consuming and direct 
detection of the responsible mutations at the DNA level would be preferable.
1.2.3 The HGPRT Gene Structure and Function.
The HGPRT gene encodes an enzyme which belongs to the family of 
phosphoribosyltransferases. These enzymes are found in all eukaryotic 
organisms. HGPRT catalyses the condensation of 5'phosphoribosyM- 
pyrophosphate (PRPP), and the purine bases hypoxanthine and guanine in 
the formation of 5‘IMP and 5'GMP respectively (Buchanan and Hartman, 
1959, Buchanan, 1960, Kelley et al., 1983 ). This pathway is shown in figure
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1.2. These vital enzymes catalyse the salvage of hypoxanthine and guanine 
which are precursors of DNA and RNA and often act as coenzymes in 
enzymatic reactions, thus providing cells with an alternative to the energy 
expensive process of de-novo synthesis of nucleotides. HGPRT plays a 
critical role in the maintenance of intracellular purine nucleotide pools in 
cells that have a decreased ability to synthesise new nucleotides 
(Fontenelle and Henderson, 1969). 90% of free purines in humans are 
recycled indicating the importance of this enzyme.
The HGPRT enzyme is found in all human tissues at low levels as a 
cytoplasmic protein that accounts for approximately 0.005-0.04% of total 
cellular protein. HGPRT activity is greatest in the basal ganglia of the brain 
and in the testes suggesting that de novo synthesis of purines in these 
areas is very low and that these regions are probably very dependent on 
the salvage pathway (Kelley et al., 1969, Howard et al., 1970, Allsop and 
Watts, 1980, ). These tissue differences suggest a different role for the 
enzyme in different tissues and the dependence of these certain tissues on 
HGPRT activity is concordant with the disease pattern and pathology.
Wilson et al., (1982 ), determined the amino acid sequence of the 
enzyme in human erythrocytes by cleaving the protein into overlapping 
peptide fragments and subjecting these to Edman degradation . The 
functional enzyme is 217 amino acids long after the post translational 
cleavage of the amino terminal methionine and has a molecular weight of 
24,470 (Wilson et al.,1982). The native HGPRT is a multimeric enzyme 
composed of identical subunits. Holden and Kelley, (1978), investigated the 
native structure of the enzyme using cross-linking agents and these studies 
coupled with isoelectric focusing (Arnold and Kelly, 1971) predicted that the 
native HGPRT enzyme may exist as a tetramer. HGPRT is one of many 
related phosphoribos^transferases which are found in many organisms and 
many are functionally and structurally similar with sequence comparisons 
between mouse, hamster and human cDNA indicating a high degree of 
sequence homology (Chinault and Caskey, 1984). On comparison of amino 
acid sequences correlation was noted in a 120 aa residue region, 
suggesting the presence of a common structural domain and secondary 
structure predictions of this region indicate the presence of a dinucleotide 
with a characteristic (3-a-P pattern (Argos et al., 1983). This type of
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structure has been identified in many different enzymes and in the HGPRT 
enzyme is thought to be the nucleotide binding domain.
The human protein is encoded by a single gene which was localised 
to the X-chromosome by pedigree analysis of families with Lesch-Nyhan 
syndrome (Seegmiller et al., 1967). Ricciuti and Ruddle (1973), 
demonstrated by use of human-mouse somatic cell hybrids, synteny 
between the HGPRT gene and two genes on the long arm of the X- 
chromosome , glucose -6-phosphate dehyckogenase and phosphoglycerate 
kinase . Subsequent mapping by Pai and Spraki, localised the human 
HGPRT gene to Xq26-27 (Pai et al., 1980) and four nonexpressed 
pseudogenes have been detected in human DNA ( Patel et al., 1984). The 
cloned DNA sequences that are complementary to HGPRT mRNA were 
isolated (Brennand et al., 1982; Jolly et al., 1982) and the nucleotide 
sequence of a full length 1.6kb cDNA of human HG PRT  mRNA was 
determined by Jolly et al., (1983) and recently the sequence of the entire 
human HGPRT gene locus was elucidated (Edwards et al., 1990).
The isolation of cDNA recombinants facilitated the characterisation of 
the human HGPRT gene which is comprised of nine exons dispersed over 
approximately 44 kb of DNA (Melton et al., 1984; Patel et al., 1984,1986 ). 
Figure 1.3 shows the layout of the HGPRT  gene where the intron/exon 
boundaries for the human and mouse genes are identical. The eight 
intronic sequences are removed during the processing of the primary 
transcript to yield an open reading frame of 218 amino acids , which 
correspond to the protein coding region of the HGPRT gene .
Interestingly, the mouse and human HGPRT genes lack conventional 
promoter elements in particular the “CAAT” and “TATAA” sequences in the 
5' flanking sequences (Melton et al., 1984; Patel et al., 1986) . Both human 
and mouse 5’ non-coding regions are particularly GC rich and 
approximately 80% of the 250 base pair sequence 5-prime to the initiation 
codon are G or C bases. The control mechanisms are thought to involve the 
binding of promoter specific transcription factors which bind to copies of a 
hexanucleotide CCGCCC sequence which is present and methylation of 
cytosine residues is also thought to be involved in gene expression through 
its role in X- inactivation (Wolf et al., 1984). Deletion analysis suggests that 
additional factors in the promoter may play a role in transcriptional control.
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The molecular basis of the tissue variability in expression of the HGPRT  
gene has been addressed but the exact signals responsible for the elevated 
levels in the brain have not been identified. Studies using transgenic mice 
that express the human HGPRT minigene suggested that it is sequences 
within the human HGPRT transcript (cDNA) which influences its expression, 
probably via increased mRNA synthesis or stability (Stout et al., 1985).
1.2.4 Mutations in the HGPRT Gene.
Mutations in the HGPRT gene were initially described on the basis of 
altered protein or enzymatic parameters and thus were limited to mutations 
which resulted in residual HGPRT activity and excluded most patients with 
Lesch-Nyhan syndrome. Once the amino acid sequence was elucidated 
mutations could be found in terms of altered amino acids in patients with 
residual protein and one of the first mutations described, HGPRT Toronto, 
was isolated from a patient with gout and resulted from a glycine for arginine 
substitution at amino acid 50 (Wilson et al., 1983).
The analysis of Lesch-Nyhan patients with no residual enzyme, was 
first carried out by directly looking at the DNA sequence using restriction 
enzyme digestion and Southern Blotting using a full length HGPRT probe 
(Yang et al., 1984) and looking for altered restriction patterns. Many HGPRT 
mutations were identified by this approach (Yang et al., 1984; Wilson et al., 
1986). Genetic heterogeneity among Lesch-Nyhan patients was apparent 
and studies using Southern, Northern, kinetic and immunoquantitative data 
showed that most patients with the condition had unique genetic features 
with many of the phenotypes being the result of small genetic changes 
(Wilson et al., 1986). Methods were then developed and used to attempt to 
identify the exact nature of these alterations. One of the first methods used in 
the search for molecular pathologies in Lesch-Nyhan syndrome was an 
RNase cleavage method which resulted in identification of five sequence 
changes including two deletions and three small point or deletion mutations 
(Gibbs and Caskey, 1987). This technique was presumed only to detect 50% 
of possible mutations and further techniques have since been used based 
on PCR based methods to detect many further HGPRT mutations (Davidson 
et al., 1988,1989, 1991; Edwards et al., 1989; Gibbs et al., 1989; Gibbs et 
al., 1990; Marcus et al., 1992; Yamada et al., 1992; Steingrimsdottir et al., 
1992; Sege-Peterson et al., 1992; Tarle et al., 1992).
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1.3.1Duchenne/Becker Muscular Dystrophy.
The muscular dystophies represent some of the most serious human 
genetic diseases . X-linked muscular dystrophies are of the severe or mild 
types known as Duchenne and Becker muscular dystrophy (DMD and BMD) 
respectively. Duchenne muscular dystrophy (DMD), was first studied by 
Duchenne in 1868 (Duchenne, 1868) and the clinical features were later 
described by Gowers in 1879. DMD is an X-linked recessive trait with a birth 
incidence of one in 3000-3500 males (Emery, 1988).
The clinical features of DMD and their relative importance is 
largely age-related. In over half the affected boys, walking and general 
development of motor functions is delayed and in some boys there is a more 
general delay in development. An abnormal gait and general muscle 
weakness can be noted and calf and other muscle enlargement occurs due 
to an excess of adipose and connective tissue. Later, other clinical signs 
become prevalent including slight facial weakness and the intercostal 
muscles become affected. These symptoms lead to very apparent physical 
features, but In almost all DMD patients it is cardiorespiratory problems 
related to diminished respiratory capacity which are the principal causes of 
death. The milder Becker muscular dystrophy (BMD), has a later onset and 
a milder course and was first recognised by Becker in 1955. Age at death is 
also delayed in BMD and the other clinical symptoms described occur less 
frequently.
1.3.2 Diagnosis of DMD/BMD.
Diagnosis of DMD can usually be made by assessment of the clinical 
features and is aided when a family history of the disease exists. Diagnosis 
can be supported by examining the serum levels of the muscle enzyme 
serum creatine kinase (SCK) and by muscle biopsy. Ebashi et al., (1959) 
and Dreyfus et al., (1960), first noted that the activity of this enzyme is 
elevated in DMD patients. The enzyme escapes from the damaged muscle 
into the serum and this accounts for the increased levels.
Significant changes in muscle pathology are present from birth in an 
affected individual with DMD before the occurrence of obvious clinical 
symptoms (Cullen and Mastaglia, 1980). The appearance of muscle
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degeneration in BMD is very similar and these changes can be identified 
and used as suitable diagnostic indicators in both conditions.
As with other X-linked disorders, female carriers of the abnormal gene 
are generally healthy and the occurrence of DMD/BMD in a female is very 
rare. In approximately 2.5% of carriers a small degree of muscle weakness 
is apparent due to a variation in X chromosome inactivation. The severity of 
the disease in these females varies and these manifesting carriers usually 
have onset later in adult life with asymmetric wasting and weakness, an 
elevated SCK and muscle biopsy suggestive of DMD. Progression of the 
disease is generally slower than in males.
1.3.3 Genetics of DMD/BMD.
DMD shows a X-linked recessive pattern of inheritance w ith 
hemizygous males showing full penetrance. Most studies give an incidence 
of 1:3000-3500 male births . The actual new mutation rate for DMD is 
estimated to be 10~4 mutations per gene per generation and 1/3 of all 
patients should result from a new mutation, if the male and female mutation 
rates for recessive X-linked lethal disorders is equal and the reproductive 
viability of the patient is zero (Haldane, 1935). This high new mutation rate is 
also thought to reflect the large size of the DMD gene.
1.3.4 The DMD/BMD Gene and Gene Product.
Mapping and molecular genetic studies indicated that DMD/BMD is a 
result of mutations in a huge gene that encodes the protein dystrophin 
(Hoffman et al., 1987). The gene was mapped to the Xp21 region of the X- 
chromosome (figure 1.1), by a combination of techniques. (Boyd et al., 1986; 
Davies et al., 81, 83; Kingston et al., 1983, 1984; Wilcox et al., 1985; Francke 
et al., 1985). These studies coupled with the detailed positional cloning and 
molecular analysis (Kunkel et al., 1985; Ray et al., 1985) localised the DMD 
gene to the short arm of the X chromosome and the chromosomal region 
involved many kilobases of DNA. The cDNA for the DMD gene was isolated 
by Koenig et al. (1987) by looking at cross species conservation and was 
shown to represent 14kb of DNA containing more than 65 exons with the 
most recent data suggesting more than 78 exons. The gene encoded a 
protein product named dystrophin.
Q
Dystrophin (Hoffman et al., 1987), is a 3685 amino acid hydrophilic 
protein with a predicted molecular weight of 427kd. It has four distinct 
domains which share many features with the proteins spectrin anda-actinin 
(Hammonds et al., 1987). The function of the dystophin protein was 
originally speculated to be due to its linkage to an integral membrane 
glycoprotein in the sarcolema which acts as a dystrophin receptor (Campbell 
and Kahl, 1989). Dystrophin is now thought to be associated with many 
glycoproteins in the membrane and appears to serve as a specialised link 
between the actin cytoskeleton and components external to the sarcolemal 
membrane (Ervasti and Campbell, 1991).
Dystrophin transcription is apparent at different levels in many 
different tissues, being most prevalent in skeletal muscle and lower in 
smooth muscle and in many other tissues including the brain. (Chelly et al., 
1988). Expression of the large dystrophin gene is under elaborate 
transcriptional and splicing control. At least 5 independent promoters 
specify the transcription of their respective alternative first exons in a cell 
specific and developmentally controlled manner and alternative transcripts 
have been identified in many different tissues. There appear to be many 
dystrophins and it is likely that dystrophin may have many different functions 
in different tissues.
1.3.5 Detection of the Mutant Gene.
As with other X-linked disorders, detection of the mutant gene is 
problematic due to the absence of symptoms in most carriers. When a 
pedigree is informative,when a woman has two affected sons or one affected 
son and an affected close male relative, she can be designated an obligate 
carrier, otherwise the risk can be clarified by estimating the levels of SCK 
which are known to be elevated in some mothers of boys affected with DMD, 
(Emery, 1965). However, other factors can alter SCK values in females 
including exercise (Hudgson et al., 1967), age (Lane and Roses, 1981) and 
pregnancy, making carrier detection based on SCK values alone 
unreliable. The best method for carrier assignment is to assessthe 
probability carrier status using Bayesian statistics where a combination of 
pedigree data, SCK data and DNA analysis would be considered.
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In the past the only method of ensuring that no male children with 
DMD/BMD were born to females at risk was to carry out selective termination 
of all male fetuses after fetal sexing. Now fetal DNA can be analysed by 
linkage analysis using closely linked markers or gene specific probes. 
However the large size of the gene makes recombination events between 
the gene and the markers possible so it is more effective to use a number of 
markers and to use intragenic markers. Linkage analysis has further 
problems in that it is necessary to have DNA from key family members who 
may not always be available , that non-paternity may exist in one or more 
family members and that in approximately 1/3 of all cases of DMD are 
estimated to be due to a new mutation (Davie and Emery, 1978). Further 
complications arise due the similar clinical patterns of other conditions like 
DMD which have different patterns of inheritance.
It is therefore obvious that detection of the molecular pathologies 
responsible for the disease in individual families, would be the best method 
for definitive prenatal diagnosis and assignment of carrier status. Sporadic 
cases could then be identified and mothers and sisters can be excluded as 
carriers. The advent of PCR technology also negates the need for large 
quantities of good quality DNA to be available and where the index cases 
are dead small quantities of DNA from sources such as paraffin embedded 
muscle samples may be used.
1.3.6 The Molecular Pathologies Involved in DMD/BMD.
The very large size and complexity of the dystrophin gene makes the 
detection of molecular pathologies in the gene a difficult and time 
consuming task. The entire coding region spans 2.4 million bases which 
includes many large introns. Deletions and duplications account for 
approximately 70% of mutations found (Koenig et al., 1987; Hodgson et al., 
1989; Hu et al., 1989) and smaller mutations such as point mutations 
account for the remaining 30% of cases and appear to cause alteration of 
consensus splice site sequences and in premature translational termination 
or mutations in promoter elements and hence absence of a functional 
protein. BMD which is less severe is usually due to rearrangements where 
the translational reading frame is maintained (Monaco et al., 1988; Koenig at 
al., 1989).
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The region of the protein affected determines the clinical severity of 
the disease (Koenig et al., 1989). A deletion of a large part of the amino- 
terminus may lead only to the BMD phenotype while deletions in the 
carboxy-terminal domain tend to lead to DMD (Bulman et al., 1991). The 
proximal rod region appears to be relatively dispensable as deletions here 
leads to milder phenotypes and typical BMD (Ahn and Kunkel, 1993). Large 
deletions and insertions can be picked up using cDNA probes by Southern 
blotting (Gilgenkrantz et al., 1989), but these probes do not detect all of the 
deletions. In 1988, Chamberlain et al., developed a good detection system 
based on PCR where sequences flanking the exons were utilised to screen 
for the presence or absence of the exon (Chamberlain et al., 1988).
The search for smaller pathologies has proved to be more difficult. 
Several attempts to look for these in the 30% of cases with no apparent 
large alterations have been made. These have involved the utilisation of 
several techniques including looking at shifts in the electrophoretic mobility 
of exons in acrylamide gels, by CCM analysis of individual exons, direct 
sequencing and by looking for the formation of heteroduplexes in 
heterozygous individuals ( Bulman et al., 1991; Clemens et al., 1992; 
Kilimann et al.,1992; Roberts et al., 1992; Saad et al., 1992). More recently a 
protocol involving the in vitro transcription and translation of portions of the 
DNA, amplified by PCR using a primer with T7 polymerase initiation sights, 
has been used to look for premature stops in the gene, induced by frameshift 
mutations(Roberts et al., 1991;Roest et al., 1993; Van Der Luijy et al., 1994)).
1.4.1 Inherited Breast and Ovarian cancer.
Many cancers can be caused by mutations in cancer predisposing 
genes. Breast cancer is a common malignancy, affecting approximately one 
in 8-12 women during their lifetime. Many factors have been identified 
which increase a womans' lifetime risk of developing the disease and in 
particular a positive family history has been identified as a major risk factor 
in early onset breast/ovarian cancer. Segregation analysis of families with 
multiple affected individuals and linkage analysis confirmed that one or 
more autosomal dominant genes appeared to account for 5-10% of all 
breast cancers (Newman et al., 1988, Clause et al., 1991). One of the genes 
responsible(fiflC/4 7) was mapped to chromosome 17q21 in 1990 (Hall et 
al., 1990), and numerous other groups confirmed this linkage in families with
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breast cancer and in particular with early onset breast and ovarian cancers. 
However, the great majority of breast and ovarian cancers occuring in the 
population are due to acquired mutations , but despite the small percentage 
of affected patients being due to inherited mutations of the BRCA1 gene, it is 
a common genetic disease that allows the possibility for genetic counselling 
and pre-disease diagnosis.
1.4.2 The BRCA1 Gene.
The gene responsible for approximately 45% of inherited breast 
cancer and 80% of inherited breast and ovarian cancer, the BRCA1 gene, 
was identified in 1994 by Easton et al,. (Easton et al ., 1994). Risks of 
developing breast and or ovarian cancer after inheriting an aberrant 
BRCA1 gene, are extremely high, exceeding 50% before age 50 years and 
reaching 80% by age 65 years(Easton et al., 1993) . More recently a second 
succeptability gene, BRCA2 was localised to chromosome 13q12-13 
(Wooster et al., 1994). Alterations in other genes have also been shown to 
be responsible for inherited breast cancer, including many of the common 
oncogenes such as ras, the p53 gene (Malkin et al., 1990), and the 
androgen receptor gene ( Wooster et al., 1992), mutations in which can lead 
to breast cancer in males.
The BRCA1 gene encompassed 24 exons, 22 of which are thought to 
be coding, which results in a cDNA encoding a 1863 amino-acid protein . 
The function of this protein is not yet understood as much of the gene shows 
no homology to any other known protein. The exception to this is a 126 
nucleotide sequence at the amino terminus, which encodes a RING finger 
motif (Lovering et al., 1993), a motif found in other proteins that interact with 
nucleic acid and/or form protein complexes. This may suggest a role for the 
BRCA1 protein in DNA transcription although no studies to date have yet 
confirmed or disproved this theory.
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1.4.3 Mutations in the BRCA 1 Gene.
The frequency of BRCA1 germline mutations in the population has 
not yet been determined but the initial screen for germ-line mutations has 
revealed a mixture of frameshift, nonsense and regulatory mutations 
resulting from small and large deletions, insertions and substitutions (Miki et 
al 1994., Futreal et al., 1994,. Friedman et al., 1994 ; Castilla et al 1994, 
Shattuck-Eidens et al.,1995; Hogervorst et al.,1995). The initial statistics 
suggest a population carrier frequency of 1/2000 to 1/5000 but these reports 
are probably an over-estimate. These mutations are thought to produce 
both truncated and abnormal proteins as well as producing alterations in the 
regulatory mechanisms leading to abnormal and absent transcripts from the 
mutant allele. The mutations appear along the length of the gene in contrast 
to other cancer predisposing genes such as p53 and hence no apparent 
clustering of mutations has been reported. However a good proportion of 
the pathologies appear in exon 11 which encodes for the majority of the 
protein and to date three mutations appear to be relatively common in 
unrelated families, a 1bp C insertion in exon 20, a 2bp AG deletion in exon 
two and a splice mutation in intron 6. Different populations appear to show 
other more common mutations and an AA deletion in exon 11 highlighted in 
this study which appears to be relatively common in the Scottish population. 
Before the cloning of the BRCA1 gene, there was an expectation that 
somatic mutations in the gene would be found to contribute to 
tumourgenesis in the far more common sporadic forms of the disease. This 
was predicted due to the observation that loss of heterozygosity (LOH), the 
molecular genetic hallmark of tumour suppressor gene inactivation, was 
apparent in sporadic breast and ovarian cancers in the region of the BRCA 1 
gene. A large percentage of sporadic tumours contain allelic deletions at 
the 17q locus and hence it was a surprise when groups such as Futreal et al 
(1994), could find no mutations in these sporadic tumours in the BRCA1 
gene. This would not be surprising in the context of other genes such as the 
WT1 tumour suppressor gene where the gene is mutated in most familial 
cancers but rarely in sporadic disease. Further, additional mapping studies 
indicated the possible existence of other tumour suppressor genes in the 
BRCA1 region (Jacobs et al., 1993, Saito et al., 1993). However two groups 
have reported the presence of mutations in the BRCA 1 gene in at least 5 
sporadic ovarian tumours (Merajver et al., 1995, Hosking et al., 1995) and 
further reports are being made of mutations found by other groups in
14
sporadic ovarian tumours. Again there appears to be no clustering of these 
mutations as they appear along the length of the gene. There has been no 
reports however of mutations being identified in the BRCA1 gene of sporadic 
breast cancers which may indicate that this gene plays no role in the 
sporadic form of this disease.
1.5 Mutation Detection Methods.
The ability to detect changes in human DNA is fundamentally 
important in the examination and understanding of the m olecu lar 
pathologies which underly genetic disease. This can be carried out by the 
use of indirect methods for following the segregation of linked markers with 
the disease loci or by directly looking for base changes in protein coding 
genes.
1.5.1 Indirect Mutation Detection.
The detection of base changes was first done by use of restriction 
endonucleases coupled with the Southern blotting technique to detect the 
loss or gain of restriction enzyme recognition sites (Southern, 1975). This 
approach has several limitations, primarily that not all single or multiple 
base mutations altered a restriction enzyme recognition site and many 
enzymes were not commercially available or would have produced 
unacceptably small or large fragments . The resolution of this technique is 
also not suitable to pinpoint small differences in fragment length, but despite 
these problems many genetic diseases can be diagnosed by this method 
by virtue of their linkage to known restriction site polymorphisms. These 
polymorphic sites are inherited in a codominant fashion and are either 
intragenic or extragenic and co-segregate with the gene loci. By following 
the inheritance pattern of the fragments generated by restriction enzyme 
digestion of the DNA from a family, these differences in DNA sequence can 
be used as markers. In many cases however, the segregation of the linked 
marker in certain families is uninformative because DNA from key relatives 
is unavailable or because of marker homozygosity. Misdiagnosis can also 
occur because of recombination between the marker and the mutation. 
Other problems arise from non-determination of phase and from non­
paternity. Thus many factors determine the success or failure of this 
technique including how many family members are available, the quantity
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and quality of DNA available and on how close the marker is to the gene of 
interest.
Base changes which do not alter a restriction enzyme site can be 
used as markers by detection with differential hybridisation of specifically 
designed synthetic oligonucleotide probes, which can be made to have a 
sequence corresponding to a known polymorphic allele sequences. 
Stringent hybridisation is carried out on family members to screen for the 
presence of the different alleles. However this method depends on having 
available the exact sequence of the region and could be expensive if a large 
number of alleles exist and a large number of marker sites are being 
examined.
As well as using conventional RFLP’S for linkage analysis, tandemly 
repeated DNA sequences within the human genome can be used. The 
human genome contains several classes of tandemly repeated DNA which 
are frequently polymorphic (Savatier et al., 1985). One particular class of 
these are the short tandem repeats (STR) polymorphisms with mono-, di, tri, 
and tetranucleotide repeat motifs. (Litt and Luty, 1989; Weber and May, 
1989; Boylan et al., 1990; Econamou et al. , 1990; Zulani and Hobbs, 1990; 
Edwards et al., 1991). These STR’s exhibit Mendelian codominant 
inheritance and are highly polymorphic due to extensive variation in the 
number of repeat units, and many of these STR’s have heterozygosity 
values of up to 90%.
The STR’s can be easily amplified with PCR and allele lengths can 
be precisely resolved to single bases by analysis of 100-500bp amplified 
fragments on polyacrylamide sequencing gels. The frequency of particular 
STR’s is sufficiently high that it should be possible to identify a STR locus in 
most genomic segments (Edwards et al., 1991). The estimated frequency of 
the 44 possible unique trimeric and tetrameric STR’s in the genome is 
estimated to be 1 STR /10kb. Edwards et al., (1991), describe a method by 
which DNA segments flanked by an STR locus may be amplified and 
sequenced directly thus allowing oligonucleotide primers to be designed for 
their amplification.
The longer and more complex trimeric and tetrameric STR motifs 
seem to provide a greater amplification fidelity than for the smaller (AC)
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repeats. STR loci found in the primate sequences of GeneBank indicate that 
trimeric and tetrameric STR’s are found within coding, genic (introns and 
flanking sequences) and extragenic regions of the genome. Only trimeric 
STR’s were found within coding sequences.
These STR repeats have several advantages over traditional RFLP 
linkage analysis utilising blotting techniques. Of particular use in carrier 
detection in the HGPRT gene is a polymorphic (AGAT) repeat with 9-16 
copies, located within the human HGPRT gene (Edwards et al., 1991). This 
repeat would be a potentially ideal intragenic, polymorphic, reliable marker 
with which to quickly and easily trace the path of an affected X chromosome 
in a family with Lesch-Nyhan syndrome. Further, this linkage is not likely to 
be hindered by recombination between the marker and the gene due to its 
position within the HGPRT gene and only a small quantity of DNA is needed 
for analysis by PCR amplification . This has the potential to be used in 
families to quickly exclude females as carriers and will be of particular value 
where no molecular pathology has been detected.
Cases of non-paternity may interfere with this analysis and it will not 
identify new mutations in index cases allowing a number of false positive 
carrier risks to be assigned. Therefore although this protocol may have its 
advantages in this study, ideally direct mutation detection strategies would 
pinpoint the exact presence or absence of molecular pathologies.
1.5.2 Direct Mutation Detection.
There are many methods available for the direct detection of 
mutations in human genes. Some rely on the differential electrophoretic 
mobility of DNA sequences differing by as little as a single base pair or in the 
differential melting temperatures of DNA heteroduplexes and 
homoduplexes. Further methods rely on the reaction of non-paired 
nucleotides in heteroduplexes between affected and non-affected patients 
DNA or RNA with certain enzymes or chemicals, or on direct comparison of 
length ,sequence conformation of DNA or in differential hybridisation of 
oligonucleotides to normal and mutant sequences. Some of the most useful 
of these methods which will be used in this study and will now be examined.
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1.5.3 The Polymerase Chain Reaction.
in vitro DNA amplification using the polymerase chain reaction (PCR) 
(Saiki et al., 1985,88) has revolutionised molecular genetics. The procedure 
was first documented by Saiki et al., in 1985 and proposed a method which 
would circumvent the need for time consuming cloning strategies. Since 
then a wide variety of different methods which can have far reaching 
applications in DNA research have been reported. PCR allows the specific 
in vitro production of multiple copies of defined fragments of DNA. The 
reaction is highly specific and sensitive and only one copy of a sequence in 
a single cell is theoretically required for amplification to occur. The original 
theory behind the procedure was described by Kleppe et al., (1971).
Amplification involves a primer mediated enzymatic amplification of 
target sequences in genomic DNA by repeated cycles of (1) heat 
denaturation of the double stranded template, (2) primer annealing and (3) 
extension of the annealed primer with DNA polymerase. In each cycle the 
number of copies of the target sequence is exponentially doubled, resulting 
in exponential amplification.
The specificity of the amplification is determined by the sequence of 
the short oligonucleotides which hybridise to different strands of a DNA 
template in a relative orientation. The template can be a small amount of 
sequence such as a discrete molecule or a small sequence embedded in a 
vast sequence such as the human genome, a single-stranded DNA 
molecule or an RNA molecule. The product of the reaction is a discrete 
double-stranded molecule with termini corresponding to the 5' end of the 
primers used. The technique became more widely used after the 
introduction of thermostable Taq DNA polymerase, which relieved the 
necessity of adding new enzyme after each denaturation step so allowing 
automation of the procedure.
There have been many protocols suggested for the improvement of 
the PCR protocol such as the use of cosolvents to enhance the amplification 
process, UV irradiation of the reaction mix to avoid contamination of other 
DNAs, preamplification heating of the reaction mix during assembly of the 
components to improve product yield and specificity (D.aquila et al., 1991) 
and variations in the cycling times and temperatures of denaturation
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including touchdown PCR where the annealing temperature is initially 
higher than desired and is gradually brought down to the desired 
temperature.
The basic PCR protocol can be manipulated in many ways to widen 
the variety of applications it can have. For example for site-directed 
mutagenesis or for introducing novel sequences onto a DNA sequence. 
PCR is also a quick and effective way of generating probes for other DNA 
manipulations. Radioactive or biotin labelling can be achieved by 
manufacturing primers which contain a label at the end. Radioactive probes 
can be made by either 5’ end-labelling of the PCR primer prior to 
amplification, or by incorporating 32Pa-dCTP into the amplified sequence by 
including free dCTP in the amplification reaction. In general PCR plays a 
major role in direct and indirect mutation detection strategies negating the 
need for complex and time consuming cloning strategies. Several such 
strategies such as heteroduplex formation in heterozygotes, SSCP analysis 
which relies on the simultaneous labelling and amplification of gene 
regions, and direct sequencing which relies on a single-stranded product 
being produced by PCR, all rely on the amplification of specific regions and 
will be described in more depth. Other methods simply rely on PCR as a 
quick and efficient method of cloning a defined region of test DNA for further 
manipulation or for the generation of probes.
Several other techniques based on PCR have been developed for 
the analysis of mutations and particularly for mutation detection. Some of 
the most widely used are those strategies which rely on specific alleles 
being present for PCR to occur, either for correct primer annealing or for 
other aspects of the PCR to occur. Two such strategies, allele specific 
oligonulcleotide hybridisation (Saiki et al., 1986, Studencki et al., 1985) and 
oligo-ligation assay (Landegrin et al., 1988) are simple to perform, rapid and 
can be used for rapid diagnosis, but for each of these an oligonucleotide has 
to be synthesised which is complementary to each mutant sequence, so for 
conditions with heterogeneous pathologies this can be impractical and 
costly. For the analysis of the population frequency of common mutations 
however, ASO hybridisation can be a quick and effective method for quickly 
screening large numbers of samples.
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There are disadvantages to using the PCR reaction. Primarily, 
accurate sequence information is a prerequisite to enable the designing of 
complementary oligonucleotide primers. However, methodology has been 
described where unknown sequences adjacent to regions of known 
sequence can be amplified, for example with primers directed to repetitive 
sequences which can pair with a primer specific to the region of interest , or 
inverse PCR where the target DNA is circularised before amplification . 
However these methods are technically difficult and have many limitations. 
Secondly, stringent methods are required to ensure that only the desired 
template is amplified and no other DNA templates are present in the reaction 
causing contamination during the PCR. Thirdly each primer pair has specific 
requirements to produce optimum results and time is often required to 
optimise each PCR reaction.
1.5.4 Chemical Cleavage of Mismatches (CCM)
In 1988, Cotton et al., described a method they claimed would detect 
all point mutations, based on the chemical reactivity of mismatched bases in 
DNA-DNA heteroduplexes. They described the use of reagents first used in 
the study of the secondary structure of tRNA and then in DNA sequencing 
(Maxam and Gilbert, 1980), that led to the subsequent cleavage of the DNA 
chain on reaction with piperidine. The chemicals shown to be most effective 
were osmium tetroxide and hydroxylamine which reacted with mismatched 
thymidines and cytidines respectively. These chemicals react specifically 
with pyrimidine bases in DNA. Hydroxylamine at pH 6 modifies the C5=C6 
double bond in cytosine which then labilises the ring to internal 
rearrangement and cleavage (Rubin and Schmidd, 1980). Osmium 
tetroxide modification is a thymidine specific reaction in which the C5=C6 
double bond is oxidised (Burtan and Riley, 1966; Friedmann and Brown, 
1978, ). Double-stranded DNA is attacked very slowly while single stranded 
regions such as at the site of mismatches are readily modified. These 
modifications are recognised and cleaved by piperidine.
The protocol used for COM is outlined in figure 1.4. Reference DNA 
probe is mixed with excess test DNA or RNA and heteroduplexes are 
encouraged to form by melting the DNA and cooling at op tim um  
temperatures. During melting and reannealing several species of duplexes 
are present, and these are then treated as shown in figure 1.4. After the
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Figure 1.4. Strategy for COM analysis. A n  asterisk denotes the position of 
the 32P at termini of end-label led probe strands. WT= wild-type, MUT= mutant. 
•  = modified DNA.
modification and cleavage occurs, the fragments obtained can be visualised 
and sized against a labelled 1 kb ladder on a polyacrylamide sequencing 
gel. All classes of C and T mismatches (C=C, C=T, C=A, T=T, T=G, and T= 
C) are cleaved and complete screening of a double stranded target for point 
mutations can be achieved by using probes for both senses. In the case of 
point mutations , mismatched G and A bases will not be directly detected but 
they are transposed to mismatched C and T bases respectively by use of 
probes of the opposite sense. Also bases close or adjacent to mismatched 
bases become reactive themselves (Cotton et al., 1988, Cotton and 
Campbell, 1989), and can indicate the presence of mutations several bases 
away allowing detection of all species of mutations including unmatched 
bases such as is the case with deletions and insertions. In single stranded 
targets such as mRNA increased reactivity of matched C and T base near 
the mismatched or unmatched base allows detection, but to be sure of 
detection all classes of mutations, cDNA needs to be made for heteroduplex 
formation with probes of both senses.
This technique can be used with different types of probes which can 
be uniformly labelled by incorporation of a labelled nucleotide during PCR 
or end-labelled at one or both ends. If only one primer is labelled, one 
cleavage fragment will be seen and the size of this fragment gives an 
indication of the number of bases the cleavage has occured from the end of 
the probe. The uniformly labelled probe will give two cleavage products and 
will indicate the presence of a mismatch but little sense on the position of the 
mutation will be obtained. Other groups have also used 35S to label the 
probe rather than 32P and suggest that this provides a clearer 
autoradiograph picture with more discrete bands (Saleeba and Cotton, 
1991), and further methods which would avoid the use of hazardous 32P 
including silver staining of the gel have been suggested . Further, CCM can 
be carries out using probes from the patients themselves and forming 
duplexes with the patients own DNA (Dianzani et al., 1991).
CCM has been successfully utilised in the study of many genetic 
diseases to date including haemophilia B (Montadon et al., 1989,), ornithine 
transcarbamylase deficiency (Grompe et al., 1989,1991), dihydropteindine 
reductase gene (Howells et al., 1990) and Tay-Sachs disease (Akli et al., 
1991). It has been shown to detect the majority of mutations but does have 
the disadvantages of involving the use of highly toxic chemicals and in being
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a relatively time-consuming procedure involving many stages. It would 
therefore not be a suitable method for quickly screening large numbers of 
samples.
Another method which relies on the cleavage of mismatches in 
duplexes is the RNase cleavage method. This involves enzymatic cleavage 
of RNA at single base mismatches in a RNA:DNA hybrid. It utilises RNA 
probes and depends on the property of many ribonucleases that they are 
specific for single-stranded RNA under appropriate conditions . This has 
been used previously for the detection of mutations in Lesch-Nyhan 
syndrome (Gibbs et al., 1987) but it has been reported that it is mismatch 
type dependent and may only detect 50% of mutations opposed to the 
proposed 100% detected by CCM . A similar method was proposed for 
cleavage of DNA:DNA duplexes using the single strand specific S1 
nuclease. This, however, resulted in only a low efficiency of mismatch 
cleavage. More recently, several enzymes have been described which are 
claimed to cleave DNA at the site of mismatches. These enzymes are 
claimed to cleave the majority of mismatches without the time consuming 
use of hazardous chemicals, but to date the enzymes are not easily 
commercially available and definitive information is not available as to their 
efficiency.
1.5.5 Single-Strand Conformational Polymorphism Analysis (SSCP)
This technique , known as single strand conformation polymorphism 
(SSCP) analysis (Orita et al., 1989,90), was originally carried out by 
digestion of genomic DNA with restriction enzymes before denaturation of 
the DNA and electrophoresis on a neutral polyacrylamide gel. 
Polymorphisms in the fragments caused band shifts that were thought to be 
due to base changes which resulted in conformational changes in the 
single-stranded DNA. Under non-denaturing conditions, single-stranded 
DNA has a folded conformation that is stabilised by interstrand interactions. 
Consequently, the conformation and hence the mobility is dependant on the 
sequence. Subsequent publications utilised the polymerase chain reaction 
to radioactively label and amplify regions of the genome before SSCP 
analysis (Orita et al., 1989). More recently a non-isotopic method was 
suggested and applied to the analysis of molecular pathologies in Tay- 
Sachs disease (Ainsworth et al. ,1990).
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The original SSCP conditions suggested the optimisation of two 
parameters to obtain maximum separation of the single strands.the 
presence and concentration of glycerol in the polyacrylamide gel and the 
running temperature of the gel which is usually approximately 4 °C . 
Although the exact role of glycerol is unknown, it has been hypothesised that 
its weak denaturing action on nucleic acids partially opens up the folded 
structure of single-stranded DNA so that more surface area of the molecule 
is exposed so there is more chance for the acrylamide matrix to distinguish 
the structural changes caused by the mutation . The percentage of 
acrylamide is also important as it is known that complementary single 
strands are better separated in gels with low cross linking . A gel with a 
lower percentage of crosslinking is more soft and has a larger pore size and 
seems to be more sensitive to conformation . As these conditions sometimes 
lead to incomplete separation of the strands or failure of mutations to be 
recognised, Spinardi et al., (1991) suggested alterations in the standard 
parameters by reducing the glycerol concentration and the ionic strength of 
the running buffer and alterations in the running conditions a n d  
temperatures. Ravnik-Glavac et al., (1994), suggested further alterations in 
gel matrix make up and running conditions which they suggest, further 
improve the detection rates, by looking for the formation of heteroduplexes 
as well as gel shifts on SSCP gels. These results suggested that the 
mobility of single stranded molecules can be affected by variations in the 
electrophoresis conditions and that it is possible to take advantage of these 
variations to optimise the protocol for different DNA segments to detect 
different point mutations.
Variations on the basic SSCP methodology have recently been 
suggested including the suggestion of two dimensional SSCP analysis 
(Kovar et al., 1991), to identify point mutations, deletions and insertions in 
long DNA fragments. Non-isotopic methods employing silver staining 
(Ainsworth et al. 1990), and ethidium bromide staining (Yap and McGee, 
1991 ) have also been used. RNA-SSCP analysis has also been carried out 
and has ben suggested to yield better results than standard DNA-SSCP. 
Further, Sarkar et al., (1992), suggested a method for detection of single 
base changes which combines dideoxy sequencing and conventional 
SSCP analysis. Primarily a sequencing protocol is carried out using one of 
the four standard dideoxy sequencing reactions which is then run on a non­
denaturing polyacrylamide gel. Depending on the nature of the sequence
change the conformation of the bands running on the gel will be altered 
relative to the normal sequence and a mutation can be identified. It was 
claimed that this protocol would detect 100% of mutations but relies on the 
ability to obtain good sequence data.
The standard SSCP technique although unable to give exact 
information as to the exact position and nature of the nucleotide change, can 
when optimised, indicate in which segment of the DNA or gene it is located. 
It is also a quick and simple and relatively inexpensive protocol which 
requires no specialist equipment. The effect of sequence change on 
electrophoretic mobility is however unpredictable and a percentage of 
sequence changes may not appreciably change the mobility leading to non­
detection of the mutations.
All the available information would suggest that smaller sized 
amplified fragments are the most suitable for SSCP analysis. Orita et al. 
(1990), suggested that the technique can be applied to fragments up to 400 
bp in size and they quote a sensitivity of 83% in 12 samples. Beck et al., 
(personal communication), carried out a comprehensive study of the 
mutation detection efficiency in a variety of fragments varying in length from 
11 5bp to 600bp. The highest detection efficiency (97%) was detected in 
fragments of 155bp and only 1/29 mutations were detected in fragments of 
600bp. Their final conclusion was that 80% of single base substitutions 
could be detected in fragments of 200bp or less. Other groups (Condie et 
al., 1993), suggest a greater overall detection rate of 90% in fragments of 
less than 400bp and different studies from different groups suggest that 
when a spectrum of conditions altering the electrophoresis conditions and 
gel make up are employed, the majority of mutations can be detected.
1.5.6 Heteroduplex Detection on Hvdrolink Gels(HDHG).
In 1989, Nagamine et al., reported a PCR artefact , the formation of 
heteroduplexes from the products of a PCR reaction amplifying homologous 
loci from the candidate gene for the mouse testes determining Y-gene, mYfin 
(Nagamine et al., 1989). Extra, slower migrating bands were visualised after 
the resolution of the PCR product obtained from amplification of a region 
containing two homologous sequences later discovered to differ by an 18bp 
deletion. The extra bands were concluded to be heteroduplexes made up of
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one strand of each of the two homologous sequences of the mYfin gene on 
the mouse Y chromosome. These heteroduplex bands were only seen 
when the PCR products were run on a polyacrylamide gel . The anomalous 
migration of these heteroduplex bands was originally postulated to be due to 
the secondary structure of the heteroduplexes which caused a change in 
migration relative to the homoduplexes, and to differences in nucleotide 
composition. Nagamine et al., (1989), proposed two possibilities, firstly that 
the secondary structure in the heteroduplexes was due to the two strands 
being annealed along their length with the 18bp unpaired region which was 
deleted in one but not the other strand, forming a bulge. The second 
possibility was that the strands of the heteroduplexes were annealed only 3’ 
to the deletion with the 5’ ends being unpaired. Regardless of the 
mechanism, Nagamine et al., (1989) suggested that such heteroduplexes 
produce a secondary structure that slows migration through the gel and that 
this migration retardation is dependant on the base composition of the 
heteroduplex. Triggs-Raine and Gravel (1990) however, used a double 
strand specific restriction endonuclease to cleave a heteroduplex formed 
during the PCR amplification of a region of the HEX-A gene which is 
mutated in Tay-Sachs disease, (Triggs-Raine and Gravel, 1990) to cleave 
the heteroduplex to completion. This indicated that the heteroduplexes were 
annealed along their length.
This generation of heteroduplexes will theoretically occur in any PCR 
reaction in which two or more homologous alleles are amplified using the 
same set of primers. Angliani et al., (1990) suggested that heteroduplexes 
form during the latter stages of PCR because the DNA concentration begins 
to increase to such a level that the complementary strands reanneal and 
outcompete the hybridisation of the primers with their template strand. 
Nagamine et al., (1989), suggested that this phenomena would only be of 
use in the detection of largish deletions or insertions but Triggs-Raine and 
Gravel, (1990), showed that differences as small as four base pairs could 
even be detected using suitable gel matrices. Single base mutations have 
been identified by utilising the formation of heteroduplexes that are identified 
by electrophoresis on a denaturing gradient gel (Sheffield et al., 1989).
Identification of heteroduplexes on non-DGGE gels has been used for 
detection of heterozygotes for several diseases including Tay-Sachs 
disease (Triggs-Raine et al., 1990) and cystic fibrosis (Rommens et al.,
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1990, Angliani et al., 1990). All these studies detected the heteroduplex on 
polyacrylamide or Nusieve (SeaKem) agarose gels and identified 
heteroduplexes differing by 3 or more base pairs. Keen et al., (1991), 
introduced a new type of non-denaturing gel matrix, Hydrolink (AT 
Biochem), for the detection of single base mismatches. This protocol 
employed a modified PCR strategy including an extra final 
denaturation/renaturation step and was successfully used to pick up a point 
mutations in an autosomal dominant retinitus pigmentosa family (ADRP) and 
several point mutations causing cystic fibrosis. Since then Artlich et al., 
(1992) and Inglehearn at al., (1992) among others, have used the 
methodology successfully to screen for mutations in the rhodopsin gene in a 
panel of patients with ADRP. A modified Hydrolink matrix the MDE (mutation 
detection enhancement ) gel is claimed to have an increased detection 
sensitivity and has been used for the identification of base changes in 
several diseases including Duchenne muscular dystrophy. Several 
modifications to the original protocols have been suggested which change 
both PCR conditions and gel matrixes. No studies had pinpointed the 
percentage of mutations that this technique could detect but initial studies 
suggested that it identified the majority of those analysed.
1.5.7 Allele Specific Oligonucleotide Hybridisation (ASO).
Allele Specific Oligonucleotide hybridisation (ASO)(Saiki et al.,
1986), is a method for the specific detection of known nucleotide changes in 
a given sequence. The method relies on the differentiation of normal and 
mutant sequences by hybridisation of a labelled probe under stringent 
conditions. This technique relies on accurate sequencing information being 
available, in order to design a small oligo of the mutated sequence which 
may differ from the consensus sequence by as little as one nucleotide 
substitution. This oligo is labelled and hybridised under very stringent 
conditions to amplified regions of DNA immobilised on a membrane. The 
conditions of hybridisation are crucial as differential hybridisation to one 
sequence differing to another by such a small change requires optimisation. 
However once optimised mutant and normal sequence can be distinguished 
and many DNA samples can be immobilised and screened simultaneously, 
producing a quick and efficient method for screening for the presence of a 
known mutation in a large number of samples. ASO hybridisation is ideal for 
screening for common mutations in a large number of samples, but the
requirement for different oligos to be designed for each individual mutation, 
makes it less useful for the analysis of mutations in heterogeneous diseases 
where only one family harbours a particular mutation.
1.5.8 Direct Sequencing of PCR products.
Sequencing of DNA has evolved greatly since the advent of the 
chain-termination sequencing method (Sanger et al., 1977). This involves 
the synthesis of a DNA strand by a DNA polymerase in vitro using a single­
stranded DNA template. An oligonucleotide primer is annealed to the 
single-stranded template and synthesis is initiated at this site and terminated 
by the incorporation of a nucleotide analogues dideoxynucleotide, that will 
not support continued DNA elongation. These 2’3’ dideoxynucleotides 
(ddNTP’s) do not have a 3-OH group and and it is due to this group that the 
base cannot form a phosphodiester bond with the next incoming nucleotide. 
Four reactions, each with a different nucleotide take place, and the products 
of these reactions are a series of incompletely elongated segments . Mixes 
of dNTP’s and one of the four ddNTP’s, cause enzyme-catalysed 
polymerisation to be terminated in a proportion of population of chains at 
each site where the specific ddNTP can be incorporated. To visualise the 
sequence information a radioactive nucleotide is incorporated in the 
synthesis so the collection of chains of varying lengths can be visualised on 
a denaturing polyacrylamide sequencing gel.
To work optimally, the chain termination method requires a single­
stranded DNA template for the subsequent strand synthesis, but double 
stranded DNA that has been denatured by heat or alkali can also 
theoretically be used. This can be achieved by traditional cloning methods 
such as by use of a M13 cloning vector (Messing, 1983), or by other more 
recent PCR based strategies. By using M13 cloning, a good yield of pure 
single-stranded DNA is obtained and most sequencing kits provide primers 
for use with these vectors. The methodology however is technically time 
consuming and • if a large number of samples are to be sequenced, 
clones must be obtained for each. The advent of PCR technology has 
provided an alternative for obtaining single-stranded DNA. One such 
strategy, asymmetric PCR ( Gyllensten et al., 1988), involves a two step PCR 
protocol where a conventional PCR is initially carried out using two primers 
flanking the region of interest. The double stranded product is then used as
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a template for a second amplification using one of the primers in vast excess 
of the other limiting primer in the hope of obtaining a single-stranded DNA 
as the limiting primer is present in very small concentrations and is used up 
very quickly. The product can be obtained very quickly and can be easily 
cleaned to the standard required for sequencing and the whole protocol can 
be completed in a much shorter time than with M13 cloning . Many factors 
determine the quality and quantity of sequence obtained . The type of 
radioactivity used is an important consideration. Initially, high energy 32P 
was used but by using the lower energy 35S the technique is safer and the 
resolution was increased (Biggin et al., 1983). The DNA template has to be 
of sufficient quality and quantity to yield a good sequence and the type and 
quality of the DNA polymerase is also important. Ideally this would result in 
equal numbers of chains terminating at each nucleotide with no false 
termination resulting in uniform intensities of bands with no background 
bands.
There are a number of polymerases that can be used in dideoxy 
sequencing . Each of these have different properties and the polymerase 
used can affect the sequence obtained. Sanger originally used the Klenow 
fragment which had a low processivity (the average number of nucleotides 
synthesised before the polymerase dissociates from the template) causing a 
high rate of random terminations and limiting the length of DNA that could be 
sequenced. The best enzymes to use are the Sequenases and Sequenase 
2.0 (USB) has been genetically engineered to have no 3 -5 ’ exonuclease 
activity, a high procesivity and efficient use of nucleotide analogues. 
Sequenases are therefore the enzymes of choice for determining the 
sequences of long tracts of DNA. As an alternative, Taq polymerase is 
useful for determining the sequence of single-stranded DNA templates that 
form extensive secondary structures at 37°C. As it is stable and works 
efficiently at 70-75°C this temperature precludes the formation of these 
structures in the template which lead to unreadable and unsatisfactory 
sequences.
Kits are now commercially available for sequencing and these kits 
contain a variety of reagents which can be used to optimise the reactions 
when problems are encountered. One such artefact that can occur, 
compressions, arise when regions of DNA with diad symmetry containing dG 
and dC residues are not fully denatured during electrophoresis causing
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anomalous patterns of migration in which bands of DNA become 
compressed to the point where they are difficult to read. Compressions are 
dependent on the secondary structure of the DNA and can be resolved by 
using a nucleotide analogue for dGTP(dlTP or 7-deaza-dGTP) which pairs 
weakly with conventional bases and are good substrates for DNA 
polymerases. These base analogues when used in sequencing reactions 
can eliminate most compressions. Other reagents are also available which 
can increase the effectiveness of the polymerase and others which can 
optimise the sequence produced in regions of the DNA close to the 
sequencing primer.
As well as chemical modification the gel running conditions can also 
be altered to provide the maximum sequence data. The nature and 
concentration of the sequencing primer is also thought to be a consideration. 
Once optimised, this method of sequencing can provide sequence data very 
quickly but the level of success has been reported to be very sequence and 
primer dependant. Other protocols have been suggested for obtaining 
single-stranded DNA, including methods which produce a double-stranded 
product where one strand can then be separated from the other. This can be 
done by digestion of a phosphorylated primer which has been used for 
amplification of one of the strands of the product or by use of columns which 
retain one strand due to a modified primer. The best, of these protocols 
appears to be the use of one primer which has a magnetic bead attached 
which can then be retained on a magnetic column. However many of these 
approaches are technically difficult, time consuming or expensive as is the 
case with the magnetic sequencing strategy.
1.5.9 Automated Fluorescent Sequencing.
Automated fluorescent sequencing is a rapidly developing technology 
for the sequencing of DNA templates, including double-stranded PCR 
products, plasmids and single-stranded templates. The automated DNA 
sequencer allows the interpretation of fluorescent labelled sequences using 
a variety of sequencing chemistries.
The most commonly employed technique for determining DNA 
sequence is the chain termination sequencing chemistry previously 
described , utilising the ability of DNA polymerase to synthesise , in vitro a
?Q
complementary copy of a DNA strand. In 1985 Smith et al., described a 
method negating the need for the use of radiochemicals. This method 
involved the attachment of synthetic fluorescent dyes to the 5’-termini of 
synthetic oligonucleotides and sequencing chemistries and apparatus were 
subsequently adapted and developed (Smith et al., 1986 ; Connell et al.,
1987).
The fluorescent dyes can be attached to the dideoxynucleotides or 
the primers and both systems have their merits and drawbacks. Sequencing 
can be carried out using single or double-stranded DNA templates. However 
a different approach utilising PCR in conjunction with a sequencing protocol 
can be used to allow easy sequencing of PCR products, without the 
drawbacks of obtaining a single-stranded template. The cycle sequencing 
protocol using labelled dye terminators offers a convenient approach to 
fluorescent sequencing of double-stranded PCR products and would be 
useful in this study to directly sequence amplified exons from the genes of 
interest.
In this sequencing chemistry, extension products are labelled by the 
incorporation of dideoxynucleoside triphosphates with the fluorescent dyes 
attached using Taq Polymerase, in vitro DNA synthesis requires a single­
stranded template and during cycle sequencing, DNA molecules are 
denatured using heat to break the hydrogen bonds and then primer 
annealing occurs when the temperature is brought down below the primer 
melting temperature. By using a thermostable polymerase;extension can 
occur and the process can be repeated continuously with repeated cycles of 
denaturation, annealing and extension. The fluorescent signal can then be 
amplified to levels which allow enhanced sequencing data to be obtained 
and interpreted by suitable software. This offers an alternative to 
conventional sequencing and may allow areas which are problematic for 
conventional methodology due to difficulty in obtaining a single-stranded 
product to be sequenced.
TO
1.6 Aims of the Project.
The overall aim of the present study was to optimise and compare 
several PCR based mutation detection strategies by using the multi-exonic 
HGPRT ,DMD and BRCA1 genes as model genes . The specific targets are 
summarised as follows:
1) To optimise several mutation detection strategies including SSCP, 
chemical cleavage of mismatches, heteroduplex detection using hydrolink 
gels, PCR based linkage analysis and different sequencing strategies , 
using a panel of 10 previously characterised HGPRT pathologies.
2) To apply the mutation detection protocol to the identification of mutations 
in individuals with HGPRT deficiency.
3) To use the technology established coupled with linkage analysis using a 
tetranucleotide repeat located within the HGPRT gene to designate carrier 
status to as many females as possible from families with an affected boy with 
Lesch-Nyhan syndrome.
4) To use the optimised protocols to look for small mutations in boys with 
DMD/BMD where the presence of a large deletion had previously been 
excluded.
5) To use the optimised protocols to identify mutations and polymorphisms 
in the BRCA1 gene, in families with multiple breast/ovarian cancer cases .
CHAPTER 2
MATERIALS AND METHODS
2.1 Patients.
2.1.1 HGPRT Deficiency.
The patients in this study had clinically designated Lesch-Nyhan 
syndrome or HGPRT associated gout. Some of the index cases and family 
members were referred to the Duncan Guthrie Institute of Medical Genetics 
for biochemical diagnosis and DNA analysis or for confirmation of a 
biochemical analysis carried out elsewhere. The remainder of the families 
were originally given to us by Dr Dorothy Gibbs as frozen blood or 
lymphoblastoid and fibroblast cell lines.
2.1.2 Duchenne/Becker Muscular Dystrophy.
The 14 patients (DMD and BMD) in this study, were referred to the 
Duncan Guthrie Institute of Medical Genetics which as part of the Scottish 
Molecular Genetics Consortium is responsible for prenatal and carrier 
detection of X-linked muscular dystrophies. Each case has been clinically 
assessed with muscle histology undertaken and DMD and BMD 
differentiated. The patients chosen showed no large exon deletions with 
Southern blotting or PCR analysis.
2.1 .3 BRCA1 Families.
DNA samples were supplied by several sources. Familial and 
sporadic cancer DNA samples extracted from blood, were supplied from 
familial cancer clinics in Glasgow and from other clinics in Scotland via 
Professor Michael Steel. Sporadic ovarian cancer blood samples were 
obtained from the Beatson Oncology unit at the Western infirmary in 
Glasgow and DNA was extracted as described below.
2.2 DNA Extraction from Blood.
DNA was isolated from blood based on the protocol described by 
Miller et al., (1988). The blood samples were thawed , transferred to a falcon
tube and lysis buffer ( 0.32 M sucrose, 10 mM Tris pH 7.5 , 5 mM MgCl2 ,1% 
Triton x 100 ) added to fill up the tube. After mixing the samples were spun 
at 2.8 K for 10 min, the top layer discarded and the pellet resuspended in 3 
ml nuclei lysis mix (10 mM Tris, 0.4 M NaCI, 2 mM EDTA pH 8.2 ) . 200 |il 
10% SDS and 100 |il Proteinase K were added and the mixture incubated 
at 55°C for 4h. 1ml of 6M NaCI was added and the sample shaken 
vigorously and spun at 2.5 K for 15 min. The top layer was removed to a 
fresh tube and 2 volumes of phenol /chloroform added before spinning for 
15 min. The top layer was then removed and the previous step repeated 
using again phenol/chloroform and then once again using chloroform alone 
to remove any remaining phenol. The DNA was precipitated by the addition
of 30 \i\ 3M Na acetate and 2 volumes of 100% ethanol and was then
p
spooled-out using a sealed pasteur pipette , air dried and resuspended in 
500|xI 1x T.E. buffer. The concentration of DNA was calculated by 
measuring the optical density at 260 nm and the DNA stored at 4°C.
2.3 DNA Extraction from Lvmphoblastoid and Fibroblast Cell Lines.
The frozen cell samples were defrosted on ice before the cells were 
pelleted by spinning at 2K for 10 minutes. The medium was removed and 
the cell pellet washed X2 with chorion buffer (50mM Tris pH 7.5, 100mM 
NaCI, 1mM EDTA). After the final spin all the liquid was removed and the 
cell pellet resuspended in 500 |il of chorion buffer. 20% SDS (2.5^1/100^1) 
and Proteinase K( 1 |xl/100|xl), were added and the sample mixed well but 
gently before incubation at 37°C for 3 hours until the tissue fragment 
disappears. The DNA was then phenol extracted, precipitated and 
resuspended as described for DNA extracted from blood.
2.4 Agarose Gel Electrophoresis.
A 1 % agarose gel was prepared by dissolving 0.5 g agarose powder 
( SEA KEM GTG,FMC Bioproducts ) in 50 ml 1x TBE buffer. The mixture 
was boiled ,cooled and before casting ethidium bromide added. After 
setting, samples were mixed with 1/3 volume of loading buffer(0.25% 
bromophenolblue, 0.25% xylene cyanol , 40% (w/v) sucrose in water), 
loaded and the gel subjected to electrophoresis at 100 mA for 45 min. The 
DNA was then visualised using a standard U.V. transilluminator and 
photographed using a polaroid camera fitted with a red filter.
T4
2.5 Amplification of Single Exons of the HGPRT Gene by PCR.
For the amplification of single exons of the HGPRT gene, the primers 
sequences used are shown in Table 2.1 . Each PCR reaction used 500ng of 
extracted genomic DNA as a template in a reaction mix containing 50ng of 
the relevant sense and anti-sense primer, in a total volume of 50|xI 
containing 250|xM of each of the four deoxynucleotides and 2.5 units of Taq 
DNA polymerase BoeJiringer), in 5|il of the 10X buffer specified by the 
manufacturer. The reactions were mixed and overlaid with mineral oil 
(Sigma).
The samples were subjected to 28 cycles of denaturation at 94°C for 
1 min, annealing at 61 °C for 1 min and extension at 68°C for 1 min 30 secs. 
A final extension step of 68°C for 7 mins was then carried out before the 
products were checked by electrophoresis on a 1% agarose gel. The PCR’s 
were carried out on a Techne PHC-3 thermocycler.
2.6 Amplification of Single Exons of the DMD Gene by PCR.
Amplification of individual exons of the DMD gene was carried out 
using primer sets described by Chamberlain et al., ( 1988, 1990), Beggs et 
al., (1990) and Abbs et al., (1991) . Their sequence and the sizes of the 
amplified fragments are shown in Table 2.2a and 2.2b. The PCR reaction for 
amplification of exons designated a, b,c,d,f,g,h and i were carried out 
according to the protocol suggested by Kataki, (1992). A 50|xl reaction mix 
was set up containing 30pm of each of the relevant sense and anti-sense 
primers, 500ng of genomic DNA , 8|xl of dNTP mix containing 1.25mM of 
each nucleotide and 5|xl of 10x PCR reaction buffer (Boeringer) and 2.5 units 
of Taq polymerase (Boeringer). The PCR reaction mix was mixed and 
overlaid with mineral oil (Sigma), before 31 cycles of amplification were 
carried out. The following cyding parameters were used: With primer sets i, c 
and d : 94°C for 30 seconds, 55°C for 30 seconds and 73°C for 50 seconds 
with a final extension at 73°C for 7 minutes. For primer set a a,b,e,g and h : 
94°C for 60 seconds, 55°C for 60 seconds, 73°C for 120 seconds and a 
final extension at 73°C for 7 minutes. For primer set f 94°C for 30 seconds, 
53^C for 30 seconds and 65°C for 55 seconds with a final extension at 65°C 
for 7 minutes.
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For amplification of the remaining exons using primer sets 
Pm,3,6,13,42,43,44,47,50,52,53 and 60, 50pm of each primer were used 
and the cycling parameters were the same as for exons a,b,e,g and h.
2.7 Amplification of Single Exons of the BRCA1 Gene by PCR.
For the amplification of single exons of the BRCA1 gene the primer 
sequences used are shown in Table 2.3.a and b. and are similar to those 
suggested by Friedman et al., 1994. Each PCR reaction used 500ng of 
extracted genomic DNA as a template, in a reaction mix containing 100ng of 
the relevant sense and antisense primers in a total volume of 50|xI 
containing 20|xM of each of the four deoxynucleotides, 5mM MgC^, 1X 
sequencing buffer specified by the manufacturer (Gibco BRL/ Life 
Technologies) and 2.5 units of Taq polymerase (Gibco BRL/ Life 
Technologies). The reactions were mixed and overlaid with mineral oil .
The exons were amplified using a touchdown PCR involving; 4 cycles 
of denaturation at 95°C for 10sec, annealing at 68°C for 10 secs and 
extension at 72°C for 10secs, 4 cycles of denaturation at 95°C for 10sec, 
annealing at 66°C for 10secs and extension at 72°C for 10secs, 4 cycles of 
denaturation at 95°C for 10sec, annealing at 64°C for 10secs and extension 
at 72°C for 10 secs, 4 cycles of denaturation at 95°C for 10sec, annealing at 
62°C for 10secs and extension at 72°C for 10secs. This was followed by 30 
cycles of denaturation at 95°C for 10sec, annealing at 60°C for 10secs and 
extension at 72°C for 10secs. The PCR reactions were carried out on a PTC- 
100 Programmable Thermal Controller (MJ Research Inc.).
2.8 Amplification of cDNA from the HPRT Gene.
For the amplification of cDNA for the HGPRT gene the primers 581 
(CTCTGCTCCGCCACCGGCTTCCT) and 365 (CCGCCCAAAGGGAACTGA 
TAGTC) were used(Jolly et al., 1983). cDNA was prepared and provided by 
Yorkhill DNA diagnostic service and the internal primers described above 
were used to amplify the region of interest. The same PCR conditions were 
used as for the amplification of the individual exons reaction using 500ng of 
total cDNA as a template.
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2.9. Visualisation of PCR Products.
10% of the PCR product was mixed with 1/3 volume of loading buffer 
and and the products run in a 1% agarose mini gel as described in 2.4 with 
the products being sized against a 1 kb ladder (BRL).
2.10 Manufacture. Preparation and Purification of Oligonucleotide Primers.
A number of oligonucleotide primers were manufactured ‘in house’ 
on an Applied Biosystems (ABI) PCR mate oligonucleotide primer 
synthesiser. For this study the primers were initially synthesised with the trityl 
group off. The primers were cleaved from the support by passing 1 ml of 
concentrated ammonium hydroxide through the column containing the oligo 
in three stages, passing 330|xl through the column every 20 minutes , 
collecting the ammonium hydroxide in a tube. The volume of ammonium 
hydroxide containing the cleaved primer was then increased to 2ml and the 
oligo deprotected by incubation at 55°C overnight. The primers were then 
left open in a fumehood for 12 hours to allow the remaining ammonia to 
vapourise and the oligonucleotide primers then precipitated from the mix by 
salt/ethanol precipitation, washed with 70% ethanol and resuspended in a 
suitable volume of ddH20. The concentration of the oligonucleotide was 
then determined by finding the O.D. at 260nm.
Due to the sensitivity of several of the amplification reactions for the 
HGPRT gene, many of the primers were manufactured with the trityl group 
on, to allow further purification of the primer through a OPC (oligonucleotide 
purification cartridge) column (ABI). After completion of the trityl-on 
synthesis, the oligo was cleaved from the support and deprotected as above. 
An OPC cartridge was then washed by flushing with 5ml HPLC grade 
acetonitryl followed by 5ml of 2.0M triethylamine acetate. An aliquot of a final 
volume of 1-4 ml containing approximately 20 O.D. units of the deprotected 
oligo diluted with one third volume of deionized water was then taken into a 
polypropylene syringe and slowly pushed through the cartridge, the eluted 
fraction collected and pushed through he cartridge again. The cartridge was 
again washed with 3X5ml of 1.5M ammonium hydroxide and 2X5ml 
deionised water.
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The OPC bound oligo was then detritylated by addition to the column 
of 5ml of 2% triflouroacetic acid solution where 1 ml was primarily pushed 
through the column and left for 5 minutes before the remainder was pushed 
through. The cartridge was again washed by flushing with 2X5ml deionised 
water before the purified, detritylated oligonucleotide was eluted by slowly 
washing the cartridge with 1ml of 20% acetonitryl solution. The O.D. at 
260nm was then determined.
2.11 Cleaning of Genomic DNA and Oligonucleotide Primers.
Genomic DNA and oligonucleotide primers were cleaned by 
ethanol/salt precipitation. An aliquot of the DNA or primer was mixed with 
1/10 volume of 3M sodium acetate (pH 5.5) and 2.5 X total volume of filtered 
100% ethanol. The DNA was precipitated at -70°C for one hour before the 
pellet was obtained by centrifugation at top speed in a microcentrifuge for 15 
minutes. The DNA pellet was then washed twice with 70% ethanol and air 
dried for 1 5 minutes before the DNA was resuspended in an appropriate 
volume of T.E. buffer. The oligonucleotide primers were resuspended in 
ddH20 and the concentration of each determined by finding the O.D. at 
260nm.
2.12 Linkage Analysis Using a Tetranucleotide Repeat Located Within the 
HGPRT Gene.
The STR within the HGPRT gene was amplified using flanking 
primers with the sequences; 5-ATG CCA CAG ATA ATA CAC ATC CCC-3’ 
and 5- CTCTCCAGAATAGTTAGATGTAGG-3’. PCR was carried out in a 
total volume of 50|xl containing 5(xl of PCR buffer 200|xM of each of the four 
dNTP’s, 500ng of genomic DNA and 35pm of each purified primer one of 
which had been end labelled with 32Py-ATP using T4 polynucleotide 
kinase (NBL). After addition of 2.5 units of Taq polymerase amplification 
was performed with an initial denaturation of 94°C for 5 min followed by 25 
cycles of denaturation at 94°C for 2 min, annealing at 60°C for 1 min and 
extension at 72°C for 2 min. At the end of the PCR reaction , 2 units of the 
Klenow fragment of DNA polymerase (BRL) was added to each sample, and 
incubation was continued at 37°C for 15 min. 2jxl of the final product was 
then mixed with 6|il of a formamide loading buffer and electrophoresed on a 
4% polyacrylamide /7M urea sequencing gel for 4-8 hours depending on the
TR
degree of separation required. The gel was dried and subjected to 
autoradiography for the required time period.
2.13 Heteroduplex Detection Using Hvdrolink Gels(HDHG).
This method was based on the protocol provided by Jeffrey Keen 
(personal communication), and is a modification of that described by Keen et 
al., (1991).
PCR amplification was carried out using the reaction mixtures 
previously described for the individual HGPRT and DMD exons with the 
modification that for analysis of male DNA, 250ng of patient DNA and 250ng 
of control male DNA were present in each amplification reaction mix for the 
X-linked genes, thus creating a potential false heterozygous state. The 
primers used are as described previously in tables 2.1, 2.2 and 2.3 and the 
panel of known HGPRT mutations analysed is summarised in table 2.4. For 
amplification of the HGPRT exons, an initial 2 step denaturation cycle of 
94°C for 2 minutes and 60°C for 5 minutes was followed by 30 cycles of 
denaturation at 94°C for 30 seconds and a single annealing /extension step 
of 60°C for 5 minutes, followed by a final denaturing/renaturing step of 94°C 
for 30 seconds and 70°C for approximately 1-16 hours. This increased the 
chance of heteroduplex formation between non-homologous strands. For 
the DMD gene, the PCR conditions were as for the amplification of the 
individual exons with the final denaturation/renaturation step as described .
The reannealed double-stranded PCR products were then subjected 
to electrophoresis on hydrolink D-5000 gels to resolve heteroduplex from 
homoduplex fragments. The gels were cast vertically in a sandwich 
consisting of 2 , 20x20cm or 20 X30cm plates clamped together and 
separated by 1.5 mm spacers and sealed at the bottom with plasticine. A 
mix containing 35.4 mis of Hydrolink D-5000 (AT Biochem) and 4mls 10 x 
TBE buffer was polymerised by addition of 25 |il N,N,N',N' 
tetramethylenediamine (TEMED)(Sigma) and 750 |xl fresh 10 % ammonium 
persulphate. This was poured between the two plates, a 10 well comb 
inserted and the gel left to set for approximately 1 hour. After removing the 
comb the wells were rinsed with the running buffer (1 xTBE buffer), and 16 |xl 
of the PCR product + 4 jil of the loading buffer (5% sucrose, 0.06% orange 
G) were loaded and run at different voltages for different times depending on
TQ
MUTATION SEQUENCE
CHANGE CHANGE
HGRRT
CODICOTE
T298a P
HGPRT
CHELTENHAM
GT&
288-289
P
HGPRT
MASHAD
A59T D20V
HGPRT
SHEFFORD
C151T R51X
HPRT
BANBURY
G152C R51P
HGPRT
RUNCORN
T395C I132T
HGPRT
FARNHAM
C486G S162R
HGPRT
NORTH
MYMMS
C508T R170X
HGPRT
MARLOW
C527T P176L
HGPRT
READING
G617A C206Y
Table 2.4 Summary of the panel of known 
mutations in families with Lesch-Nyhan syndrome . The 
amino acid and nucleotide changes present are indicated, 
a-indicates an insertion, b-indicates a deletion, P-indicates 
premature termination.
the size of amplification product to be analysed (Table 3.1)(Boyd et al., 
(1993)).
The gel was then stained with ethidium bromide for 20 minutes 
followed by destaining in the running buffer for 4 hours and the DNA 
visualised and photographed as previously described.
2.14 Purification of PCR Products.
2.14.1 Geneclean.
Geneclean was used to purify non-radioactive PCR products of over 
500 bp in size. After removal of the mineral oil the total PCR product was 
transferred to a 1.5 ml eppendorf tube and the product was cleaned using 
Geneclean 2 . kit (Bio 101 inc.). Three volumes of sodium iodide solution 
and 5|xl of glassmilk suspension were added and the sample vortexed and 
incubated on ice for 5 minutes, mixing every two minutes, to allow the 
binding of DNA to the silica matrix. The glassmilk/DNA was then pelleted 
and washed three times with NEW WASH( 10ml dH20, 11ml 100% ETOH, 
500|il NEW concentrate). After the third wash the pellet was then ckied and 
the DNA eluted from the glassmilk by dissolving the pellet in 20|il of T.E. 
buffer and incubated at 55°C for 3 minutes. The mix was then spun at top 
speed in a microcentrifuge to pellet the glass milk and the supernatant 
containing the DNA removed to a new tube.
2.14.2 Purification of PCR Products Through an Agarose Gel.
This method was used to purify radioactive PCR products and 
products smaller than 500bp. After mixing with 10% volume of loading 
buffer, the entire PCR product was subjected to electrophoresis through a 
1% agarose gel containing ethidium bromide, for 45 minutes at 100 Volts. 
The product was visualised on a U.V. transilluminator with a thick perspex 
sheet between the gel and the U.V. source to minimalise the degradation of 
the DNA by the U.V. light. The slice of gel containing the amplified fragment 
was cut from the gel and placed into a 1.5 ml autoclaved eppendorf with a 
hole in the bottom, and which was half filled with siliconised, autoclaved 
glass wool. A second eppendorf was placed under the first, both were 
labelled and the double eppendorf placed in a suitable centrifuge and spun
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at top speed for 15 minutes or until the entire gel slice had collapsed to a 
liquid containing the DNA in the bottom eppendorf. The DNA was then 
precipitated by salt/ethanol precipitation, washed with 70% ethanol and 
resuspended in 200|xl of ddH2 0 .
2.15 Radioactive Labelling of Oligonucleotide Primers.
Oligonucleotide primers were 5’-end labelled individually with 
enough primer for two PCR reactions being labelled in one reaction tube. 
The labelling mix containing the primers, 10 units of T4 polynucleotide 
kinase, 1x 1 phos-all buffer( Pharmacia) and 25|xci of 32Py-ATP was mixed 
before incubation at 37°C for one hour before half of each reaction mix was 
used for each PCR reaction.
2.16 PCR-SSCP Analysis.
PCR was carried out for the individual HGPRT, DMD and BRCA1 
exons as described in 2.5, 2.6 and 2.7 either using the 5’-end labelled 
primers or containing 25|xci ofa-dCTP as described for internal labelling . 
The kinased primers were added without purification.
The amplified products were diluted 1:25 with 1% SDS, 10mM EDTA, 
followed by a 1:2 dilution in 95% formamide, 20mM EDTA, 0.05% 
bromophenol blue and 0.05% Xylene cyanol. The sample was heated to 
100°C for 10 minutes to denature the DNA and then snap cooled on ice 
before loading on a 6.5% non-denaturing polyacrylamide gel containing 
varying concentrations of glycerol and was run at different wattages for 
different times to obtain optimum separation of the single strands. The 6.5 % 
non-denaturing polyacrylamide gels were prepared as with denaturing 
sequencing gels as described in 2.26 with the absence of urea and glycerol 
added at the relevant concentration. The gels containing glycerol were run 
at room temperature with a fan directed at the plates to ensure the gels were 
cool. Gels without glycerol were run in the cold room at 4°C. The gels were 
dried on a gel drier and subject to autoradiography at -70°C overnight.
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2.17 Autoradiography.
The gel was placed beside an X-ray film (Kodak Diagnostic: X-OMAT 
TM AR 5) in a light tight cassette containing intensifying screens. The 
cassette was left for the desired time in a - 70° C freezer and the film 
developed using a Fugi X-Ray film processor.
2.18 Restriction Enzyme Digestion of PCR Products.
Non-labelled PCR products were digested with the relative restriction 
enzymes by incubating at 37°C for 1 hour, 15(xl of PCR product with 2jxl of 
restriction enzyme and 2|il of the correct react buffer and 1 jxl of ddH2 0 . 
Exons 2 and 5 were digested with Dde 1, exon 3 with Alu 1, exon 7 with Hinf 
1 . For SSCP analysis, the PCR product was digested as above and 5|il of 
the digested fragment was incubated at 37°C for 1 hour with 2|xl 1-phos-all 
buffer (Pharmacia), 3|xl of y-ATP 2 units of T4 polynucleotide kinase and the 
volume made to 20 |il with ddH2 0 .
2.19 Chemical Cleavage of Mismatches (CCMT
To screen for mutations , the CCM method described by Cotton et al., 
(1988) and Dahl et al., (1989), was originally used before the modified 
version of the protocol as documented by Howells et al., (1990), was 
employed.
The nature of the chemicals used in this procedure merited caution in 
the handling and disposal of the solutions. The procedure was carried out in 
afumehood, with the apparatus used being used only for this protocol. No 
other work was carried out in the fumehood while the toxic chemicals were 
in use and special protective clothing, facemasks, safety glasses and double 
gloves were used. The chemicals were disposed of only down the 
fumehood sink and plasticware and gloves which was in contact with the 
chemicals was placed in a cinbin in the hood and disposed of once full by 
burning. The chemicals were stored in the fumehood or in specially labelled 
containers in special fridges not in general use.
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2.19.1 Method 1, (Cotton et al. , (1988))
The regions of the patient DNA of interest ,were amplified according 
to the protocols previously described in 2.5 and 2.6. The PCR products were 
then directly cleaned using a Geneclean II Kit (BIO 101 Inc.) if the amplified 
fragment was greater than 500 bp in size as described in 2.14.1. If the 
amplified fragment was less than 500 bp in size the fragment was purified 
through agarose gel as described in 2.14.2. The final cleaned DNA was 
either eluted or resuspended in a final volume of 20 |xl of T.E. buffer.
The original probes were prepared by kinase labelling of the 
amplified fragment, (Maniatis et al. (1989)). 100 ng of the PCR product was 
labelled by addition of IxKinase buffer(0.5M Tris-CI(pH 7.6),0.1 M MgC^, 50 
mM dithiothreitol,1mM spermidine, 1 mM EDTA,),20 n,Ci ^py-A T P , 10 units 
of T4 polynucleotide kinase(NBL) and dH20 to 20 |il. After mixing, the 
reaction was incubated at 37°C for 30 minutes. The labelled DNA was then 
precipitated by addition of 2 volumes of 2M ammonium acetate and 3 
volumes of 100% ethanol. After precipitation for 1 hour at -70°C, the DNA 
was spun down and washed x2 with 70% ethanol before drying and 
resuspension in 50 |xl of ddh^O. The amount of incorporated radioactivity 
was calculated by measuring the counts per minute using a scintillation 
counter. 2 |xl of a 1:2 dilution of 5|xl of the labelled product was spotted onto 
2 separate circles of Wattman filter paper. One of these was then washed 
x4 with 0.5M Na2HPo4, x2 with ddh^O and x1 with 100 % ethanol. Both 
pieces were then dried placed in a polyurathane scintillation vial containing 
scintillation fluid and the counts per minute of the washed and unwashed 
DNA samples measured and compared. Only probes with more than 20% 
incorporation of radioactivity were used.
2-5 ng of labelled control DNA was mixed with at least 12x excess of 
unlabelled test DNA or unlabelled control DNA in a screw capped 1.5 ml 
Sarstedt vial. To this an equal volume of 2x annealing buffer(1.2M NaCI, 
12mM Tris-HCI pH 7.5, 14mM MgCl2) was added and the mixture boiled for 
5 minutes before removal to a 42°C to allow annealing of the strands. After 
1 hour incubation the heteroduplexes were precipitated in an equal volume 
of 5M sodium acetate(pH 5.5)and 2.5 volumes of 100 % ethanol with 4|xl of 
20mg/ml glycogen(Boehringer) added to facilitate precipitation. After
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spinning down, washing and drying the pellet in the usual manner, the pellet 
was resuspended in 12 \i\ ddh^O.
6 |xl of the heteroduplex mixture was added to two fresh Sarstedt 
tubes. To one tube 20(il of hydroxylamine solution (Aldrich) ( 1.39g 
hydroxylamine in 1.6ml ddH20, adjusted to pH 6.0 by addition of 1ml 
diethylamine (Aldrich)) was added and the mixtures incubated for 60 
minutes at 37°C. 2.5|xl of 10X OSO4 buffer (10mM Tris-HCL pH 7.7, 1mM 
EDTA, 1.5% pyridine) and 15|xl of a 1/5 dilution of OSO4 (Aldrich) (0.5g/12.5 
ml distilled water) were added to the other tube and this was incubated at 
37°C for 5 minutes. After incubation the reaction was stopped by addition of 
200|il of “HOT STOP” solution ( 0.3M sodium acetate pH 5.2, 0.1 mM EDTA, 
25mg tRNA/ml), and 750|il of 100% ethanol were added and the DNA 
precipitated at -70°C. After centrifugation the DNA was resuspended in 
200|xl of 0.3M sodium acetate pH 5.2 and 500|il 100% ethanol added and 
the DNA was reprecipitated, ethanol washed and dried.
50jxl of 10% piperidine (Aldrich) was added to each dried pellet which 
was then vortexed for 10 seconds before incubation at 90°C for 30 minutes. 
After cooling on ice the heteroduplexes were then precipitated at -70°C by 
addition of 50|xl of 0 .6M sodium acetate pH 5.2 and 300|il of 100% ethanol 
before centrifugation and washing with 70% ethanol. After drying the pellets 
were resuspended in 8|xl of loading buffer (0.05% bromophenol blue, 0.05% 
xylene cyanol FF, and 0.2 ml of 0.5mM EDTA dissolved in 10ml formamide). 
The samples were boiled for 10 minutes and cooled on ice before loading 
on an 8% denaturing polyacrylamide gel prepared as described in 2.26 with 
a labelled 1 kb ladder . The gels were run for approximately two hours or 
until the bromophenol blue marker had run 30cm and the gel was then fixed 
and dried as described. The gel was then subjected to autoradiography at - 
70°C as described for 7 days.
2.19.2 Method 2 .
This method utilised different methods of probe preparation and was 
based on the methodology suggested by Howells et al., (1990). Two 
different strategies were employed to achieve optimal labelling of the DNA 
probe, namely, incorporation of 32P a-dCTP into the DNA during
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amplification and labelling of the oliginucleotide primers by 5’ end-labelling 
using 32Py-ATP.
For incorporation of radioactivity along the whole length of the DNA 
probe the PCR for the individual exons was as described in 2.5 and 2.6 with 
the modification that 20pm of 32Pa-dCTP (60pci) were added to the 
reaction mix and the quantity of non-radioactice dCTP was reduced from 
200pM to 6jiM . To avoid misincorporation of alternative dNTPs as dCTP 
concentrations fell only 25 PCR cycles were performed. For an end-labelled 
probe, the primers were 5-end labelled as described in 2.15 and the PCR 
was carried out otherwise as described in 2.5 and 2.6 . The entire PCR 
product was run in a 1% agarose gel and the probe purified and isolated as 
described in 2.14.2, before resuspension in 1X T.E. (10mm Tris-HCL, 1mm 
EDTA, pH 7.4) at 1000cpm/ml.
The heteroduplexes and control homoduplexes were formed in 
siliconised Sarstedt tubes . 200 ng of test DNA (approximately 1/4 of the 
PCR product) and 20ng of purified probe (56,000 cpm) were added to the 
siliconised tubes and ddH20 added to the volume of 1 28|xl. 128 pi of 
annealing buffer as described above was added and the tubes capped with 
punctured non-siliconised lids before boiling for 5 minutes. The tubes were 
then capped with non-punctured siliconised caps and the heteroduplexes 
were formed at 42°C for 60 minutes as described. The remainder of the 
protocol was as described for method 1, but after the piperidine cleavage 
and addition of the formamide buffer the DNA was left to resuspend 
overnight before electrophoresis.
2.20 Radioactive Labelling of a 1 kb Ladder.
The DNA fragments of the 1 kb ladder were 5’-end labelled using 32P 
y-ATP. 3.5pl of ladder (BRL) was incubated at 37°C for 1 hour with 2.5|xl of 
32P y-ATP, 1 |xl of 10x one-phos-all buffer (Pharmacia), 10 units of T4 
polynucleotide kinase (NBL) and ddH20  to make the volume to 10pl. The 
labelled ladder was stored at -70°C and before electrophoresis an aliquot of 
the ladder( depen ding on the age of the ladder) was mixed with 1/2 volume 
of formamide loading buffer and heated to 100°C for 5 minutes immediately 
before loading.
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2.21 Allele Specific Oligonucleotide Hybridisation.
PCR reaction were carried out for the exons of interest as described 
previously in 2.7. 20 |il of each PCR reaction was transferred to a fresh tube 
and the samples heated to 95°C before chilling on ice. An equal volume of 
20X SSC was added and the samples spotted in 5(xl aliquots onto a 
Hybond N + membrane prewetted with 10X SSC and stamped with an ink 
grid. The samples were allowed to dry before the addition of the next DNA 
aliquot. The membrane was then denatured by placing DNA side up on a 
piece of filter paper soaked in deaturation solution ( 1.5M NaCI, 0.5M NaOH) 
for 5 minutes. The filter was then placed on a piece of filter paper soaked in 
neutralising solution ( 1.5M NaCI, 0.5M Tris-HCI pH 7.2, 0.001M EDTA) for 1 
min. and then air dried before fixing by U.V. crosslinking.
Membranes were pre-hybridised for 2 h at 52°C with 5ml of a solution 
containing 3.0M tetramethyl ammoniumchloride (TMAC), 0.1 M NaPo4 pH 
6 . 8 , 1mM EDTA, 5X Denhardts solution, 0.6% SDS and 100^ig/ml yeast 
tRNA. The membranes were then probed overnight at 52°C by addition of all 
of BOOng of a y32P end labelled oligonucleotide primer , whose sequece 
corresponded to the mutated sequences of the AG deletion in exon 2 the C 
insertion in exon 20, and the AA deletion in exon 11. The sequences of 
these were ATC TTA GTG TCC CAT CT, GAG AAT CCC CAG GAC AG and 
GTC CTT AAA GAC AAA GT respectively and the primers were designed 
with the variant sequence in the centre of the primer sequence. After 
probing the membranes were washed with 2X SSC for 20 mins. at RT with 
agitation and then for 20 mins. at 52°C in a buffer containing 3.0m TMAC, 
1mM EDTA, 10mM NaPo4 and 0.6% SDS. The filters were then air dried, 
covered with cling film and exposed to X-Ray film at -70°C for 48 hours.
2.22 Direct Sequencing of Single-Stranded DNA Templates Generated by 
Asymmetric PCR.
Direct sequencing of single-stranded asymmetric PCR products was 
carried out using a Sequenase Version 2.0 sequencing kit (United States 
Biochemical). Single-stranded DNA templates were prepared by carrying 
out a PCR reaction with the concentration of either the sense of antisense 
primer being in 50 - 75 x excess of the other primer. The PCR reaction 
mixture and conditions were otherwise the same as previously described
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for PCR amplification of the individual HGPRT and DMD exons except that 
the reactions were carried out in a final volume of 10Opul with 3.5 units of 
Taq polymerase and 10 more cycles of amplification were carried out. The 
asymmetric PCR product was checked for the presence of a potential single 
stranded product on a 1% agarose mini gel . The product was cleaned by 
precipitating the DNA at room temperature for 30 minutes with the addition 
of equal volumes of 4M ammonium acetate and 2.5 x total volume of 100% 
isopropanol before precipitation of the DNA in a microcentrifuge for 15 
minutes at top speed, washing of the DNA in 70% ethanol and after drying , 
resuspending the pellet in 7|il of ddH20 (Charles Mgone, personal 
communication).
Direct sequencing was carried out using the chain-termination DNA 
sequencing method (Sanger et al., 1977). This was carried out according to 
the manufacturers of the sequenase version 2.0 kit instructions. 1 pm of the 
primer limited in the asymmetric PCR was added to the annealing mixture 
containing 7|xl of single stranded DNA (the entire PCR product) and 2^ 1 of 
5X sequencing buffer before annealing was carried out by heating the 
mixture to 65°C for two minutes before slow cooling to below 35°C. The 
labelling reaction consisting of 1|il of 0.1M Dithiothreitol (DTT), 2|xl diluted 
labelling mix (1.5 mM each of dGTP, dCTP and dTTP), 1000mCi/mMol of 
35S dATP and 3 units of Sequenase T7 DNA polymerase being incubated 
at room temperature for 5 minutes . 3.5|xl of the labelling reaction was 
transferred to 2 .5ptl of each dideoxy termination mix prewarmed to 37°C. The 
termination reaction was carried out at 37°C for 4 minutes before the 
reactions were stopped by addition of 4|xl of Stop solution.
Samples were heated to 75°C for two minutes, snap cooled on ice 
and loaded on a 5% polyacrylamide sequencing gel. Different modifications 
were used in an attempt to optimise the signal including; addition of Mn 
Buffer which is a reagent which takes advantage of the enhanced activity of 
the Sequenase 2.0 enzyme in the presence of mn 2+ions altering the 
concentration of primer used, increasing the concentration of DNA in the 
reaction and using nucleotide analogues provided in the kit to weaken the 
CG bonds and limit stops in the sequencing reaction and altering the 
extension and termination temperatures and times.
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2.23 Sequencing of Double-Stranded PCR Products.
The exon of interest was amplified as normal using the PCR reaction 
and the double-stranded DNA product was precipitated at -70°C after 
addition of 1/10 volume of 3M Sodium Acetate (pH5.5) and 2.5X volume of 
100% ethanol. The pellet was washed with 70% ethanol and air dried. To 
denature the DS DNA, a final concentration of 0.2M NaOH and 0.2 mM 
EDTA (pH 8) was added to the DNA which was incubated at 37°C for 30 
minutes. The reaction was then neutralised by addition of 1/10 volume of 
3M sodium acetate (pH 5.5). The samples were ethanol precipitated, 
washed at least twice with 70% ETOH and the pellets of DNA resuspended 
in 7|xl of ddH20. The samples were thereafter treated according to the 
protocol provided with the Sequenase 2 kit as described in 2.22.
2.24 Sequencing with Formamide.
This was carried out according to the protocol suggested by Zhang et 
al., (1991). 50% of a double-stranded PCR product (1 Ojxl) was cleaned 
using geneclean and mixed with a five molar excess of sequencing primer 
in 1X sequencing buffer with 3|il of formamide. The annealing mixture was 
boiled for 10 minutes and cooled in a dry ice/ethanol bath. The sequencing 
reaction was then carried out as described in 2.22 with the exception that 
the sequencing reaction was carried out on ice for ten minutes and the 
termination reaction at 42°C fro 10 minutes. Before loading on a sequencing 
gel the reactions were denatured at 95°C for 3 minutes.
2.25 Production of a Single-Stranded DNA Template bv Exonuclease 
Digestion.
This was carried out according to the method described by Higuchi 
and Ochman, (1989). 50pm of one of the oligonucleotide primers is 5-end 
labelled using 2 units of T4 polynucleotide kinase and 1mm of ATP at 37°C 
for 1 hour. The kinased primers were then precipitated in 0.3M sodium 
acetate, 0.01 mM MgCl2 and 2 volumes of 100% ethanol and the 
resuspended primer added to a PCR reaction mix containing an equal 
concentration of the opposing non-kinased primer and amplification was 
carried out using the normal conditions. After amplification the double­
stranded product was extracted with phenol, precipitated with 3M sodium
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acetate and 100% ethanol and treated at 37°C for 15 minutes with 4 units of 
lambda exonuclease (BRL) in 50|il of a buffer containing 67mM glycine- 
NaOH (pH 9.4), and 2.5mM MgCl2. The single-stranded product was 
extracted twice with phenol, once with phenol/chloroform and ethanol 
precipitated as previously described. The single stranded template was 
then sequenced as usual using the Sequenase 2.0 kit (USB)( 2.22) and the 
sequence visualised on a denaturing sequencing gel.
2.26 Preparation of Sequencing Gels.
8% denaturing sequencing gels were prepared in a vertical gel cast 
as follows. The glass plates were washed thoroughly with decon, rinsed 
with distilled water and cleaned with 70% ethanol. 0.4mm spacers were 
placed along the edge of one of the glass plates and the plates clamped 
together. The bottom edge of the plates were sealed and a mix containing 
12 mis 40 % acrylamide (40 % (w/v) acrylamide <19;1 > bisacrylamide 
solution, (NBL)), 6ml 10X TBE buffer, 42ml dH20 and 25g urea(7M) was 
polymerised by addition of 100 |xl each of 20 % ammonium persulphate and 
TEMED and carefully poured down the edge avoiding the formation of air 
bubbles.
A comb was placed at the top edge of the gel which was left to set for 
one hour. The comb was carefully removed and the wells cleaned 
thoroughly by flushing with the running buffer to remove any urea and 
excess acrylamide.
2.21 Electrophoresis of Denaturing Sequencing Gels.
Sequencing gels were run at approximately 2000 volts and before 
loading of the samples, gels were preheated to 50°C. After running for 
variable amounts of time depending on which part of the sequence was 
required , the gel was fixed in 10% methanol, 10 % acetic acid for 15 
minutes and dried for 30 minutes in a gel drier before exposure to an X-Ray 
film.
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2.28 Analysis of Sequencing Gels.
The sequencing gels were read manually and the data compared 
with the published sequence of the entire HGPRT gene (Edwards et al., 
1990) or to a control sample of the amplified exon of interest for the DMD 
gene.
2.29. Fluorescent Automated Sequencing of Double-Stranded PCR 
Products Using Tag Terminator Chemistry and Cycle Sequencing.
2.29. 1 Preparation of DNA for Cycle Sequencing.
Double-stranded PCR products were prepared as described in2.5,2.6 
and 2.7. 5 |xl were run on a 1% agarose mini-gel to check for the presence 
of a product of the correct size. If one clean band was present, the 
remaining product was run through a Pharmacia Microspin S-400 column 
(Pharmacia Biotech). If more than one band was present , the desired band 
was isolated by cutting from a 1% agarose mini-gel as described in 2.14.2.
2.29.2 Cycle Sequencing of PCR Products Using Taq Terminator 
Sequencing.
7|xl of the cleaned PCR product was mixed with 3.2pm of one of the 
primers used for the initial PCR. The volume was made up to 10.5|xl by 
addition of 9.5 |xl of PRISM Ready Reaction Dyedeoxy Terminator Cycle 
Sequencing premix added (Applied Biosystems). Cycle sequencing was 
carried out using a PTC-100 Programmable Thermal Controller (MJ 
Research Inc.) involving 25 cycles of denaturation at 96°C for 15 secs, 
annealing at 50°C for 15 secs and extension at 60°C for 4 mins.
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2.29.3 Cleaning of Sequencing Reactions.
80|xl of ddH20 was added to the sequencing reactions and two 
phenol/chi or of or m/water (68:18:14) (ABI), extractions were carried out. The 
labelled DNA was then precipitated by the addition to the aqueous phase of 
1 5|xl of 2M sodium acetate (pH 4.5) and 300|xl 100% ethanol followed by 
standing at -70 °C for 15 mins. The pellet was then collected by spinning for 
15 mins at full speed in a microcentrifuge and washing in 70% ethanol
SO
before the pellet was dried for 5 mins. in a vacuum dryer. 4|il of loading 
buffer(appendix 1) was added before the sample was denatured at 92°C for 
2 mins, quenching on ice and loaded on a 5.75% denaturing sequencing 
gel on the ABI automated sequencing apparatus.
2.29.4 Running of Sequencing Reactions on an ABI automated Sequencer.
5.75% denaturing gels were prepared and run by Robert McFarlane 
according to the parameters suggested by ABI. The gel matrix was 
degassed before pouring onto plates which had been stringently cleaned to 
avoid smearing and background mess which could be misinterpreted by the 
scanner as fluorescent signal. The gels were prerun before loading and 
scanned for signal artefacts caused by dirt on the plates.
2.29.5 Analysis of Sequencing Gels.
The model 373A DNA sequencer system consists of two separate 
instuments, the 373A sequencer and a Mackintosh Centris 650 computer. 
The sequencer comprises of the microprocessor-controlled electrophoresis 
and fluorescent detection system and the computer receives data from the 
sequencer and processes it. Data was presented in several forms but was 
collected in the form of analysed data which was presented as a 
chromatogram with four coloured peaks representing the four bases with the 
base designation also given above each peak. Heteroduplexes 
represented by double peaks were identified by eye and confirmed by 
sequencing in the opposite direction.
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CHAPTER 3
RESULTS
3.1 Lesch-Nvhan Syndrome.
3.1.1 Optimisation of the PCR reactions.
The initial stage of the mutation detection methods used in this study 
involved amplification of particular segments of the HGPRT gene. The 
amplification reactions required optimisation, involving modification of one of 
two parameters, the reaction components and the cycling parameters. As 
the oligonucleotide primers used were those suggested by Gibbs et al., 
(1990), the initial conditions used were as suggested and these are 
described in section 2.5. The PCR initially used the primer set which 
amplified exon 1 and these conditions did not produce an amplification 
product. Various parameters were then modified as follows.
a) Alteration of the Reaction Components.
The reaction components in the PCR reaction were altered 
individually while other components remained constant. Primarily the 
reaction buffer, dNTP stock solutions and Taq polymerase were checked by 
using several different stock solutions of each. No amplification was seen 
using any combinations of solutions.
The DNA quality and concentration were then analysed. Increasing 
concentrations of DNA from 50 ng to 1j(rtg were used. No amplification at 
any concentration was seen . The quality of DNA was then under suspicion 
and aliquots of the control samples being used for amplification were run on 
a 1% agarose gel. The DNA did not appear to be degraded. To rule out the 
possibility of contaminants in the DNA which would inhibit amplification such 
as phenol from the DNA extractions, aliquots of DNA from colleagues which 
were known to be good templates were used in the reaction and still no 
amplification was seen.
Gibbs et al. (1990), suggested the addition of 6.7mM magnesium
chloride to the reaction mix. The reactions were then carried out in the
absence and with increasing concentrations of magnesium chloride to a
fina l va lue  of 5x th e |S u g g e s te d  value. No am plification  w a s  seen  a t any  
manufacturers
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concentration. It was also suggested that the cosolvent dimethyl sulfoxide 
be included in the PCR reaction. Cosolvents have been shown to overcome 
some of the difficulties seen in a PCR reaction due to the hindering effects of 
secondary structures which arise due to G/C rich DNA. Varying 
concentrations of DMSO were added to the reaction mix from 1% to 20% 
and still no amplification was seen. Similarly TMAC was added up to a 
value of 10% of the reaction mix and again no difference was noted.
Primer concentration has been shown to be very important to the 
efficiency of the PCR reaction. The primer concentrations were altered an 
values between 10pM and 1/ttM were used with no concentration variation 
producing an amplification product.
The final reaction component to be looked at was the concentration of 
dNTPs used in the reaction mix. The concentration suggested by Gibbs et 
al., (1990), was very high compared to other PCR reactions which were 
working successfully in the laboratory. Therefore the concentration of 
dNTPS were altered and a range of concentrations were used with no 
amplification product being seen.
b) Cycling Parameters.
The modifications in the reaction components were carried out while 
the cycling parameters were held at the suggested temperatures and times 
with an annealing temperature of 57°C. The second set of modifications 
involved varying the annealing temperatures from 52°C to 65°C . 
Amplification did not occur at any of the annealing temperatures. Different 
reaction mixes were then tried at the range of temperatures and cycle 
numbers and still no amplification was seen.
The initial publication used a Perkin-Elmer Cetus thermocycler for the 
reactions and the previous described manipulations were carried out on a 
Techne 1. The reactions were then tried on a Perkin-Elmer/Cetus and a 
Techne PH3 but no amplification occured.
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c) Oligonucleotide Primers.
The lack of amplification appeared to be due to the deficiency of a 
major component of the PCR reaction mix. One of the most important 
components are the oligonucleotide primers and two further possibilities 
existed for a deficiency in this component. Firstly, the primer sequence could 
be wrong in either a human error in ordering of the primers or in a mistake in 
their manufacture. Secondly, the primers may have been impure, degraded 
or contained many incomplete sequences making them unsuitable for 
amplification. To exclude these possibilities the primers were firstly run on a 
5% denaturing polyacrylamide gel to identify either a discrete band if the 
primers were of a pure quality and not degraded or a smear if they were of 
poor quality. A discrete band was seen and is shown in figire 3.1 .
If the primer sequence was wrong or not compatible for amplification 
any range of amplification conditions could be tried and no amplification 
would ever occur. Therefore a second primer sequence was manufactured 
and purified by HPLC and these primer sequences flanked exon 2. Different 
reaction conditions and cycling parameters were used with the new primer 
set and on decreasing of the dNTP concentration and using an annealing 
temperature of 57°C an amplification product of the correct size was seen on 
one occasion. However, this amplification was not reproducible although a 
degree of smearing was seen on the gel after electrophoresis of several 
reaction mixes and conditions (figure 3.2) . This suggested that some non­
specific amplification had occured using the exon two primer set and that 
another critical reaction component other than the primers used was 
inhibiting amplification.
d) PCR Buffer.
Gibbs et al. (1990), suggested an unusual reaction buffer for use in 
the PCR reaction which was made up in the laboratory and was not similar 
to the composition of the buffer supplied with the Taq polymerase. Therefore 
either the buffer had not been made correctly which was unlikely as several 
different batches were prepared and used ,or the buffer was not suitable for 
amplification under the conditions used. Parallel reactions were set up 
using both exon one and two primer sets at different annealing temperatures 
with low and high dNTP concentrations and with the suggested laboratory
Figure 3.1: Electrophoresis o f HGP oligonucleotide primers.
Both lanes labelled 1 represent the sense and antisense 
exon 1 primers and both lanes labelled 2 represent the sense 
and antisense exon 2 primers.
Figure 3.2 : Products of a pre-optimised PCR reaction run 
on an agarose gel. Lanes 1-6 represent amplification of 
exon 2 of the HGPRT gene, using different PCR parameters 
and conditions. Lane 7 contains the 1kb ladder.
made buffer and with the reaction buffer supplied by Boeringer. At an 
annealing temperature of 56°C a band of the correct size as well as non­
specific products were seen with exon 2 primers, with the low concentration 
dNTP mix and the Boeringer supplied buffer . The exon 1 amplification 
reaction however showed many non-specific bands of the wrong size (figure 
3.3) . Different annealing temperatures were used for amplification of exon 
two and for primers made for exon five and amplification occurred optimally 
at an annealing temperature of 61 °C for all exons except exon 1 which 
would not produce an amplification product of the correct size even with the 
use of new HPLC purified primers. The amplified product of exons two to 
nine are shown in figure 3.4.
3.1.2 PCR Failure.
Despite optimisation, at several stages during the study individual 
exons and all the exons simultaneously failed to amplify on several 
occasions. If one exon failed to amplify while the others showed no such 
problem the amplification could usually be reinstated by either cleaning of 
the primers by ethanol/salt precipitation or if that failed, manufacture of a 
new primer set which was either HPLC purified (Oswell DNA) or purified 
after manufacture in the department by purification through an OPC column 
(ABI). Primers which were manufactured in the department which were not 
purified in such a way were generally unreliable in this PCR reaction and 
produced either non-amplification or became useless after a few freezing 
and thawing events. Therefore the purity and quality of the primers were 
obviously very important to this non-robust PCR.
If all exons failed to amplify simultaneously then all the reaction 
components were checked until the problem area was identified. This 
involved primarily changing the dNTP stock solutions or PCR buffer or Taq 
polymerase. If none of these components were faulty a control template 
DNA which was working for other PCR,s in the lab was used and if the DNA 
template was the faulty component, it was cleaned up by either phenol 
extraction or ethanol precipitation. A further problem area on two occasions 
was a contaminated double-distilled water source. The supply contained 
some form of contaminant which was found to inhibit both restriction enzyme 
cutting capacity and Taq polymerase in the less robust PCR reactions. This 
was found by the reinstatement of amplification following use of bought
Figure 3.3: Agarose gel showing the amplification 
products from a PCR using exon 1 primers after 
optimisation of the conditions. Lane 1 shows the 
non-specific products obtained from the exon 1 
primers and lane L shows a 1kb ladder.
1234567L
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Figure 3 .4: Agarose gel showing amplification products from 
PCR reactions utilising primer sets from exons 2-9. Exons 7 
and 8 are amplified as a single amplification product. Lanes 
1-7 contain exons 2-9 with exons 7/8 as one product shown 
in lane 6. A 123bp ladder is shown in lane L.
bottled ddhteO. The final cause for lack of amplification was contamination 
of the reaction tubes or the tips used to set up the reaction. On two 
occasions these were found to have been contaminated by rust in the 
autoclave. As a positive control for the viability of the reaction components, 
part of the CF gene was amplified. This is a very robust PCR, which if failed, 
indicated a fault with a component which if then altered allowed 
reinstatment of amplification.
3.1.3 Optimisation of Heteroduplex Detection on Hvdrolink Gels.
A protocol for heteroduplex detection using hydrolink gels (HDHG) 
was optimised using a panel of 10 known mutations present in seven 
different exons. The base changes in these mutated exons and the size of 
the amplified fragment which contains them are shown in Table 3.1.
The mutation HGPRT Farnham (C486G) amplification fragment was 
primarily used to establish the optimum conditions. Due to the presence of 
one X chromosome in males a potential heterozygous state was created by 
addition of normal male DNA to the PCR reaction. The conditions 
suggested by Keen et al., (1991), which included an extra
denaturing/renaturing step after PCR of 94°C for 2.5 minutes 0°C for 2 
minutes then room temperature for 60 minutes, were initially used for 
enhancing the formation of heteroduplexes. This methodology did not show 
the presence of heteroduplex bands. Keen et al. (personnel communication) 
then suggested a two step PCR reaction to prevent the formation of ghost 
bands and different methods of heteroduplex formation after PCR were 
assayed. The optimum results were obtained using a two step PCR with a 
final denaturation/renaturation step of 94°C for 30 seconds and 70°C for 1- 
16 hours. Figure 3.5.1 shows the ethidium bromide stained hydrolink gel 
showing the amplified exon of the HGPRT gene containing this mutation 
C486G (HGPRT Farnham) after heteroduplex formation.
The remaining nine mutations were then analysed in a similar way. 
Different parameters were altered to find the optimum conditions for 
detection of each mutation. The optimum thickness of gel used was found to 
be 1.5mm thick, and the mutations were run either on a 20cmx20cm or 
20cmx30cm gel depending on the size of the amplified fragment that 
contained the mutation. Different electrophoresis conditions were also 
applied depending on the size of the fragment and these conditions are 
summarised in Table 3.1
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Figure 3.5.1 : Detection of a heteroduplex on hydrolink gels in 
exon 6 of the Index case with the mutation HGPRT Farnham. 
Lane 1 shows the doublet heteroduplex and homoduplex band 
apparent when control DNA was added to the reaction tube with 
the mutant DNA. Lane 2 shows the single band product of a 
PCR reaction where control DNA was mixed with DNA from a 
normal individual.
Heteroduplex detection using hydrolink gel electrophoresis initially 
detected nine of the ten mutations represented in the panel. The patterns 
obtained are shown in figure 3.5.2a-h. Some of the heteroduplexes were 
less convincing(c and d), and unequal loading of the sample and control 
caused less convincing results(a,e and f). HGPRT Marlow (C527T) present 
in an amplification fragment of 1553 bp in size was not detected at first but 
by using primers which produced an amplification product of 433bp in size 
which contained the mutation.it could be detected (Figure 3.5.3). With 
the majority of mutations a second slightly slower migrating band present 
close above the first was apparent representing the formation of a 
heteroduplex between the mutant and control DNA, for example with C486G 
(HGPRT Farnham)(Figure3.5.1).This is the pattern seen with the majority of 
mutations with the exception of GT288-289(HGPRT Cheltenham) when 
longer hydrolink gels were run and T395C(HGPRT Runcorn). With these 
mutations there were further more slowly migrating heteroduplex bands 
(figures 3.5.2 b and f) which were absent from the controls. No false 
positives were seen in this gene with the panel of known mutations.
3.1.4 Single-Strand Conformational Polymorphism Analysis (SSCP)
SSCP was carried out using the protocol described by Kataki, 
(1992), and each of the mutations identified by HDHG were analysed by 
SSCP in order to compare the two techniques and to identify which would 
be the best as a first screening strategy. None of the ten mutations from the 
initial panel were detected on a non-denaturing gel containing 10% glycerol 
run at room temperature . After modification of the gel running conditions 
two mutations, HGPRT Mashad present in the 572 bp exon 2 amplification 
fragment and HGPRT Marlow present in the 433 bp exon 7 amplification 
fragment were detected when the glycerol concentration was reduced to 5% 
and the gel run at 4°C (Figure 3.6 and 3.7). However these mutations were 
not consistently detected.
The remaining mutations could not be detected by this protocol so 
three exons (3, 5 and 7) were digested with relevant restriction enzymes , 
labelled and subjected to SSCP analysis. The results obtained for each 
exon were confusing and extra bands were apparent even in control lanes 
making interpretation of the results difficult. The detection rates of the two 
protocols, HDHG and SSCP are summarised in figure 3.8.
Figure 3.5.2 : Hydrolink gels showing heteroduplex detection 
of previously described mutations. The following mutations 
were detected and are shown In figures a-h respectively ;(a) 
exon 2 of the Index case with the mutation HGPRT Mashad, 
the index case DNA is in lane 2 and normal DNA in lane 1 
; (b) exon 3 of the Index case with the mutation HGPRT 
Cheltenham, the Index case DNA Is shown In lane 1, with 
normal DNA in lanes 2 and 3; (c) exon 3 of the index case 
with the mutation HGPRT Codlcote, the Index case DNA Is 
shown In lane 1 and normal DNA In lane 2;(d) exon 3 of the 
index case with the mutation HGPRT Banbury and the 
index case DNA Is shown In lane 1, with normal DNA In lane 
2; (e) exon 3 of the Index case with the mutation HGPRT 
Shefford, the index case DNA is shown in lane 1, with 
normal DNA In lane 2; (1) exon 5 of the Index case with the 
mutation HGPRT Runcorn,the index case DNA Is shown In 
lane 2, with normal DNA in lane 1; (g) exon 7 of the index 
case with the mutation HGPRT North Mymms,the index case 
DNA Is shown In lane 1, with normal DNA In lane 2;(h) exon 
9 of the index case with the mutation HGPRT Reading, the 
Index case DNA is shown in lane 1, with normal DNA in lane 
2. The DNA from both the Index case and the normal DNA Is 
mixed with a control DNA sample. The heteroduplex bands 
are indicated by an arrow and the actual base changes are 
shown In table 2.4.
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Figure 3.5.3: Hydrolink gels showing non-detection and detection 
of the mutation In exon 7 of the Index case with the mutation 
HGPRT Marlow in two different sized PCR amplification fragments. 
Lanes 1 and 2 show the affected and control samples respectively, 
after amplification with normal DNA using primers which produce 
a PCR product of approximately 1.5 kb. Lanes 3 and 4 show the 
affected and control DNA samples respectively, after amplification 
with normal DNA, using primers which produce an amplification 
product of 433bp.
Figure 3 .6 : Autoradiograph showing the results of SSCP 
analysis on exon 2 from the Index case with the mutation 
HGPRT Mashad (lane 3) aginst exon 2 from normal individuals 
(lanes 1,2 and 4). The band shift Is indicted by an arrow.
Figure 3 .7: Autoradiograph showing the results of SSCP 
analysis on exon 7 of an index case with Lesch-Nyhan 
syndrome. This shows exon 7 of the index case with the 
mutation HGPRT Marlow. The index case is shown in 
lane 2 with a band shift indicated by an arrow, relative 
to two normal males shown In lanes 1 and 3.
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Figure 3.8: Graph showing the relative efficiency of the 
two mutation screening strategies(SSCP and HDHG) In 
detecting ten known mutations in the HGPRT gene.
The solid red box Indicates the base changes which were definitively 
detected by the HDHG protocol and the shadedred box indicated base 
changes which were detected butwhere the heteroduplexes were less 
clear and may be missed If the presence of the mutation was not known.
3.1.5 Optimisation of Chemical Cleavage of Mismatches.
This protocol was optimised using two mutations, The cystic fibrosis 
G551D mutation which results from a G to A substitution and a mutation in 
intron 44 of the dystrophin gene (Kataki,1992) which also resulted in a G to 
A substitution. These changes resulted in an A:C mismatch which should be 
detected by piperidine cleavage after modification of the mismatch using 
hydroxylamine.
The original protocol based on that suggested by Cotton et al., (1988), 
is described in 2.19.1, where the probe was prepared by labelling of a PCR 
product and was applied to the G551D mutation after PCR of the mutation 
containing region . However, neither homoduplex or cleaved heteroduplex 
band were seen in the control or test DNA lanes. Different quantities of 
labelled probe of 1x - 6x the suggested levels were then mixed with 
corresponding quantities of unlabelled test DNA and the protocol repeated. 
On this occasion uncleaved bands were seen in the control and test lanes 
with the strength of the signal varying with the quantity of probe added 
(figure 3.9. lanes 1). However, no cleavage product was seen and 
increased quantities of DNA present were presumed to be interfering with 
the reaction inhibiting heteroduplex formation, modification and/or 
cleavage.
Alternative methods for probe preparation involving labelling of the 
primers before PCR and incorporation of radioactivity during PCR were then 
used in order to obtain a more efficiently labelled probe. These are outlined 
in 2.19.2. CCM was carried out using these probes and while uncleaved 
bands were visible on the autoradiograph at lower concentrations of probe 
still no cleavage was seen.
A modified CCM protocol was applied as is outlined in 2.19.2., using 
probes which had been made by incorporation of 32Pa-dCTP along the 
length of the probe during PCR. This altered protocol using siliconised 
tubes and different methods of probe preparation yielded two cleavage 
products after CCM and the autoradiograph is shown in figure 3.9., lanes 2. 
The protocol was repeated for the DMD mutation using a probe which had 
been made by PCR using yATP end-labelled primers and cleavage occured 
with only one cleaved band being visible as expected as the probe was end-
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Figure 3.9 : Autoradiograph of CCM analysis of the cystic 
fibrosis G551D mutation using two different CCM 
methodologies. The lanes numbered 1 show CCM using 
method 1 described in chapter 2 and the lanes numbered 
2 show CCM using method 2 as described in chapter 2. 
The probe was internally labelled , with the uncut 
homoduplex bands and the cleavage products being 
Indicated by arrows. A labelled 1kb ladder is shown 
In lane L.
labelled at only one end (figure 3.10.). This method of CCM was then 
elected for use. Once again, unequal loading of the control lanes relative to 
the test sample in all the CCM results led to less clear results
3.1.6 Screening for Molecular Pathologies in Lesch-Nvhan Syndrome.
After optimisation of the various mutation detection protocols a 
strategy for detection of the molecular pathologies responsible for Lesch- 
Nyhan syndrome in 13 families where the mutation had not been 
characterised , was developed and is outlined in figure 3.11. After screening 
for large length mutations in individual exons of the HGPRT gene by PCR, 
the mutation containing exon was identified by heteroduplex detection using 
hydrolink gels before confirmation was obtained by CCM analysis and the 
exact nature of the mutation detetmined by sequencing.
3.1.7 PCR Amplification of Individual Exons of the HGPRT Gene.
The individual exons of the HGPRT gene were amplified as 
described in 2.5 and the products sized on an agarose gel against a 1 kb 
ladder. The results of the PCR amplification from 13 families with Lesch- 
Nyhan syndrome where the molecular pathologies were unknown are 
shown in Table 3.2. The individual exons excluding exon 1 from 11 
pedigrees were all analysed and from two pedigrees(10208 and 10213) 
there was insufficient DNA for amplification of exons 7/8 and 9. DNA from 
the index case was analysed where possible with the exception of 
pedigrees 10426 and 10208 where there was no available DNA from the 
index cases and the maternal DNA was used. For pedigree 10426 the 
mother was an obligate carrier.
Three abnormal PCR patterns were found. The DNA from the index 
case from pedigree 10427 failed to amplify for exons 7/8. An internal control 
was successfully simultaneously amplified and still no amplification product 
for exons 7/8 was seen. Different primer sets were designed and 
manufactured for amplification of exons 7 and 8 individually to discover 
whether either of the exons were deleted. Both primer sets produced an 
amplification product of the correct size. The original primer set was then 
used for amplification in conjunction with the new sets in an attempt to 
establish if a mutation was present at one of the primer sites. Amplification
6 0
Figure 3.10: Autoradiograph of CCM analysis of a polymorphic 
site in Intron 44 of the dystrophin gene. Method two was used 
with increasing quantities of a S’-end-labelled probe added to 
the test DNA (lanes 1). A normal DNA sample was mixed with 
the probe and analysed and the results shown in lane C. A 
labelled 1kb ladder is shown In lane L. The cleavage product 
Is shown by an arrow.
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Figure 3.11: Schematic representation of the strategy for 
detection of molecular pathologies In the HGPRT gene.
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occured with all combinations of primer sets with the exception of the 
original exon 7/8 sets used together. These results are shown in figure 3.12.
The index case from pedigree 7293 showed an amplification product 
for exon 4 that was much larger than the expected product. This was sized 
on an agarose gel and was found to be approximately 370bp larger than 
expected (figure 3.13.). The obligate carrier from pedigree 10426 showed 
the presence of an extra band of a larger than expected size as well as the -  
band of normal size, after amplification of exon 3. This band was not 
consistent but appeared in 3 of 6 amplifications. All other exons tested from 
the remaining pedigrees produced amplification products of a normal size.
3.1.8 Heteroduplex Detection in the HGPRT Gene Using Hvdrolink Gels.
Exons 2-9 from the 13 individuals with Lesch-Nyhan syndrome were 
screened by HDHG for the presence of heteroduplexes indicative of 
nucleotide sequence changes. DNA was available for only a portion of the 
index case and where DNA was not available the maternal DNA was 
analysed (Table 3.3).
Heteroduplex bands were clearly present in four individuals, exon 2 
of the index case from pedigree 7292, exon 6 of the index case from 
pedigree 7291, exon 3 from the pedigree 10213 and exon 5 from the
I mother of the index case from pedigree 10195 (figure 3.14. a, b, c and d respectively). Several other exons from other pedigrees showed bands that were suspicious but where a definite extra band was not clear. The other pedigrees showed no abnormal or heteroduplex bands but exons 7/8 and 9 were not analysed in some due to lack of DNA, and pedigree 7293 which 
had a larger exon 4 amplification product after PCR also showed no 
heteroduplex bands when the other exons were examined. For the 
pedigree 10427, no abnormal heteroduplex bands were seen. cDNA was 
available for the index case from this family and when run on an agarose gel 
was seen to be approximately 60bp larger than a normal cDNA. Once 
again, unequal loading of the control DNA relative to the test sample 
devalued the results particularly figures 3.14b and d.
(51
Figure 3.12: Ethidium  stained agarose gel showing results 
of PCR am plification of exons 7 /8  from the Index case from  
pedigree 10427 using different prim er sets. Lanes L show a 
1kb ladder. Lanes 1 and 2 show am plification using the exon 
7/8 prim er set described by Gibbs et al., 1990, am plifying  
control DNA and the index case DNA respectively. Lanes 3 
and 4 show am plification of exons 7 and 8 Independently, 
from  the index DNA using primers designed by u s .________
1 2 3 L
larger B y­
product
Figure 3.13: Ethidium bromide stained agarose gel showing 
amplified exon 4 from a normal Individual (2) and the Index case 
(1) from the pedigree 7293. A 1kb ladder is shown in lane L.
o IT—** © ©©X
r-f © —r COr4* O ©
© Q. <C ©cr -n
© — ©3 CD crCL X ©co
r+ZT
O’©3
1o
© Q.> © ©
© 3©© •■o<cn COc co'cn 3 ■T3 CL
o' o' 1
o'c:CO
a©© 3'CL
© o'Z ©c
©
H r+©CO CO
5' ■O ©CL o'
o’ o' ©© c 3 'r+© w CQ© cr ©
r+ ©zr Z3 O’© CL ©r+ 3
E?
r-+zr Q.
© ©
©X co'
o r+ 5’ZJ zr CL
o' o'< 7s ©©cn © —*
r+©CO
3 r-¥zr r-yOr—
fB^B
©3
3"
©
© 3 ■0wr-^©Q.
O -«
3
-» © CO CD
CO
CO
cn ©CO
8 3
o
CO
Q . O ’ O  * <
 — • m
r+© Q.=5. C CO 03
O3
CO
©
-o
©CO
©3o
CD
© r t
o  CO 3_ _
'C 3O -, 9:CD 3 <
o a s•=1 © c
3 —03 ©
i f
o
PO
CO
oro
ooo
*
-siro
CD
-virocoro
-Nlrococo
orooro
o
ro~nI ooCO
-nIroco
*
o-p^roo>
*
CO
CJ1
*
00cn#■
CO
*
ro m 
x  
O
mx
O
CO
m
X
O
mx
O
cn
m
X
o
O)
m
is °  00 z
mx
O
Z
CO
Figure 3.14: Hydrolink gels showing the detection of 
previously unknown mutations responsible for Lesch-Nyhan 
syndrome in 4 families. Both the Index case and control DNA 
samples were mixed with normal DNA. (a) exon 2 of the index 
case from the pedigree GLA 7292 (lane 2) and a normal exon
2 (lane 1); (b) exon 6 of the Ind9''case from the pedigree 
GLA 7291 (lane 1) and a normal exon 6(lane 2); (c) exon 3 of the 
index case from the pedigree 10213(lane 2) and a normal exon
3 (lane 1); (d) exon 5 of the mother of the Index case from the 
pedigree 10195 (lane 2) and a normal exon 5 (lane 1 ). The 
Heteroduplex bands are indicated by an arrow.
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3.1.9 Detection of Molecular Pathologies in the HGPRT Gene Using CCM 
Analysis.
Exons 2-9 were amplified from individuals from all the 13 pedigrees 
where DNA was available and CCM carried out after modification of 
potential mismatches with both hydroxylamine and osmium tetroxide. The 
results are summarised in Table 3.4.
Due to the nature of the CCM , degradation of probe, non-specific 
cleavage of regions of exons (particularly exon 5 and 7) and inadequate 
labelling of probe, the results were often difficult to interpret. The non­
specific cleavage product constantly seen for exon 7 and the excessive 
background signals often obtained, particularly with larger amplification 
products, are shown in figures 3.15 and 3.16 . A definite cleavage product 
was seen in the following cases : exon 2 of the index case from pedigree 
7292 after modification with hydroxylamine; exon 6 of the index case from 
pedigree 7291 after modification with hydroxylamine and exon 5 of the 
mother of the index case from the pedigree 10195 after modification by both 
osmium tetroxide and hydroxylamine; (Figures 3.17 a-c). Further individuals 
showed possible cleavage products and these are summarised in Table 3.4.
3.1.10 Optimisation of Manual Sequencing and Mutations Found in the 
HGPRT Gene.
All exons of all individuals which showed a possible heteroduplex on 
hydrolink gels or showed a probable cleavage product after CCM analysis 
were amplified by an asymmetric PCR to obtain a single-stranded product 
for direct sequencing. The sequences obtained were compared to the 
expected sequence published by Edwards et al., (1990).
Asymmetric products could not be obtained for all exons, with exons 
2, 4, and 6 producing single-stranded products frequently while a single­
stranded product appeared difficult to obtain for exons 3,5,7/8 and 9. A 
typical succesful asymmetric PCR showing the presence of single and 
double stranded DNA is shown in figure 3.18. Where a single-stranded 
product could not be obtained several modifications were applied to the 
asymmetric PCR in an attempt to obtain a product. Primarily the primer ratio 
of the limiting primer was altered and values of 1: 1/25, 1/50, 1/75, 1/100,
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Figure 3.15: Autoradiograph of CCM analysis of 
exon 7 of the HGPRT gene showing a non-specific 
cleavage product in all lanes. Lanes 1-4 are family 
members from the pedigree HPRT North Mymms 
and lane 5 is a control sample.
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Figure 3.16: Autoradiograph of CCM analysis of 
exon 3 of the  HGPRTgene. Lane 1 shows the
analysis of exon 3 of the index case from the 
pedigree HPRT Codicote while lanes 2-4 show 
the cleavage of exon 3 from normal individuals. 
The non-specific cleavage products are indicated 
by arrows.
Figure 3.17: Autoradiograph of CCM analysis showing 
cleavage In three exons In three Individuals from families 
with Lesch-Nyhan syndrome... Figure A lane 1 shows 
cleavage after hydroxylamine modification of exon 2 of 
the Index case from the family Gla 7292 annealed to an 
internally labelled probe. A labelled 1kb ladder was run 
in lane L. Figure B, lane 2 shows cleavage following 
hydroxylamine modification of exon 6 of the Index case 
from family GLA 7291 annealed to an end-labelled 
probe. A labelled 1kb ladder was run in lane L and a 
control sample annealed to the same probe and treated 
in an identical manner to the index case DNA, is run in 
lane 1. Figure C, lane 2 shows the cleavage following 
modification by osmium tetroxlde of exon 5 from the 
mother of the index case from the pedigree 10195 after 
annealing to an end-labelled probe. A control DNA sample 
annealed to the same probe and treated Identically to the 
mothers sample, Is shown in lane 1.
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Figure 3.18: Ethldlum bromide stained agarose gel showing 
the single and double-stranded DNA generated by an 
asymmetric PCR using exon 2 primers. Lane 1 shows the 
products obtained when exon 2 sense primers were In 
excess and lane 2, the products obtained when exon 2 
antisense primers were In excess. Lane 3 shows the 
products generated from an asymmetric PCR using 
exon 2 primers with the antisense primer In excess 
and with a higher ratio of antisense to sense primer.
1/150, 1/200 were used. Secondly, the DNA from the original PCR reaction 
used as a template for the asymmetric PCR was used in a normal PCR 
reaction to ensure that the DNA was suitable to allow amplification. Figure 
3.19. shows the results of these modifications with the asymmetric PCR for 
exon 7. No bands single or double-stranded were seen after asymmetric 
amplification using any primer ratios, while a double-stranded product was 
seen when a normal PCR using equal primer concentrations was carried out 
using the eluted DNA as a template. A similar situation was apparent with 
all the attempted exon 3 asymmetric PCR’s. When primers amplifing exon 5 
were used for asymmetric PCR a smear is consistently seen but no clear 
single or double-stranded bands are present. When used as a template for 
sequencing no sequence was ever seen using this product.
For the exons where a single-stranded product was obtained , 
sequencing was primarily attempted using the same primers which were 
used for the PCR reaction. Sequence data was obtained only for exon two . 
Internal primers were then designed (Table 2.1) and some sequence data 
was obtained for exons 6 and 4. Where an exon would not produce an 
asymmetric PCR product, other strategies were attempted to obtain 
products which could be sequenced including utilisation of double-stranded 
PCR products as a sequencing template and phosphorylation of one primer 
in a PCR reaction with the product then being digested with a phosphatase 
in an attempt to obtain a single-stranded product. Double-stranded 
sequencing produced no sequence data while the phosphatase approach 
produced a small quantity of very poor sequence in some of the exons 
tested. Formamide was also used in the sequencing reactions but this did 
not improve the sequence obtained. An asymmetric product could not be 
obtained from the double-stranded cDNA from pedigree10427.
Sequence changes were found in 3 pedigrees. The index case from 
the pedigree 7291 had a 1 bp deletion in exon 6, namely a T deleted at 
position 462 (figure 3.20) which would result in a premature termination of 
transcription in exon 7 and therfore the production of a truncated protein. 
There was no DNA remaining for clarification of this mutation by automated 
sequencing and the manual sequence is shown . Sequence could only be 
obtained for one strand of the exon. However a heteroduplex band was 
clearly seen in exon 6 of the index case and the position of the deletion is 
consistant with the size of the cleavage product after CCM analysis. The
FT
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Figure 3.19: Ethldium bromide stained agarose gel showing the 
products of a symmetric and asymmetric PCR amplification 
using exon 7 primers. Lane 1 shows an aliquot of the eluted 
template DNA run out on the gel, lanes 2-5 show different ratios 
of the excess to limiting primers from 1:25 to 1:100. Lane 6 
shows the product of a symmetric PCR using exon 7 primers 
with the template shown in lane 1 used as the template for this 
reaction. A Ikb ladder Is shown In lane 7.
EXON 6 EXON 7
NORM: DIIDTGKTMQTLLSLVRQYNPKMVKVASLLVKRTPR 
AFFECT: D11DTGKTMQTLLSLVRQYNQRWSRSQACW*KGP
Figure 3.20: Autoradiograph of part of a gel showing the manual 
sequence of the sense strand of exon 6 from the index case with 
the mutation HGPRT Gla 7291. The gel shows a deletion of a T 
nucleotide at position 462 of the HGPRT gene. The normal 
sequence is given In column N, the mutant sequence in 
column M. The altered protein sequence showing the 
premature stop codon is also shown.
index case from pedigree 7292 had a single G to A nucleotide substitution at 
position 134 in exon 2 which would result in a substitution of a lysine for an 
arginine at this position. This mutation was also sequenced using the 
automated sequencer which gave a better resolution of the mutation 
originally identified by manual sequencing. The sequence of the index case 
is shown in figure 3.21. Sequence information was available for both strands 
and confirmed the mutation. This mutation although not resulting in a 
truncated protein or a change in the charge of the amino acid, results in a 
change in the last coding base of exon 2. This may lead to a splicing 
abberation in the RNA, but no RNA was available from this family to confirm 
this by the identification of an altered cDNA. The change is unlikely to be a 
polymorphism as it was not present in any of the other families sequenced 
but is present in other female family members.
For the pedigree 7293 where a larger exon 4 product was seen, 
despite obtaining an asymmetric product and obtaining a sequence from a 
control DNA sample, sequence data could not be obtained using manual 
sequencing. This was due to the sequence of the exon involving runs of 
identical bases which thwarted the sequencing chemistry. Further, the 
larger than normal cDNA from pedigree 10427 could not be sequenced 
manually as an asymmertic product could not be obtained for sequencing.
3.1.11 Optimisation of Automated Sequencing Chemistry and Mutations 
Found in the HGPRT Gene.
The automated sequencing chemistry involving cycle sequencing 
was optimised for the HGPRT gene using the HGPRT GLA 7292 mutation 
in the index case as a control. This exon sequenced well and the mutation 
was clearly identified (figure 3.21 ). The mother of the index case, a 
heterozygote was then sequenced and the hererozygote peak was 
identified . The samples where a mutation had been indicated but could not 
be identified were then sequenced using the same primers as were used for 
PCR. The insertion in exon 4 of the index case from the pedigree 7293 
could not be sequenced in either direction using this chemistry due to the 
preva lence of strings of identical bases in the exon. The mother of the index 
case from pedigree 10195 which showed a heteroduplex band in exon 5 
was sequenced. However this exon did not produce a clean sequence and 
a real double peak could not be identified from amplified background noise
6 4
A/G substitution
sense normal sequence : TATGGACAGGTAAG 
sense mutant sequence : TATGGACAAGTAAG 
heterozygote a/g
B
Figure 3.21 : Part of a chromatogram from an automated 
sequencer showing the mutation In exon 2 from the Index 
case from the family Gla 7292. The sequence of the sense 
strand is shown in A with the position of the A/G substitution 
Indicated. The mutant and normal sequences are shown In 
figure B.
At nucleotide N at base position 285, the double 
peak(A/C) ,is due to the sequencing chemistry and is 
often seen in sequences and is read as a chemistry 
artefact.
which resulted due to the poor quality of the template. However it did appear 
that no insertions or deletions were present as these can clearly be 
identified using automated squencing chemistry. This mutation could not be 
further characterised and the possibility that this change was a 
polymorphism could not be excluded.
The index case from pedigree 10427 showed abnormal PCR 
amplification patterns in exon 7. cDNA was available for the index case and 
this was shown to be approximately 60bp larger than the normal cDNA. This 
was sequenced using the automated sequencer chemistry using internal 
primers close to exon 7. The sequence shown in figure 3.22 contained a 
60bp addition. When this sequence was compared to a sequence database 
it was shown to be an alu repeat which had been inserted between exons 6 
and 7. As this region could not be sequenced from the DNA due to the 
amplification problems, the exact position of the insertion in the DNA or the 
possible splice site alterations could not be pinpointed. However, no 
abnormalities were seen in exon 6 or the following intronic regions so it is 
most likely that the abnormality occured in the region of exon 7. This change 
is very significant and the large size of the insertion will obviously lead to a 
truncated protein and probably alters the entire folded conformation of the 
protein. DNA was not available for automated sequencing from other 
pedigrees.
3.1.12 Carrier Detection in the HGPRT Gene.
3.1.12. 1 Linkage Analysis Using a Tetranucleotide Repeat.
A PCR based strategy was used for linkage analysis in 9 pedigrees 
where DNA was available from key family relatives. Edwards et al., (1991) 
reported the existence of a tetranucleotide short tandem repeat located 
within the HGPRT gene and oligonucleotide primers were manufactured 
which were complementary to the sequences flanking this repeat. The 
primers were 5’-end labelled using y-ATP and PCR carried out according to 
the conditions described in 2.12 before the allele length were resolved on a 
denaturing polyacrylamide gel.
The PCR reaction was very efficient and product bands of the correct 
size were identified by comparison of the products to a labelled 1 kb ladder.
Figure 3.22: Part of a chromatogram from an automated 
sequencer showing the sequence of the sense strand of 
the cDNA from the Index case from the pedigree 10427. 
Figure A shows the chromatogram with the insertion 
begining at base 130. Figure B shows the sequence of 
the normal and mutant cDNA with the Insertion being 
highlighted in italics. Figure C shows the position of the 
insertion into the cDNA of the HGPRT gene in this family.
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Normal cDNA: GGTCGCAAGCTTGCTGGTGAAAAG 
Mutant cDNA : GGTCGCAAGGTATATGCTGTGGAA
TTGAGATAGACTGGTTCGTGAGCG
AGAGATTTTGTGTTGCCACAGCTTG
CTGGTGAAAAG
B
EXON 6 EXON 7
AAGGTCGCAAG ICTTGCTGGTGAAAA
t
Insertion point
C
No non-specific product bands were seen. The gels were run for varying 
times to obtain optimum separation of the alleles and the majority of alleles 
could be separated by running the gels at 2000 Volts for 6-8 hours. 
Autoradiography was carried out for varying lengths of time depending on 
the intensity of the signal obtained after 2 hours. Three different PCR 
reactions were carried out and at least three different gels run for each 
linkage analysis before results were reported.
DNA was available from the necessary relatives in 9 families with an 
index case with Lesch-Nyhan syndrome. The 9 families were the pedigree 
numbers: 10202, 10189, 7293, 10188,10185,10196, 10198 , 7292 and 
10195. The pedigrees of eight of the families and the autoradiographs 
showing the alleles amplified from the family members are shown in figures
3.23 a-h. At this stage in the project it was not known which of the index 
cases were affected as the result of a new mutation.
In families 10202, 10189, 7293, 10188 (figures 3.23.a,.b,.c and .d 
respectively), the mothers are informative and female relatives who have 
inherited the presumed affected allele can be clearly identified. In families 
10185 and 10196 (figures 3.23e and 3.23f), the grandpaternal and 
grandmaternal genes help to establish the inheritance pattern to the aunts of 
the index cases and allows further clarification of their carrier status. In family 
10185 (figure 3.23e), although DNA was not available from the 
grandparents their alleles could be determined (presuming paternity is as 
expected) by looking at the alleles inherited by the mother and aunt on the 
index case. This shows that the presumed affected allele designated allele 
A, although inherited by the aunt , is of grandpaternal origin. As the 
grandfather had only one X-chromosome and was not affected by Lesch- 
Nyhan syndrome, it can be presumed that either the mother of the index 
case is the originator of the mutation or that the boy himself is a new 
mutation, indicating that the aunt is not a carrier unless the grandfather was 
a gonadal mosaic, which is a less likely possibility. The DNA was available 
from the grandparents of the family 10196 (figure 3.23 f) . Again the 
presumed affected X-chromosome(allele A) is of grandpaternal origin 
therefore despite having inherited the allele which cosegregates with the 
disease the aunt is probably not a carrier, barring the possibility of gonadal 
mosaicism. The sisters also appear not to be carriers as they have inherited 
the B allele which does not segregate with the disease.
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3.23: Autoradiographs showing linkage analysis In eight 
Lesch-Nyhan families using a tetranucleotide repeat 
located within the HGPRT gen. In each family the pedigree 
Is shown, with the lanes corresponding to the designated 
number of the family member given in the pedigree. The 
allele status of the Individual Is also shown. Figures a-h 
represent pedigrees 10202,10189,7293,10188,10185,
10196,10198 and 7292 respectively.
3 4 5
4 2 5
^  allele A
16 5 4 3 2 1
allele c
allele B 
alleH  A' * > '■  £  . ,n-'
AD B D BA BC A
Figure 3.23.b
11 2  3 4
AB B A AB
ALLELE A
ALLELE B
Figure 3.23.C
o
2
1
1
AB A AB BB B
allele A
allele B
1
AB AB AB BB B
allele A 
allele B
Figure 3.23.d
1 2  3 4
allele A  
allele C 
allele B
CB AC A AB
Figure 3.23.e
13 4 5
1 3 4 2 5 6 7
allele A 
allele B
AB A BB AB BB AB AA
Figure 3.23.f
1
FAIL
3 4 5 6
1
A ALLELE 
B ALLELE
AA AA AB A AA AA
Figure 3.23.g
r2 3
I  -  ♦
ALLELE A
AB A
Figure 3.23.h
In family 10198 (figure 3.23.g) the maternal and grandmaternal 
alleles are homozygous and are therefore uninformative as was the case 
with family 10195(results not shown). With family 7292 (figure 3.23.h) the 
paternal DNA is not available making it uncertain which allele has been 
inherited from the mother.
The remaining families could not be analysed in this way due to the 
lack of DNA from key family members.
3.1. 12.2 Carrier Detection Using Direct Mutation Detection in the HGPRT 
Gene
Where DNA was available direct mutation detection strategies were 
employed to further strengthen the carrier assignments designated by the 
linkage analysis. This was the case with eight pedigrees where DNA was 
available for at least some of the female relatives including pedigrees: 
10196, 7292, 10188, 10195, 10199, 10197, 7293, 10198.
The results from these analyses are shown in figures 3.24-31. Figure
3.24 shows the hydrolink results from a long and short gel from all the 
available female family relatives and the CCM results from some of the 
female relatives of the index case, with the mutation HGPRT Cheltenham 
(pedigree 10196). The sequences generated from the automated sequencer 
for some key female relatives are also shown in figure E. The linkage results 
are shown in figure 3.23.f. From the absence of heteroduplex bands in all of 
the female relatives with the exception of the mother of the index case (6), it 
is clear that only she is a carrier. The CCM results confirm this finding with a 
cleavage product only being seen in the mother of the index case. These 
results support the linkage results and as both the aunt and cousin of the 
index case inherited the grandpaternal allele, the possibility of gonadal 
mosaisism in the grandfather resulting in the aunt (2) being a carrier is 
negligible. To rule out this possiblity and to confirm the other data, the DNA 
from the mother(6) ,sister (4) and aunt(2), was sequenced . One sister only 
was sequenced as the linkage data shows that both sisters carry the same 
alleles and hence the same chromosomes. The mother clearly has the 
mutation while the others show a normal sequence, supporting the data 
obtained from the other protocols. The written sequence from the index case 
and a normal individual is also shown.
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fFigure 3.24 - 3.31: Carrier detection in females from eight 
families with Lesch-Nyhan syndrome.
Figure 3.24. : Carrier detection in exon 3 of the family HGPRT 
Cheltenham. Figure A shows an ETBR stained hydrolink gel 
with the results of heteroduplex detection analysis on female 
family members available while figure B, shows a 30cm gel 
loaded and run with a different PCR reaction using the DNA from 
the family members. The lane numbers correspond to the 
numbers beside the individuals in the pedigree and the 
heteroduplex and homoduplex bands are indicated by arrows. 
On the longer gels second slower migrating bands are 
sometimes apparent with this mutation and these are 
indicated by arrows. Figure C, shows the results of CCM 
analysis on the mother of the Index case (lane 1) and the 
grandmother (lane 2) and aunt (lane 3) of the Index case, 
after modification of the duplexes formed with osmium 
tetroxlde. The probe was Internally labelled and the arrows 
Indicate the cleavage products. A partial family pedigree Is 
shown in figure D. Figure E, shows part of a chromatogram 
from an automated sequencer, showing the sequence of the 
sense strand from exon 3 of the mother (A), Index case (B), 
aunt of the index case (C) and sister of the index case (D).
The position of the GT deletion Is Indicated In the Index case 
and mother and the position where the GT deletion would be, 
is indicated in the other two samples. The normal and mutant 
sequences are also shown and compared.
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Figure 3.25 : Carrier detectionln exon 2 in the family Gla 7292.
Figure A, shows an ethidium bromide stained hydrolink gel with
results of heteroduplex detection analysis on family members.
The lane numbers correspond to numbers beside the Individuals
in the pedigree shown in figure C and the hetroduplex and
homoduplex bands are Indicated by arrows. Figure B, shows the
results of CCM analysis on the mother (lane 1) and one sister (3),
(lane 2), after modification of the duplexes by hydroxylamine.
The probes were Internally labelled and the cleavage products
in both lanes are indicated by arrows. Figure D, shows part of
chromatograms from an automated sequencer, showing the 
sequence of the sense strand of the mother(1)(A), sister (3)(B)
and index case (2)(C) from the family with a G/A substitution
in exon 2. The position of the substitution is indicated by an
arrow and normal and mutant sequences are shown and
compared. No DNA was available from the second sister (4)
for CCM or sequence analysis.
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sense normal sequence: ATGGACAGGTAAGTAA 
sense mutant sequence: ATGGACAAGTAAGTAA 
heterozygote a/g
Figure 3.26 : Carrier detection in exon 7 in the family HGPRT 
North Mymms. Figure A, shows an ethidium bromide stained 
hydrolink gel with the results of heteroduplex detection 
analysis on family members.The lane numbers correspond 
to numbers beside the individualsin the pedigree shown in 
figure B and the hetroduplex and homoduplex bands are 
indicated by arrows. The CCM analysis was uninformative in 
this family. Figure C shows part of a chromatogram showing 
sequence of the sense strand of exon 7 from the mother (1)(A), 
and sister (3)(B), of the index case. The position of the C-T 
substitution present in the index case is indicated by an 
arrow. DNA was not available from the Index case or other 
family members for sequence analysis.
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sense normal sequence : GGACCCCACGAAGTGTT 
sense mutant sequence : GGACCCCATGAAGTGTT 
Heterozygote : c/t
Figure 3.26.C
Figure 3.27 : Carrier detection In exon 5 in the family HGPRT 
10195. Figure A, shows an ETBR stained hydrolink gel 
with the results of heteroduplex detection analysis on the 
maternal DNA The hetroduplex bands are Indicated by arrows. 
Figures B and C, shows a positive and negative image of the 
results of CCM analysis on the mother (lane 1) and a control 
sample (lane 2), after modification of the duplexes by adding 
hydroxylamine. The probes were end-labelled and the cleavage 
products are indicated by arrows. No DNA was available for the 
Index case from this family and only maternal DNA was 
available for analysis at this point.
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Figure 3.28 : Carrier detection in exon 5 in the family HGPRT 
Runcorn. Figure A, shows an ETBR stained hydrolink gel 
with the results of heteroduplex detection analysis on exon 5 
DNA from family members. The lane numbers correspond to 
the numbers beside the Individuals In the pedigree shown In 
figure B and lane 1 shows exon 5 from a control individual. 
The heteroduplexes and homoduplexes are Indicated by 
arrows. Insufficient DNA was available for CCM or sequence 
analysis In this family.
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Figure 3.29: Carrier detection in exon 2 In the family HGPRT 
Mashad. Figure A, shows an ETBR stained hydrolink gel 
with the results of heteroduplex detection analysis on family 
members. The lane numbers correspond to numbers beside 
the individuals in the pedigree shown in figure B and the 
hetroduplex and homoduplex bands are Indicated by arrows. 
HDHG analysis was uninformative in this family. Figure C, 
shows part of a chromatogram from an automated sequencer, 
showing the sequence of the sense strand of exon 2 of one 
sister (3) of the index case from the family. The remaining 
sisters showed the same pattern of peaks. The position of the 
A/T substitution, present In the Index case, Is Indicated by 
arrows and normal and mutant sequences are shown and 
compared. No DNA was aviailable from the index case for 
sequence analysis.
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sense normal sequence : TATGACCTTGATTT 
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Figure 3.30 : Carrier detection In exon 4 In the family HGPRT 
Gla 7293. Figure B shows an ethidlum bromide stained agarose 
gel with results of PCR analysis on family members. The lane 
numbers correspond to numbers beside the Individuals In the 
pedigree shown In figure A and the mutant larger and normal 
bands are Indicated. A 1kb ladder is shown in lane L.
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Figure 3.31 : Carrier detection in exon 3 In the family HGPRT 
Codicote. Figure A shows the -ve image of an ethidium bromide 
stained hydrolink gel with the results of heteroduplex detection 
analysis on family members.The lane numbers correspond to 
numbers beside the individuals in the pedigree shown in figure 
C and the heteroduplex and homoduplex bands are Indicated by 
arrows. Figure B, shows the results of CCM analysis on the 
index case(1)(lane 1), sister (2)(lane 2), and aunt of the index 
case (3)(lane 3), after modification of the duplexes by addition 
of hydroxylamine. The probes were internally labelled and the 
cleavage products In lane 1 are indicated by arrows. No 
DNA was available from the other family members for HDHG or 
CCM analysis. Figure D, show.'> part of chromatograms from an 
automated sequencer, showing the sequence of the sense 
strand of exon 3 of the sister (2) and aunt (3) of the Index case 
(chromatograms A and B respectively). No DNA was available 
from the index case or his mother for sequence analysis. The 
position of the potential T Insertion Is Indicated by arrows and 
normal and mutant sequences are shown and compared.
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Figure 3.25 shows the hydrolink , CCM and sequencing results for 
family members from the pedigree 7292. Using direct mutation detection 
strategies this individual was found to have a point mutation in exon 2 which 
could be seen as a heteroduplex band on hyckolink gels and as a cleavage 
product after modification with hydroxylamine. DNA was available for the 
mother(1) and one sister (3) but only a small quantity of frozen lyphoblastoid 
cells were available for the other sister (4), providing enough DNA only for 
hydrolink analysis. The hydrolink (figure A) and CCM results (figure B) are 
shown. The linkage analysis was uninformative for this family. A 
heteroduplex band is clearly seen for the mother (1) and sister (3) while this 
band is absent from the second sister (4). The chemical cleavage results 
show a cleavage product for the mother (1) and sister (3) although these 
bands in the sister are very faint. (Lanes 1 and 2 , figure B) while sister (4) 
was not tested . This indicated that the mother(1) and one sister (3) are 
definitely carriers while the second sister (4) is probably not a carrier. This 
designation was supported by the automated sequencing results (E).
Figure 3.26 shows the hydrolink (figure A) and sequence results(C) 
from the mother and sisters of the index case with the mutation HGPRT 
North Mymms(pedigree 10188). Linkage analysis was informative and is 
shown in figure 3.23.d. The linkage analysis suggests that one sister(3) (4 in 
the linkage pedigree) carries the affected maternal chromosome(allele A), 
while the other sister does not. CCM analysis was uninformative for this 
exon. The hydrolink and sequence data show that the mother and sisters do 
not carry the mutation. Figure C, shows the sequence of this part of the 
exon 7 from the mother(1)(A) and sister (3)(B)of the index case (2). DNA 
was not available to show the mutation in the index case by sequence 
analysis but coupled with the hydrolink and linkage data, it appears that the 
index case is a new mutation.
Figure 3.27 shows the and hydrolink results (figure A) and CCM 
analysis (B) and (C) from the mother of the index case from the pedigree 
10195. Very little DNA was available from the index case and only PCR of 
the individual exons from this boy was possible to exclude large length 
mutations. The direct mutation detection was carried out on the maternal 
DNA and a mutation was indicated in exon 5 (figure A) with the presence of 
a heteroduplex band in exon 5 . The CCM results (B) and (C) also shows a 
cleavage product in this exon. The mother is shown by direct mutation
ftp*
detection probably to be a carrier. Automated sequencing showed no 
definate mutation in the mother and no further DNA was available for 
hydrolink analysis on the other family members and the linkage analysis 
was uninformative, so no further data could be given to this family.
Figure 3.28 Shows a partial pedigree (figure B) with the hydrolink 
data (figure A) for several family members with the mutation HGPRT Runcorn 
(pedigree 10199). Small quantities of DNA were available for the index case 
and insufficient DNA was left to carry out linkage analysis or CCM. The 
HDHG results are shown for exon 5 of the index case (3) mother (4) and 
aunt (2). All three individuals show the presence of a heteroduplex band 
indicated by an arrow. The carrier status of these family members could 
however not be confirmed as sequence could not be obtained for this exon 
as insufficient DNA was available for sequence analysis, but the hydrolink 
results are among the clearest found.
Figure 3.29 shows the HDHG (figure A), partial pedigree (figure B) 
and sequence data (figure C) for individuals from the family with the 
mutation HGPRT Mashad (pedigree 10197). The linkage data was 
uninformative due to the absence of maternal DNA and the CCM protocol 
did not yield a cleavage product for any individuals after modification with 
either chemical. The hydrolink data indicated that none of the sisters were 
carriers with all the sisters (lanes 2,3 and 4) appearing to show a single 
band. No DNA remained for sequencing of the index case DNA but the 
sequence of the sisters DNA confirmed the absence of the mutation as no 
double peaks were seen at the point of the mutation as were seen in the 
other carrier females from other families. The sequence from one sister only 
is shown, but all sisters yielded similar chromatograms.
Figure 3.30 shows the PCR amplification products from exon 4 from 
the family with pedigree 7293. Due to the presence of a large insertion in 
exon 4 the carrier status of female family members could be easily assigned 
by the presence of the large band in addition to a normal sized exon 4 band. 
These results confirm the linkage analysis.
Figure 3.31 Shows the HDHG (figure A), CCM (figure B) and 
sequence (D) results from the family with the mutation HGPRT Codicote 
(pedigree 10198). A partial pedigree is shown in figure C. The linkage
FQ
analysis was uninformative due to homozygosity of the markerffigure 
3.23.g). No DNA was available for further analysis of the maternal DNA, but 
as a second male fetus was terminated and was found to have Lesch-Nyhan 
syndrome, it can be concluded that the mother is an obligate carrier. Exon 3 
was problematic for CCM but cleavage products were seen in the index 
case but not in the sister (2) or aunt(3). The HDHG shows the presence of a 
double band in the index case DNA but not in the DNA from the aunt(3) or 
sister(2). The sister and aunt of the index case were sequenced as no further 
DNA was available from the mother or index case. No mutation was seen in 
either and as a T insertion would result in double peaks thereafter in the 
sequence it can be presumed that no mutation is present in these samples. 
DNA was not available for the remainder of the female family members.
3.2 Duchenne Muscular Dystrophy.
3.2.1 Screening for Point Mutations in DMD/BMD Patients With No Larue 
Deletions.
Fourteen DMD/BMD patients with no apparent deletions were studied 
using heteroduplex detection using HDHG and CCM analysis to screen 21 
regions of the gene for the presence of small mutations. Ten of the boys had 
exons a-i previously screened using SSCP analysis but no mutations had 
been found (Kataki, 1992). The remaining boys had been screened only for 
the presence of large length mutations .
3.2.2 Heteroduplex Detection Using Hydrolink Gel Electrophoresis in the 
DMD Gene.
The 21 regions of the DMD gene were amplified in each boy by the 
modified PCR protocol described in 2.6., with control DNA added to each 
reaction tube to enable creation of a potential heterozygote state. After 
amplification, the duplexes were run on a hydrolink gel, the DNA stained 
with ethidium bromide and each exon examined for the presence of extra 
bands indicating the presence of heteroduplexes.
Three patterns were observed . The exons were scored either as 
definite negatives indicated by definite positives indicated by +; or 
suspicious indicated by ?. A suspicious score was recorded if the band was
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abnormal in some way but did not have the presence of definite extra bands. 
This could be due to a thickening of the band relative to the others on the 
gel, if an extra band was seen present some distance from the homoduplex 
band or if the same exon from different boys showed a duplex band on the 
same gel indicating that a loading artefact may have occured resulting from 
incorrect formation of the wells on the gel. Each exon was analysed at least 
twice using two separate amplification products with two different control 
DNA’s run on separate gels.
The results from these gels are summarised in Tables 3.5.a,and 3.5.b. 
The positive results are shown in figure 3.32.a-c.
3.2.3 CCM Analysis of Suspicious DMD Exons.
CCM analysis using both hydroxylamine and osmium tetroxide was 
carried out on all exons which gave a suspicious or positive result with 
HDHG. The results obtained are summarised inTable 3.6.a and 3.6.b.
Of the exons analysed in the first PCR reaction amplifying exons a-i 
two revealed a cleavage and several gave a possible cleavage result that 
was difficult to interpret. The positive cleavage results are shown in figure 
3.33 A and B. In the second set of PCR reactions no definite cleavages and 
4 suspicious results were seen.
Figure 3.33.a shows the cleavage of exon a after modification with 
osmium tetroxide from the index case of pedigree 6397. Figure 3.33.b 
shows cleavage after modification with hydroxylamine of exon b of the index 
case from the pedigree 5117. Unclear cleavage results were obtained from; 
exon a of the index case from the pedigree 5113, exon c of the index case 
from the pedigree 5104 and exon f of the index case from the pedigree 
5117 , exon i of the index case from the pedigree 5108 and exon 60 of the 
index case from the pedigree 5100. Exon g could not be analysed using 
CCM due to the unavailability of primers. Three further potential cleavage 
events were seen, in exons 42 and Pm (after modification by osmium 
tetroxide and hydroxylamine respectively) , from the pedigree 4252 and 
exon 13 of the index case from the pedigree 5113, after modification by 
hydroxylamine.
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Figure 3.32 : Ethidium bromide stained hydrolink geis showing 
exons from index cases with DMD, which gave heteroduplexes. 
The figures show the formation of heteroduplex bands In the 
index cases in lanes 2, against normal control DNA, in lanes 1. 
(a) shows exon a of the index case from pedigree 6397, (b) 
shows exon b of the Index case from pedigree 5117 and (c) 
shows exon 13 of the index case form pedigree 5113. The 
heterodupiex bands are indicated by arrows.
1 2
m W M  < + m  heterodupiex  
■
a
1 2
heterodupiex
bands
1
b
1 2
heterodupiex
bands
©■o ^ H>< 3 |g .
® IT <T>
o'g.co
® 3 ?>a x  u
©
o
3
£©w
3o
© X 3 ©
§■8 © ppp 
©© © 0 3 0
3" Q-
'3 ?  8
9-3  ^o' §: ©
^  3©  £ - ©  
w
^ 3  »*-•■ O o 
3  Q . ^O =± © 
O O Xg- ©. o© C* U 
©  O  CO
§ 13 © co a* _i.
® O -
o §  §  
O  3
O’O*<C/i■o®
1 1
© +© _.^  ©3" a. -
© o ’ ro03 —^  7+
m ®© ©
© ®© "O
E .o  >-*■ ©
£
D
©
Q.
O'
©
CO ©  ©wo
©
c
3  _  0_ 05
® ^  05 ©=* (Q* ©
3
oQ.
o'
©
> i §
0 5 - 0Q3 .r^  TH 7+
©
©
©.
CO 
- h'O 3- ^
® §. 
c  o
©
14861- 
DM
D
15108- 
DM
D
11987- 
BM
D
13591- 
DM
D
17499- 
DM
D
15117- 
DM
D
14252- 
DM
D
15104- 
DM
D
15113- 
DM
D
14221- 
DM
D
15100- 
BM
D
19436- 
?
14287- 
DM
D
16397- 
?
PED 
/B
M
D
:D
M
D
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
•0
1
1
1
1
1
1
1
1
1
1
+ 0 
H
>
1
1
1
1
1
1
1
1
1
1
+
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
H 
0 CD
1
1
1
1
1
1
1
1
1
1
1
1
1
1
■O
1
1
1
1
1
1
1
1
1
1
1
1
1
H 
0 O
1 1 1 1 1 1 1 1 1 1 1 1 1 1 X
1 1 1 1 1 1 1 1 1 1 1 1 1 1 O D
1 1 1 1 1 1 1 1 1 1 1 1 1 1 X
1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 m
1 1 1 1 1 1 1 1 1 1 1 1 1 1 X
1 1 1 1 1 •O 1 1 1 1 1 1 1 1 0
T |
NA NA NA NA NA NA NA N A NA NA NA NA NA NA
H 
0 0
1 1 1 1 1 1 1 a 1 1 1 1 1 1 X
1 1 1 1 1 1 1 1 1 1 1 1 1 1 O X
1
1
•O
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
H 
0 —
O  5 ‘ H  
®g O 2
©  £  ©  
CQ CD CO 
o  co b
3  3  J  
Q . O  ■
£§•23
05 ~  CD 
~  o  tn  3  9) r  
CQ = r  ^  O 05 
I T  3
CD
T3
"0 — 
. O O  © I O  
S-D 2—■» " I
5  o 0)
£  0 -  3  
® C JD
a s ?
05 S.5T 
3  S o
©
s “ S 
? g g
fl) o
l ' i . 3  
9 : 3  « •O © =T
& ©  ®  
©  13 CO » o ® _ O 
3 -  O  O  
©  ^  
13 Q -  
3  0—_
o o 2a s 2  
©  ©  -^  
©  CO 3
§ 3 g 
®  9 ;  O '0 ^ 3  
O  O  (0  
O  ©  ^c =?■• 13
m  °  2o 3 'P-o-gj-O^ S  
5  * w  =**
9 - 3  §
0 c d 
S 3  -* © Z. ■*•
w  ©  c r
1  S'S
o! <3^  © <. © • q:
3  +  “  
g 3  2
^  9 :  U§ 8 00 05 —CO ©co C3
3  0> ‘
—  T3 .? © O 
©  ©
<
©
14861-
15108-
11987-
13591-
17499-
15117-
rocnro■
cn
o
■
15113-
14221-
15100-
[col
CO
o>
1
14287-
fo>|CO
CO
-s j1
"0
m
o
DM
D
DM
D
BM
D
DM
D
DM
D
DM
D
DM
D
DM
D
DM
D
DM
D
BM
D
•o DM
D
■o 03
2
D■ ■
O
2
O
i
I
I
I
i
i
i
i
a
a
a
a
■o
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a 0 
H 
1
“0
2
i l i i a a a a a a a a a a X
i i i i a a a a a a a a a a o
CO
i i i | i a a a a a a a a a a X
i i i a a a a a a a i a a a O
05
i
I
i
i
a
a
a
a
a
a
a
a
a
a
■o
a
a
a
1
a a
a
a
a
a
H 
0 CO
i I i a a a a a a a a a a a X
i i i a a a •o a a a a a a a o ro
1 r LLHUUI
i i a a a a a a a a a a X
i j I l i a a a a a a a | a a a O CO
i i i a a | a a a a a a a a a X
i i i a a a a a a a a a o
i i i a a a a a a a a a a a X
i i i a a a a a a a a a a o
i i i a a a a a a a a a a X
i I i a a a
___
a a a | a a a a a O cno
i i i
__
a a a a a a a a a a X
I i i a a a a a
__
i a a a a a o
cnro
I i i a a a a a a a a a a a X
i I i a a a a a a a a a a a O
cn
CO
i I i a a a a a a a a a a a X
i I I a a a a a a a ••O a a a O
CDo
Figure 3.33 : Autoradiograph showing cleavage of end-labelled 
probes In exons of patients with DMD/BMD. Figure 3.33.a shows 
cleavage after modification by osmium tetroxide of exon a of the 
index case from the pedigree 6397, the cleavage product Is 
marked by an arrow. Figure 3.33.b shows cleavage after 
modification by hydroxylamine of exon b of the Index case 
from pedigree 5117, the cleavage product Is indicated by 
an arrow. The control samples are shown In lane 2 and In 
lanes 2 and 3 respectively.
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3.2.4 Sequencing of Suspicious DMD Exons.
A single-stranded product was attempted to be obtained for the 
exons which showed positive and suspicious CCM results and these were 
attempted to be sequenced using direct sequencing to give exact 
information as to the nature of the nucleotide change. Asymmetric products 
could be obtained for exons a, b, i, and 44. Of these single-stranded 
products sequence could only be obtained for exons a and b by using both 
sequencing strategies and the sequence was of poor quality containing 
many stops. No definite sequence changes could be identified in the 
exons sequenced from the affected individuals as not all the sequence 
could be clearly read.
3.3 Mutation Detection in the BRCA1 Gene.
3.3.1 PCR of The individual Exons of the BRCA1 Gene.
The individual exons of the BRCA1 gene were amplified according to 
the protocol described in 2.7 using a touchdown PCR recommended by 
Miriad Genetics, the designers of the majority of the primers. Genomic DNA 
was used as the template for the amplifications and this was generally in 
plentiful supply and of good quality. The PCR was very robust and 
consistently amplification occured for the majority of the exons producing a 
large quantity of product. All of the exons with the exception of exons 6/7 
and 11 were amplified in PCR products encompassing the individual exon 
plus flanking intron sequences giving products of 200-300bp in size. Exons 
6 and 7 were amplified as a single product and due to the large size of exon 
11 it was amplified using 17 overlapping primer sets amplifing fragments of 
approximately 200bp.
All exons amplified with the fresh primer sets, but several exons 
including exons 2, 11j and 5 ceased to amplify after several weeks of primer 
storage. Manufacture of new primer sets for these exons allowed 
amplification to proceed.
7?
3.3.2 Screening for Molecular Pathologies in the BRCA1 Gene.
Due to the large number of exons in the BRCA1 gene, the number of 
DNA samples and to the small size of the amplification products produced 
by use of the chosen primers, it was decided to screen the gene by SSCP 
analysis. Any suspect exons from the patients was then sequenced using an 
ABI automated sequencer. Two SSCP gel conditions were used to obtain 
maximum screening efficiency , one gel was run at room temperature with 
5% glycerol added to the gel and one gel was run in the cold room with no 
glycerol. A strategy was devised where the previously reported common 
mutations were screened for primarily in the family samples and the 
sporadic breast and ovarian tumours DNA samples were then screened 
using ASO dot blotting for these mutations. The remainder of the exons 
were then screened with exon 11 being firstly analysed as it encodes for the 
majority of the protein. Due to the autosomal nature of the gene any 
mutations found in the blood samples are likely to be heterozygous and in 
the carriers two sequences are seen.
Four different mutations were found in 60 family DNA samples 
analysed many of which did not have linkage confirmed due to the lack of 
DNA from key family members. These families had two or more cases of 
breast or breast/ovarian cancer. Figure 3.34.a shows the SSCP gel 
showing a band shift in exon 20 of the index case from pedigree Edin.BRI 
relative to control samples. Figure 3.34.b shows the sequence of the sense 
strand of this exon from the index case revealing a C insertion at nucleotide 
position 5382 in exon 20 (5382 ins C>ter 1892), and the normal sequence 
of a control individual. The mutation was confirmed in the other strand by 
sequencing using the antisense primer. This mutation results in premature 
stop at base 1892 resulting in a shortened protein. This mutation has been 
reported as one of the most common mutations found in unrelated families 
with early onset breast /ovarian cancers throught the world. Figure 3.35.a 
shows a portion of the SSCP gel showing the band shift relative to control 
samples in exon 2 of the index case from pedigree CRC 3550. Figure 3.35.b 
shows the mutant sequence from the sense strand revealing an AG deletion 
at position 185 in the gene(185 del AG>ter 39). The normal sequence of 
this region is also shown. This results in premature termination of the 
protein at position 39 and hence a shortened protein. Once again this 
mutation has been reported in other families worldwide but in most cases
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Figure 3.34 a : Autoradiograph showing part of a gel showing 
results of SSCP analysis of exon 20 of DNA from breast/ovarian 
cancer families. No band shift was seen In the single-stranded 
(ss) DNA but a band due to a heterodupiex was seen above the 
double-stranded (ds) DNA in lane 8. The sequence of this exon 
from this Individual Is shown In figure 3.34.b. The blank lanes 
represent PCR reactions which have failed.
Figure 3.34.b : Part of a chromatogram from an automated 
sequencer, showing part of the sequence of exon 20 from 
an individual from a family with inherited breast/ovarian 
cancer. The sequence of the sense strand from the affected 
Individual (A) and from a control sample (B) Is shown and 
the position of the C insertion is indicated by an arrow in 
the affected individual. The position of the insertion is also 
indicated In the control sample although no Insertion Is 
present. The normal and mutant sequences are also shown.
C insertion in mutant
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sense normal sequence : AGAATCCCAGGACA 
sense mutant sequence: AGAATCCCCAGGACA
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Figure 3.35.a .: Autoradiograph of part of a gel showing analysis 
of exon 2 DNA from breast /ovarian cancer families. The two 
strands do not separate but a band shift was seen in lane 6 
relative to the normal DNA samples(lanes 1,2,3,4,5 and 7).
The sequence of this mutation Is shown In figure 3.35.b
Figure 3.35.b: Part of a chromatogram from an automated 
sequencer, showing part of the sequence of exon 2 from 
an individual from a family with inherited breast/ovarian 
cancer. The sequence of the sense strand from the affected 
individual (A) and from a control sample (B) is shown and 
the position of the AG deletion is indicated by an arrow in 
the affected Individual. The position of the deletion Is also 
Indicated in the control sample although no deletion Is 
present. The normal and mutant sequences are also shown.
AG del in mutant
AG del in mutant 
*
B
sense normal sequence : AAAATCTTAGAGTGTCCC 
sense mutant sequence: AAAATCTTAGTGTCCC 
Heterozygote : **************
these mutations are present in families which can be traced back to the 
Ashkanasi Jewish population and hence a founder effect may have occured 
with this mutation in these families coming from one individual. No 
information is available as to the linkage of this family to the others but more 
detailed geneology is being carried out. Figure 3.36.a shows a portion of 
the SSCP gel showing the band shift relative to control samples in exon 2 of 
the index case from pedigree GLA. br1. Figure 3.36.b shows the mutant 
and normal sequences. Both strands of the mutant sequence are shown. 
This reveals an A to G substitution at base 180 which results in an lie to Val 
amino acid substitution. The position of the substitution was analysed and 
was found to be present at the second base of the first RING finger motif and 
hence despite no change in the charge of the protein due to the amino acid 
substitution, the change at this position may affect the stucture of the RING 
Finger. The possibility remains that this change may be a polymorphism, 
and hence be functionally insignificant, but it was not found in any of the 
other 60 individuals analysed and untill further information is available as to 
the nature and function of the protein encoded by BRCA1, it is impossible to 
understand the importance of this mutation. Figure 3.37. a shows a portion 
of the SSCP gel showing the band shift relative to control samples in exon 
11 j of the index case from pedigrees Edin.br2 and Edin.br12. Figure 3.37.b 
shows a portion of the SSCP gel showing band shifts in the DNA of the 
index cases from pedigrees GLA475(lane 2) and Gla12343(lane 3). The 
sequence of the antisense strand of these mutations relative to the normal 
are shown in figure 3.37.C and shows a TT deletion in the antisense 
strand(AA in the sense strand) at nucleotide position 2800 which results in a 
premature stop at position 901(2800 del AA>ter 901), leading to a shortened 
protein. This mutation was previously described in one other American 
family (Friedman et al 1994). The discovery of the change in four Scottish 
families, may indicate the presence of a common Scottish mutation which is 
important from a diagnostic point of view. These families are at present 
being investigated to discover if they are related and if indeed they are 
related to the original American family to establish if the mutation comes 
from one common ancestor or if this region of the gene is specifically prone 
to mutation.
Several polymorphisms were also detected and the SSCP gels for 
these are shown in figure 3.38. a-c. The sequence of these polymorphisms 
in shown in figure 3.39.a-c A G to A substitution was found in intron 16
74
1 2 3 4 5 6 7 8 9  1011
ssDNA 
<4— band si
Figure 3.36.a: Autoradiograph of part of a gel showing results 
of SSCP analysis on exon 2 of DNA from breast/ovarian cancer 
families. The single-strands do not separate and the shifted 
band Is indicated by an arrow. The band shift Is shown In lane 2 
with spillover of the mutant product into lane 3. The sequence o 
the shifted band Is shown In figure 3.36.b.
Figure 3.36.b : Part of a chromatogram from an automated 
sequencer, showing part of a sequence of exon 2 from 
an Individual from a family with Inherited breast/ovarian 
cancer. The sequence of the sense and antisense strand 
from the affected Individual ( A and B respectively) and 
the sequence of the antisense strand from a normal 
Individual Is shown (C). The position of the A-G substitution 
is indicated by arrows. The normal and mutant sequences 
are also shown.
A/G subst.
|  A/G(T/C) subst.
X A/G(T/C) subst.
sense normal: TGCAGAAAATCTTAG 
'‘sense mutant: TGCAGAAAGTCTTAG 
heterozygote a/g
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Figure 3.37.a ; Autoradiograph of part of a gel showing results 
of SSCP analysis on exon 11 of DNA from breast/ovarian cancer 
families. Lanes 3 and 4 show normal exons while lanes 1 and 2 
show band shifts due to mutant sequences present In two 
families, Edin.br2(lane 1) and Edln.br12(lane 2). The normal 
pattern of separation from normal DNA samples is shown 
In lanes 3 and 4. The sequence of the mutant bands Is 
shown In figure 3.37.C.
•♦■HETERODUPLEX
♦ -  DS DNA
MUTANT DS DNA
Figure 3.37.b: Autoradiograph of part of a gel showing results of 
SSCP analysis on exon 11 of DNA from breast/ovarian cancer 
families. Lanes 1,4 and 5 show the pattern from normal exons, 
while lanes 2 and 3 show the mutant pattern from DNA from 
pedigrees Gla 475 and Gla 12343. Normal bands are indicated 
by N and the mutant bands are indicated by M. The sequence 
of the mutant exons are shown In figure 3.37.C.
Figure 3.37.C: Part of a chromatogram from an automated 
sequencer, showing part of the sequence of exon 11 from  
four individuals from families with inherited breast/ovarian 
cancer. The pedigrees of these families are given in the text. 
The sequence of the antisense strand from the affected 
individuals (A - D) and from a control sample (E) is shown 
and the position of the TT deletion is indicated by an arrow 
In the affected Individuals. The position of the deletion Is AF 
also indicated in the control sample although no deletion 
is present. The normal and mutant sequences are also shown.
TT del in mutant 
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TT del in mutant
TT del in mutant
G G A C T  T T G N  Cg T C T A A G G A C ^ C N N A G N G G G ^ A G
TT del in mutant
0
TT del in mutant
E
antkAne^ " T al S 6 q U e n C 8  : 'n'GGACTTTGTTTCTTT antisense mutant sequence: TTGGACTTTGTCTTTAA
Heterozygote :
Figure 3.38.a: Autoradiograph of part of a gel showing results 
of SSCP analysis of intron 16 DNA from breast/ovarian cancer 
families. Lanes 2 and 6 show the shifted pattern showing a 
polymorphism, the sequence of which is shown in figure 
3.39.a. No homozygotes for the polymorphism were seen.
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Figure 3.38.C : Autoradiograph of part of a gel showing results 
of SSCP analysis of part of exon 11 of DNA from breast /  ovarian 
cancer families. Lanes 2 show the homozygous normal sequence, 
lanes 1 the heterozygous sequence and lanes 3 the homozygous 
mutant sequence. The sequence of this polymorphism Is shown 
in figure 3.39.C.
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Figure 3 .39: Part of chromatograms showing part of the 
sequences from three regions of the BRCA1 gene showing 
the sequence of polymorphisms. Figure 3.39. a shows part 
of the antisense strand sequence of the A/G polymorphism 
in intron 16 of a heterozygote, figure 3.39. b shows the 
sequence of the sense strand of exon 13 from a heterozygote, 
a normal and homozygote for an Intra-exonlc C/T polymorphism, 
and figure 3.39.C shows the sequence the sense strand of part 
of exon 11 showing the C/T polymorphism from a heterozygote. 
The normal and polymorphic sequences are also given for 
each region of the gene.
antisense normal sequence: ACCTACGTAG 
antisense mutant sequence: ACCTATGTAG
heterozygote : T/c
Figure 3.39.a
A norm al sequence
l c
B polym orphism  hom ozygote 
|  T/C
C polym orphism  heterozygote
sense norm al sequence : GTGACTCTTCTGCCC  
sense m utant sequ ence: GTGACTCCTCTGCCC  
Heterozygote :
Figure 3.39.b
4<vr
sense normal sequence: TTTGCTCCG1111 
sense mutant sequence: TTTGCTCTGTI11 
heterozygote : c/T
Figure 3.39.C
(fig.3.39.a), a T to C substituion in exon 13 at position 4427 (fig.3.39.b), 
resulting in no amino acid change and a C to T nucleotide substitution at 
position 2731, resulting in the substitution of a proline to a leucine(fig.3.39.c) 
was found in exon 11. These changes are known to be polymorphisms as 
they were found in many members of the families studied and also in control 
DNA samples from Lesch Nyhan syndrome and DMD patients with a similar 
frequency. They are still significant and in cases where the polymorphisms 
are informative, may help to trace the path of the affected chromosome 
through the families.
Once the family samples had been screened for mutations, the 
presumed sporadic breast and ovarian cancers were screened for the 
common mutations by ASO hybridisation. Oligonucleotides were designed 
which corresponded to the mutant sequences of the three common 
mutations in exon 2, 20 and 11. These oligonucleotides are described in 
2.21. Figure 3.40.a-c shows the results of this screening using oligo,s for the 
exon 2, 20 and 11 j mutations respectively. One autoradiograph for each 
oligo is shown although all the sporadic breast and ovarian tumours were 
screened. None of these mutations were found in the sporadic cancers.
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Figure 3.40 a: Autoradiograph showing results of an ASO 
hybridisation on 36 sporadic breast cancer DNA’s using 
an oligo with the mutant sequence for the AG deletion in 
exon 2. The lanes contain exon 2 amplified DNA. A  +ve 
control is shown in lane C9 and a -ve control in C8. These 
are indicated by arrows.
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Figure 3.40.b : Autoradiograph showing results of an ASO 
hybridisation on 94 presumed sporadic breast cancer DNA’ 
using an oligo with the mutant sequence with a C insertion 
in exon 20. A  +ve control is shown in lane H1 and a -ve 
control in lane H2.
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Figure 3.40.C : Autoradiograph showing results of an ASO 
hybridisation on 25 presumed sporadic breast cancer DNA’s 
using an ollgo with the mutant sequence of an AA deletion 
in exon 11. A +ve control is shown in lane C12 and a -ve 
control In lane C11. These are Indicated by arrows.
CHAPTER 4
DISCUSSION
4.1 Optimisation and Comparison of the Screening Strategies.
4.1.1 Optimisation of the PCR Reaction.
The optimisation of the PCR reaction for the amplification of the 
individual exons of the HGPRT gene was complex and time consuming. 
Primer sequences for amplification of the individual exons in a multiplex 
PCR reaction were described by Gibbs et al. (1990), but when the conditions 
suggested in their study were modified for the amplification of the exons 
individually, no amplification was seen even after alteration of many of the 
reaction parameters. The reasons for this were several fold. Primarily, the 
buffer suggested was of a different composition to that supplied by the 
manufacturers of Taq polymeraseflBoehringer) and appeared to b e 
completely incompatible with amplification. The reasons for this are 
uncertain, but the addition of p-mercaptoethanol and (N H ^S C U  are 
unusual additions when compared with other buffers suggested for other 
PCR reactions and of particular note, are the absence of these components 
in the reaction buffers used in the amplification of the HGPRT exons in later 
publications using different primer sequences (Marcus et al., 1992, 
Steingrimsdottir et al., 1992, Lightfoot et al., 1992). Secondly, the 
concentration of dNTP,s used in the reaction was very high, with most 
protocols using lower concentrations of approximately 200|xM of each dNTP 
rather than 1.5mM of each dNTP as suggested by Gibbs et al. The third 
problem was the unfortunate choice of exon 1 primers as the primer set to 
use for the optimisation of the PCR. The exon 1 region of the gene has a 
very GC-rich sequence and other groups later reported difficulty in 
amplification of this exon (Steingrimsdottir et al. 1992) and of the use of 
cDNA as the template for amplification of this particular exon. This was used 
due to the nature of the sequence which would be likely to later hinder direct 
sequencing from the PCR product (Marcus et al. 1992). The amplification of 
this exon was very problematic and despite eventual optimisation of the 
other exons using lower dNTP concentrations and the manufacturers 
buffer, the amplification of this exon consistently produced a ‘ladder’ of 
products on an agarose gel and the product of the correct size could not 
have been distinguished from other non-specific amplification products. As
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RNA and consequently cDNA was not available for the majority of patients 
studied, analysis of exon 1 in patients with known mutations in that exon 
and application of molecular screening strategies to this exon were not 
possible, resulting in potential inability to locate molecular pathologies that 
may have been present in this part of the gene.
Most groups report the amplification of exons seven and eight 
together in a single amplification product. In this study further primer sets 
were made for this region which produced a smaller amplification product 
due to the large size of the product produced with the primer set used by 
Gibbs et al. (1990), which proved to be too large for use in some of the 
mutation screening strategies employed. Further, primer sets were also 
designed for the amplification of exons seven and eight individually for 
analysis of an index case (pedigree 10427) which originally appeared to 
have a deletion of exon seven/eight.
After optimisation of the annealing temperature to a sufficiently high 
level, non-specific products were generally not present. This was very 
important particularly in the formation of heteroduplexes where the presence 
of extra bands may have confused the interpretation of the results.
The oligonucleotide primers used in the PCR reaction also had to be 
of good quality or the PCR reaction failed. It had already been shown by 
other groups in the laboratory, that certain PCR reactions would not work if 
the primers used had not been purified after manufacture (Agapi Kataki, 
personal communication). This proved to be the case for the majority of the 
primer sets used in amplification of the HGPRT gene. Primers obtained 
from Oswell DNA services were HPLC purified and the primer sets made in 
the department on the ABI PCR mate oligonucleotide primer machine, were 
purified after deprotection by use of an ABI OPC column.
The quantity of DNA obtained by each amplification was not as high 
as concentrations obtained with other PCR amplifications including 
amplification of the DMD and BRCA1 exons which shall be described later. 
This could be due to the fact that only 28 amplification cycles were carried 
out, but on increasing the total number of cycles to 30 no significant increase 
appeared to occur while ‘eyeballing’ the DNA concentration and a certain 
decree of smearing became apparent indicating that the quality of the DNA
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was impaired. This lower yield of product per amplification reaction was 
taken into consideration when the amplification products were used in later 
manipulations.
All PCR reactions were overlaid with mineral oil. This was particularly 
important in reaction volumes of 50 | j l I as failure to do so resulted in 
evaporation of liquid from the reaction mix and alteration of the 
concentration of the components resulting in non-amplification.
On several occasions during the course of these experiments, 
amplification of one or all of the exons failed despite original optimisation. 
Certain primer sets particularly those amplifying exons 2, 4, 6 and 7/8 
seemed fairly robust, while other primer sets, such as exons 3 and 9, 
consistently failed to produce an amplification product after the primer sets 
were only a few months old. The reason for this is uncertain, but the most 
probable explanation is that the complementarity or physical properties of 
these particular primers were not ideal and that any degradation of the 
primers caused by continual freezing and thawing or by the build up of 
contaminants in the stock solutions, could not be tolerated during 
amplification. Primer sets which appeared less robust could usually be 
rescued by cleaning up of the primer by salt/ethanol precipitation, but failing 
this, a new primer set had to be manufactured which was costly and not 
always immediately possible. This hindered the analysis of molecular 
pathologies in exons 3 ,5 and 9 in particular.
Another reason for failure of individual PCR reactions was the quality 
and quantity of the DNA used. A large proportion of the DNA samples used 
as templates, were in the form of genomic DNA which had been extracted 
from old, frozen DNA and lymphoblastoid cell lines, some of which had been 
accidently thawed during transit and were presumed to be damaged. 
Several extracted DNA samples failed to allow amplification even from the 
most robust primer sets. As many of the index cases and family relatives 
were dead or unavailable for obtaining new samples, this factor severely 
hindered many of the linkage studies and direct mutation detection studies. 
Too much DNA in the reaction mix also hindered the amplification and this 
may have been due to the presence of higher concentration of impurities in 
the DNA which inhibited the activity of the Taq polymerase. If DNA samples 
which had previously been compatible with amplification began to be
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problematic, this was usually an indication of degradation of the DNA or the 
build up of contaminants. This was the case on one particular occasion 
when many of the stock genomic DNA’s would not amplify. This was found 
to be due to a build up of contamination in the samples to levels which 
affected both Taq polymerase and restriction enzymes and the 
contamination was found to be from the pipette tips which had picked up 
some form of contamination from the autoclave. After a phenol extraction 
and ethanol precipitation many of the DNA samples could be rescued.
If all the PCR reactions failed it was usually due to a fault with one of 
the reaction components and systematic changing of each of the PCR buffer, 
dNTP stock solution or Taq polymerase in the control PCR indicated the 
problem component. The most common problem component originally, was 
the dNTP mix particularly when the dNTP’s were supplied by Boeringer. This 
was later less of a problem when the dNTP’s were alliquoted on arrival. A 
further component which affected the reaction was the millipored distilled 
water. This water stock was used fresh each time a PCR reaction was set up 
and it was noted that if the pH of the ddH20 was higher or lower than 
expected or was not as pure as needed, the PCR reaction failed. This 
occured on several occasions but amplification was reinstated by use of 
bought water.
In contrast to the amplification of the HGPRT gene, amplification of 
the exons from the DMD and BRCA1 genes were less problematic. The 
majority of the DMD exons amplified consistently which could have been 
due to the primers whose sequence had been published and which were 
used by most groups studying the gene, suggesting that the reaction 
conditions had been well optimised and tested. Further, initially the DNA 
available had been stored frozen since extraction and was in better 
condition and more plentiful than the DNA from the Lesch-Nyhan families. 
However only small quantities of DNA were available and once this was 
finished it was not possible to obtain other DNA samples as most of the 
index cases with DMD were dead.
The majority of primer sequences for amplification of the BRCA 1 
gene were supplied by Miriad genetics, part of the group who discovered the 
gene and by Friedman et al., (1994). They suggested the best primer pairs 
and amplification parameters. A touchdown PCR was suggested which 
increases the specificity and quantity of amplification product obtained. 
Further, the DNA obtained was of good quality and this apppeared to
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enhance the PCR. Several exons were difficult to amplify , including exon 
two which was the exon containing one of the common mutations. These 
primers did not produce a high concentration of product after amplification 
and after several freeze/thaw episodes or storage at 4°C of a liquots, ceased 
to amplify the exon and new primers had to be prepared. This showed 
similarity to several exons of the HGPRT gene and may have been due to 
the sequence of the primer or to the sequence of the region it was 
amplifying.
The most influential factor in the amplification of sections of the genes 
studied, appeared to be the quality of the DNA being amplified and the 
degree of optimisation of primer sequences for the best amplification. 
Therefore the HGPRT gene amplification was problematic due to the poor 
quality of DNA available and the lack of research into better primers for the 
amplification of this gene. If these factors had been more closely considered 
and higher quantities of fresher better quality DNA were available, the PCR 
on this exon may have been less problematic.
4.1.2 Optimisation and Appraisal of Heteroduplex Detection on Hyxiuiink 
Gels.CCM and SSCP for the Detection of Pathologies in the HGPRT 
Gene.
Several mutation detection strategies including SSCP, CCM and 
heteroduplex detection were optimised and compared for their ability to 
detect known mutations in the HGPRT gene.
Most succesfully a modified PCR based heteroduplex detection assay using 
hydrolink gel electrophoresis, was optimised and evaluated against a panel 
of 10 different previously characterised mutations present in different exons 
of the HGPRT gene . After optimisation all 10 mutations were detected , 
taking into consideration unequal loading and that some heteroduplexes 
were clearer than others. Further, the technique was rapid, in this gene no 
false positive results were observed and the protocol proved to be simple, 
avoiding the use of toxic chemicals and radioactivity. However only 10 
samples could be simultaneously examined which would limit its usefulness 
for analysis of larger genes.
81
Nagamine et al. (1989), reported the formation of heteroduplexes 
during PCR that could be visualised as slower moving bands in a gel. These 
heteroduplexes can be visualised as bands which migrate slower than their 
corresponding homoduplex bands due to a more open conformation which 
will result in retardation in the gel. Heteroduplexes are presumed to form 
during the later cycles of PCR probably because the DNA concentration 
increases to such a level that the complementary strands reanneal and 
outcompete the hybridisation of the primers with their template strand. Thus, 
heteroduplexes should be able to form during any PCR reaction where two 
non-homologous loci are being simultaneously amplified. It should 
therefore be possible to run a normal PCR product on a suitable gel matrix 
and visualise any heteroduplex bands, but in these experiments, 
modifications had to be made to the PCR reaction to maximise the formation 
of heteroduplexes and to provide the optimum conditions for obtaining clear 
results with no spurious or ‘ghost’ bands to confuse the interpretation. The 
optimum results were achieved by completely denaturing the duplexes by 
heating to 94°C and then holding the reactions at 70°C for up to 16 hours 
and directly loading the DNA onto the gel without cooling. To ensure a 
clean PCR product without the presence of ‘ghost’ bands, a two step PCR 
protocol was employed as suggested by Keen et al. (personnel 
communication) and later Inglehearn et al. (1992). Both suggest that the two 
step PCR coupled with the holding at such a high temperature minimise the 
formation of the extra ‘ghost bands’ which could be seen directly above the 
main product.
Before the advent of this project, the literature documented the 
application of this protocol for heteroduplex detection in autosomal single 
gene disorders such as cystic fibrosis, autosomal dominant retinitis 
pigmentosa and Tay-Sachs disease ( Triggs-Raine and Gravel, 1990; Keen 
et al. 1991). Due to the X-linked nature of both HGPRT deficiency and 
DMD/BMD, two loci would not be present to be simultaneously amplified as 
there is only one copy of the X-chromosome in males. Therefore while this 
strategy could be employed for carrier detection in female relatives, in its 
original form, it would be of no use for identification of mutations in males. 
Control DNA was therefore added to the PCR reaction to create a potentially 
heterozygote state in males and this widened the application of 
heteroduplex detection to X- linked diseases. Since then other groups have 
used this technique for analysis of X-linked disease in particular DMD (Prior
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et al. 1993). If the technique were to be used for the analysis of autosomal 
diseases no control DNA would need to be included.
Several matrices had previously been used for separation of 
heteroduplexes from homoduplexes. The early publications used 
polyacrylamide gels but the homo- and heteroduplexes in these 
experiments differed by four or more base pairs (Nagamine et al. 1989; 
Angliani et al. 1990; Triggs-Raine et al. 1990). Keen et al. (1991), introduced 
a novel non-denaturing gel matrix , hydrolink (AT Biochem) , as a more 
sensitive matrix for the separation of fragments differing by as little as one 
base-pair. This polymer had only been previously used by Keen et al.
(1991)and its use had not previously been evaluated so it was therefore 
used in this study and other groups have successfully used this matrix and 
the modified polymer ,Hydrolink-MDE for the detection of a wide variety of 
mutations in several different genes (Ingleherrn et al., 1992; Prior et al., 
1993). White et al., (1992), successfully utilised denaturing acrylamide gels 
to detect single base substitutions but this required the use of radioactive 
labelling to allow the detection of the smaller quantities of DNA that can be 
loaded on thinner acrylamide gels. One of the main advantages of hydrolink 
gels is the speed at which results can be obtained from a simple protocol 
that does not employ the used of toxic components such as radiation and for 
our purposes the hydrolink matrix serves this purpose better than an 
acrylamide one. Further, not all of the substitutions analysed by White et al.,
(1992) were detected by their methodology, while in this study all tested 
mutations were detected after optimisation .
The electrophoretic conditions used were important in the 
maximisation of the sensitivity of the protocol. Variation in the length and 
thickness of the gel used allowed detection of all 10 mutations with the 
optimum thickness of 1.5 mm allowing loading of a higher quantity of DNA 
without loss of resolution. The thicker gels were also easier to handle 
allowing easy staining of the gel negating the need for the use of 
radioactivity to detect smaller quantities of DNA on flimsier gels. The 
mutations present in larger amplification products required to be run through 
longer gels to allow separation of the different duplexes and as a rule any 
PCR products exceeding 1 kb in length were analysed on a 20 x 30cm gel. 
Some mutations, such as the GT deletion in the family HGPRT Cheltenham 
(figure 3.24.), actually produced different patterns of separation when run on
longer gels compared to the shorter gels The speed and voltage at which 
the gel was run was also critical. Gels were run as slowly as possible to 
obtain maximum separation and at low voltages to prevent the gels from 
heating up and possibly causing disassociation of the heteroduplexes due 
to the unstable nature of mismatches.
The mutation HGPRT Marlow (C527T) was amplified in a PCR 
product which simultaneously amplified exons 7 and 8 in one PCR product. 
The original PCR product was 1533bp in length and despite optimisation, 
heteroduplexes could not be detected for this mutation. A second set of 
oligonucleotide primers were subsequently designed for amplification of this 
region in a product 433 bp in length. The mutation was then easily identified 
and a heteroduplex band seen. As heteroduplex bands were visualised 
when mutations in fragments 1278bp were analysed but not in a fragment 
size of 1533bp, it can be assumed that there is an upper limit to the size of 
fragment that can be analysed in this way and that this limit is somewhere 
between 1278bp and 1533bp. However most mutation detection techniques 
have this limitation in particular SSCP analysis, where sensitivity is 
maximum with fragment sizes below 200bp in size and decreases with every 
100bp. An upper size limit of the levels witnessed with this heteroduplex 
detection in hydrolink gel protocol is therefore very useful and further 
increases the value of the technique.
Different patterns of separation were seen including single and 
doublet heteroduplex bands. Also apparent with some mutations was a 
thickening of the original heteroduplex band rather than the presence of a 
definite extra band . This could cause confusing results and indeed in some 
cases where the wells of the gel had not formed properly this thickening was 
seen in all the lanes of the gel. However it was usually clear when this had 
occured as more than one sample was affected and the use of more than 
one gel and one PCR product for each sample limited the likelihood of a 
false positive result. This however does highlight the importance of the need 
for experience to determine whether or not a band is real or an artefact and 
the use of the known mutations to analyse the effectiveness of this 
technique, allowed lessons to be learned before the protocol was used to 
look for uncharacterised mutations. Due to the nature of the gel matrix, on 
several occasions, such as with the family with the mutation HGPRT GLA 
7292 the relative mobilities of the homo and heteroduplex bands vary across
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the width of the gel as is seen in figure 3.25. This did not confuse the results 
as the presence of the extra bands was still clear and to ensure the validity 
of these results several different samples were run on several different gels.
A surprising feature of heteroduplex analysis that had been noted by 
several different groups as well as in the present study, is the apparent lack 
of correlation between type of mismatch and degree or pattern of 
separation. For example it would be expected that the 1-bp insertion 
present in exon 3 of the boy with the mutation HGPRT Codicote (T298) 
,would result in a slower moving and hence more separated heteroduplex 
band than the HGPRT Banbury mutation present in exon three as a G-C 
substitution. However the degree of separation is almost identical. Further 
the mutation HGPRT Runcorn (T395C), which results from a T-C substitution 
gives one of the best patterns of separation which is similar to the separation 
obtained with the 2-bp deletion in exon three, HGPRT Cheltenham (GT 288- 
289). The reason for this is uncertain but it could be due to the degree of 
disruption of hydrogen bonding that is caused by the relative mutations 
causing more or less open conformations around the mismatched base or 
bases. White et al., (1992), investigated this possibility and concluded that 
the identities of the nucleotides adjacent to the mismatch had a substantial 
effect on the conformation of the mismatched region in terms of the hydrogen 
bonding effects and in terms of the effects on base stacking. In these 
experiments, it is difficult to make any conclusions as to the effect of the 
particular mutation on the degree of separation due to several factors 
including the differing sizes of the amplified fragments containing the 
mutation. As all mutations are detected in the study it is very difficult to 
speculate on the mechanisms at work.
There were two negative aspects to this protocol. Primarily , the 
difficulty in recording photographically the results obtained from the ethidium 
bromide staining of the hydrolink gels. Often the gels stained non-uniformly 
creating hazy gels which did not photograph well. When diagnostic results 
are being reported, one needs to have clear data available and even the 
use of radiolabelled products on longer thinner gels did not alleviate this 
problem as the heteroduplexes on these gels were difficult to distinguish. 
Secondly, the nature of the hydrolink gels and the desire to load as much 
sample as possible into the individual wells, limited the number of samples 
which could be run at one time. This hampered the use of this protocol for
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the analysis of larger multiexonic genes such as the BRCA 1 and DMD  
genes in particular where large numbers of samples were to be analysed.
A protocol for detection of point mutations using the CCM strategy 
(Cotton et al. 1988), was established using two known mutations in the 
cystic fibrosis and DMD genes. These mutations caused a G-A mismatch 
and should result in cleavage by piperidine after modification with 
hydroxylamine.
While effective, this strategy proved to be problematic and time 
consuming and for optimisation, two strategies were employed to obtain 
cleavage of the CF G551D mutation, due to the lack of a cleavage using the 
original strategy suggested by Cotton et al. (1988). These differed primarily 
in the method of probe preparation and in the use of siliconised tubes for the 
reactions. The original protocol relied on radioactive labelling of the probe 
after PCR amplification and even after purification of the PCR product with 
geneclean to remove any components which could adversely affect the 
labelling reaction, the incorporation of label onto the probe was very low. 
Consequently, increased amounts of probe were used to set up 
heteroduplexes, thus requiring increased quantities of unlabelled test DNA. 
Despite achieving a visible signal resulting from the uncleaved probe a 
cleavage product was consistently absent.
Other factors were investigated including methodology for cleaning of 
the unlabelled test DNA, ratios of unlabelled test to labelled probe DNA, 
times of incubation with both hydroxylamine and piperidine and viability of 
stock solutions of chemicals, and solutions. However no cleavage occured 
even after variation of all of the variables. This was presumed to be due to 
vastly increased quantities of DNA used in order to achieve a signal, which 
was probably interfering with the chemistry of the reaction or inhibiting 
formation of sufficient quantities of heteroduplexes.
The second approach utilised two different methods of probe 
preparation, labelling of the PCR primers before amplification and inclusion 
of a radioactive nucleotide in the PCR reaction to achieve labelling of the 
probe along its length. Both of these methods produced better labelling of 
the probe but slightly increased levels of probe still had to be used in order 
to obtain a clear signal. Cleavage was obtained with the CF mutation using
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siliconised Sarstedt tubes as suggested by Howells et al. (1990), and a 
probe labelled along its length, produced three bands , the uncleaved band 
and the two parts of the amplification product after cleavage. The DMD  
mutation was subsequently detected using 5’-end labelled probe and only 
one cleavage band was seen as expected due to the fact that only one end 
of the probe was labelled.
Other groups utilised both of these methods successfully and 
suggested the inclusion of only one 5-prime labelled primer to give accurate 
information as to the exact positioning of the mutant gene depending on the 
size of the cleavage product. Although helpful this approach was neither 
feasible nor particularly necessary in these studies due to the low level of 
labelling which was later observed with the H G P R T  gene. As any 
suspicious exons were to be sequenced fully in the search for the molecular 
pathologies, the exact position of the mutation was not necessary 
particularly since this caused a decreased signal and could have led to the 
non-identification of a cleavage event due to the faint appearance of the 
cleaved product, as two primers needed to be labelled to ensure a signal of 
reasonable intensity.
The autoradiographs still had to be exposed to the gels for one to two 
weeks for a clear signal to be obtained. Saleeba et al. (1991), suggested 
the use of 35S-labelled probes in the CCM reaction, which they claimed 
produced a cleaner more easily interpreted signal . This was attempted for 
the CF mutation and no real difference was seen . There was the advantage 
of safer handling during probe preparation but increased quantities of 35S 
were required and this resulted in a much more expensive option.
Reports suggested that the CCM protocol should be able to detect the 
majority of mutations, but in this study, a variety of problems were 
encountered which rendered some mutations undetectable. Primarily , 
some of the exons in the HGPRT gene did not label well despite different 
labelling strategies employed. In particular exons 3 and 9 were problematic 
and this may have been due to the longer size of the amplification product. 
The PCR for exon 3 was not a robust PCR and the lower quantity of DNA 
obtained from the amplification of this exon coupled with the poor labelling, 
made CCM of this exon problematic. Often the uncleaved product could not
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be seen or was so faint that it would have been doubtful if a cleavage 
product would have been detected.
The second major restriction was caused by non-specific cleavage 
events which occured in many of the HGPRT and DMD exons. This 
resulted in cleavage bands occuring across all lanes of a particular exon as 
is shown in figure 3.15 and often resulted in masking of the true cleavage 
product. This was particularly noticeable with cleavage of exon 7 of the 
HGPRT gene, where in most cleavage reactions a non-specific band was 
consistently seen below the non-cleaved probe band. If control lanes were 
included this band could be clearly identified and with some mutations such 
as HGPRT Marlow the cleavage product could still be seen. However with 
some exon 7 mutations such as HGPRT North Mymms, a cleavage product 
could not be seen. The most likely explanation could be that either the 
sequence of this exon is such that a secondary structure could be formed at 
the lower temperatures used for the modifications by hydroxylamine and 
osmium and that these modified bases are then later cleaved by piperidine. 
Therefore if these secondary structures are formed by hairpin loops it may 
be that the actual mutation is present within the loop and may miss 
modification. A second possibility is that the actual mutation is close to the 
falsely modified siter* and therefore after cleavage by piperidine the 
fragment is so small that it is run off the bottom of the gel. This phenomena 
was seen primarily with exon 7 but several other exons also showed non 
specific cleavage and this coupled with probe degradation during the 
protocol often made results difficult to interpret.
Other mutations such as HGPRT Mashad which involved an A to T 
substitution and hence a T.T mismatch could not be detected by CCM. T.T 
mismatches have been detected in other studies (Dianzani et al. 1991), and 
although rare T.G mismatches have been reported which are not reactive. 
Therefore the reason for non-detection is uncertain but the most likely 
explanation is that the heteroduplexes did not form correctly or that the 
quality of the test DNA was not particularly good. Therefore while CCM 
appeared a very efficient protocol it must be kept in mind that some 
mutations were not detected whether due to non-reactivity of the mismatch, 
non-specific cleavage or high background and that a proportion of mutations 
may be missed using this method of screening. Further the time consuming 
nature of the protocol coupled with the use of hazardous chemicals, again
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limit the number of samples which could be handled at one time and the 
length of time required for exposure of the autorads was not practical for 
diagnostic use when large numbers of samples had to be analysed.
SSCP was not particularly effective in the detection of pathologies in 
the HGPRT gene. This was probably due to the large size of amplfication 
products containing the majority of the exons. The protocol did detect the 
mutations in the smaller amplification products, but it was i feasible at this 
point to design new primer sets for the entire gene which amplified small 
fragments, particularly when the HDHG protocol was working well with the 
existing primers. This method was therefore not fully evaluated at this point, 
but its potential role in the analysis of smaller amplification products and the 
ability of the protocol to analyse many samples at one time was noted.
4.1.3 Optimisation of DNA Sequencing Strategics.
Despite extensive optimisation, the manual sequencing of both the 
HGPRT  and DMD exons was very problematic. A direct sequencing 
strategy had been established in the lab by Charles MgGone (personal 
communication), following the protocol suggested by Gyllensten and Erlich, 
(1988), but this strategy appeared to be unsuitable for the majority of exons 
of the HGPRT and DMD genes. The first step in the protocol involved the 
production of single-stranded DNA templates and despite alteration of the 
primer ratios, cycling parameters and templates used in the asymmetric PCR 
reaction, no products, single or double-stranded, could be obtained from a 
PCR reaction where one of the primers were limiting for the majority of 
exons. This was not due to the lack of quality or quantity of the double­
stranded template as this allowed amplification when equal ratios of the 
primers were used.
Single-stranded DNA was obtained for exons 2, 4 and 6 and this 
probably reflects the robust nature of the PCR for each of these exons. The 
amplification of these exons very rarely failed and reasonable quantities of 
DNA were usually obtained. Further in the other mutation detection protocols 
these exons also produced good results. For exon 5 a smear was seen 
when the asymmetric PCR product was run on an agarose gel, but when this 
was sequenced no sequence was seen. The reason for the failure of the 
other exons to produce a product in this protocol may be primer or sequence
8Q
dependant, but also worthy of note is the fact that the exons which produced 
a product are generally the ones which are amplified in the smaller 
amplification products with the exception of exon 7, so both of these factors 
may be relevant. Further, use of sequencing primers internal to the 
amplification primers was essential to obtain sequence from the few exons 
possible.
Due to the failure of direct sequencing of asymmetric PCR products, 
other strategies were employed in an attempt to find the exact nature of the 
changes indicated by the other strategies. Primarily double-stranded PCR 
products were used as a template after chemical denaturation. This protocol 
had been successful for other groups sequencing double-stranded plasmids 
(F. Milan personal communication), but despite optimisation, no sequence 
could be obtained by sequencing of PCR products for any of the exons 
tested. This possibly reflected the quality or quantity of DNA obtained from 
the PCR product or the failure of the chemical denaturation. The probable 
explanation however is that that the structure of the PCR products, that of a 
linear double-stranded molecule, allowed renaturation of the denatured 
strands more quickly than a circular plasmid. This would explain the 
success of chemical denaturation when applied to a plasmid but not to a 
PCR product. A second approach was used in an attempt to obtain single­
stranded product, involving the phosphorylation of one primer prior to PCR 
and subsequent digestion of that primer and amplified strand by a 
phosphatase to theoretically leave one single-stranded product. This was 
attempted and despite the presence of small quantities of poor sequence it 
was apparent that this strategy would not provide the sequence data 
required.
Even when sequence was obtained , it was generally of poor quality 
and often sequence of both strands could not be obtained. With some 
exons, in particular exon 4 sequencing was problematic due to the large 
stretches of homonucleotides in the gene. These long stretches of polyA 
caused the sequenase to stutter producing unreadable sequence thus 
rendering the elucidation of the insertion in exon 4 of the pedigree 
impossible. Clearly another strategy was needed for the sequencing of 
double-stranded PCR products thus circumventing the need to obtain single­
stranded products and possible to obtain enhanced sequence from 
problematic exons.
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Towards the end of this project access to an ABI autom ated 
sequencer became possible, and so it was decided to attempt to sequence 
some of the remaining DNA samples from the Lesch-Nyhan families using 
flourescent automated sequencing, coupled to a sequencing chemistry 
which negated the need for single-stranded templates. This technique, 
cycle sequencing, had been used for manual sequencing, by others using 
radioisotope and a protocol was available for coupling this with the use of 
fluorescently labelled dideoxy terminators so the sequence could be read by 
an automated sequencer. The protocol relies on repeated cycles of 
sequence elongation from primers, resulting in signal amplification which 
enhances the detection of the sequence ladder. An optimised cycle 
sequencing protocol was supplied by ABI which should allow th e  
sequencing of the majority of sequences.
Different chemistries were available for automated sequencing, 
including the use of labelled primers or labelled terminators and in the use 
of Sequenase or Taq sequencing for analysis of single or double-stranded 
templates. Different chemistries have their benefits and drawbacks. 
Primarily the Taq terminator sequencing was chosen because a double­
stranded PCR product could be easily used as a template without 
conversion to single-stranded DNA . This allowed the original PCR primers 
to be used as sequencing primers without the expense of designing new 
nested primers or biotinylated primers for single-strand manufacture on 
magnetic beads which is the alternative approach suggested. For a 
multiexonic gene the expense employed in having multiple sets of 
biotinylated primers manufactured, plus internal sequencing primers could 
be too high in a diagnostic envirament. By using the cycle sequencing dye- 
terminator approach, all four terminators are present in one tube and are 
labelled in different colours and there is no need for each of the four 
terminators to be added to separate reactions as is the case for dye-primers. 
Thirdly, difficulty has been reported in obtaining sufficiently high quantities of 
single-stranded DNA to obtain a high signal in the dye-primer approach, 
while with cycle sequencing and dye terminators, a smaller quantity of DNA 
is required due to the PCR amplification of the signal.
There are however drawbacks to the Taq terminator chemistry. Taq 
shows characteristic patterns of incorporation of dideoxynucleotides as it 
does not incorporate all ddNTP’s with the same efficiency. This is
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exaggerated by the presence of the dyes attatched to the ddNTP’s as used 
in dye terminator reactions and the anomalous patterns are most 
pronounced in this chemistry. This is greatly dependent on the local base 
composition and sequencing artefacts can be created which are difficult to 
interpret >. This study involved looking for the presence of heterozygotes, 
seen as double peaks. In this chemistry the peakheights are variable and 
equimolar concentrations of two bases at a heteozygoi'ssite do not always 
appear as peaks of equal hight. Background peaks which are more 
apparent in this chemistry also confuse the analysis , but artefacts can often 
be recognised by several sequencing reactions and by sequencing in both 
directions. There are some constant patterns which can be seen in 
chromatograms and when these patterns are recognised bases can be 
correctly assigned. These artefacts include C and T bases after G bases 
being much weaker signals and hence smaller peaks, and varying 
strengt^ of bases in strings of the same base. These and other patterns 
can be recognised and help to distinguish between true double peaks and 
artefacts. Other problems such as removal of unincorporated ddNTP’s , 
cleaning up of the DNA templates and primers , gel artefacts such as 
unequal polymerisation , compressions and failure of sequencing due to 
bad DNA and primers still all occur.
The automated sequencing protocol was originally applied to the 
Lesch-Nyhan exon 2 which sequenced comparatively well using the 
previous strategies. This produced a good sequence and where DNA was 
available exon two from families with a mutation in that exon were analysed. 
The other exons were then sequenced used the same primer as was used 
for PCR with mixed results. Exon four could once again not be sequenced 
in either direction due to the strings of homopolymers after the primers, and 
exon five although producing a signal, still gave noisy sequence which was 
difficult to interpret. Exon three could be sequenced providing internal 
sequencing primers closer to the known mutation were designed. The 
protocol proved to be more effective than the manual sequencing, however 
the poor quality DNA and lack of DNA from several family members 
hampered a true analysis of the potential of this form of sequencing. Further, 
in cases where the mutation was known and the position and nature of the 
potential double peak was known,the presence or absence of the mutation 
could be seen. Where the mutation had not been previously identified it was 
problematic to identify a hetozygote from the backgroundartefacts and no
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new substitutions were identified in the HGPRT or DMD gene using this 
protocol. It was also easier to identify insertions or deletions in the 
heterozygotes as from the point of the base addition or subtraction the 
remaining bases were out of sequence and double peaks resulted along the 
length of the region.
This automated sequencing strategy was applied to the analysis of 
exons with band shifts in the BRCA 1 gene using the PCR primers as 
sequencing primers. Mixed results were obtained with some exons 
producing clean clear sequence and other exons proving difficult to 
sequence. However with increasing quantities of both template and primer 
and by designing a few internal primers most of these problems could be 
erradicated. Base insertion and deletions were again easier to identify but 
base substitutions were hard to notice against a background of unequal 
peak hights. The substitutions were easiest to detect when polymorphisms 
were present where the two species of homozygous sequence and the 
heterozygous sequence were sequenced and compared.
From our experience this automated sequencing was the best 
sequencing methodology available. Unfortunately by this stage there was 
no more of many of the Lesch-Nyah samples to confirm the heteroduplex 
detection, linkage analysis and CCM results. It was best applied to known 
mutations where the area of double peak could be expected therefore 
another mutation detection strategy to pinpoint the approximate location of 
the mutation once analysed by SSCP may need to be used.
4.2 Application of Screening Strategies to the Detection of M ote iu ia i 
Pathologies in Multi-exonic Genes.
After optimisation and evaluation of several mutation detection 
protocols, a strategy was needed for the detection of mutations in 
multiexonic genes. Many other groups have utilised a spectrum of mutation 
detection protocols and the most direct method appeared to be by analysis 
of the cDNA from these genes. This strategy had previously been applied to 
the analysis of the HGPRT, DMD and BRCA 1 genes and would decrease 
the workload of analysis of all exons individually as well as easily revealing 
where mutations had caused splicing aberrations due to the decreased size 
of the cDNA transcript. In this study however, this approach was not feasible
with the exception of one family, due the nature of the raw material available 
for analysis. The samples from the majority of the Lesch-Nyhan families 
available for the majority of the project, existed as old frozen blood, 
lymphoblastoid and fibroblast samples that had been temporarily thawed 
during transportation and at other stages. The material had therefore been 
damaged , and coupled with the fact that many of the lymphoblastoid and 
fibroblast cell lines tested were found to be contaminated by mycoplasma, 
(an HGPRT gene bearing organism), it was unlikely that RNA of sufficient 
quality could be harvested.
The majority of the boys with DMD/BMD were deceased and therefore 
the material available in stock, generally DNA, had to be utilised as little 
fresh samples could be obtained. Primer sets were also available for the 
amplification of the individual DMD  exons so it was concluded that a 
strategy was needed for the analysis of multiple exons of the two X-linked 
genes.
The most readily availible source of material from the majority of the 
BRCA1 families was again DNA and where RNA was available it was often 
unstable and cDNA’s derived often did not sustain amplification. Further, 
primers had been designed and the PCR optimised for an individual exon to 
exon approach and different groups in the consortium manufacturd different 
primers so no one group had to manufacturedthe entire complement.
The X-linked nature of the first two diseases studied was both 
beneficial and detrimental. The X-linked location was beneficial as deleted 
portions of genes in males could be identified by PCR as there was no 
normal copy of the DNA from which amplification could occur and block 
detection as would occur with an autosomal gene. In the cases where no 
male DNA was available, maternal DNA had to be used. It is also beneficial 
because sequencing of male DNA produces sequence from only the 
affected allele and was not confused by the presence of the sequence from 
the normal allele . Heteroduplex analysis was however problematic as 
two alleles were required for heteroduplexes to be formed. This was easily 
rectified by the addition of control DNA to male DNA during PCR prior to 
heteroduplex detection, so that a potential heterozygous state could be 
established. A polymorphism in the control DNA was easily identified as all 
lanes would contain a doublet. In this instance, another control sample 
would be added to the test DNA.
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The analysis of the mutation detection strategies revealed that in 
these experiments , heteroduplex detection using hydrolink gels was a more 
suitable strategy as a first line screening protocol in the HGPRT gene to 
determine which exon contained the mutation. This method allowed the 
detection of all tested mutations after modification, while SSCP analysis 
produced confusing results, did not detect all of the mutations and for the 
majority of mutations probably required digestion of the PCR products into 
smaller fragments for analysis or the manufacture of primers which amplified 
the exons in smaller segments. This further confused the results as weii as 
increasing the cost and amount of work required. The second reason for the 
preference, was the relative safety and speed of the two protocols. 
Heteroduplex detection using hydrolink gels allows the loading of increased 
quantities of DNA into each well on the gel without loss of resolution so the 
bands can be easily detected by ethidium bromide staining. For SSCP 
analysis on acrylamide gel matrices the products were radioactively labelled 
for detection. Protocols have been suggested for non-isotopic methods of 
SSCP analysis but these proved to be technically difficult and unsatisfactory 
in our hands. Heteroduplex detection using hydrolink gels therefore proved 
to be more convenient rapid and safe due to the lack of radioactivity and 
hence the lack of need for time consuming autoradiography and radiation 
handling. Further, SSCP has been shown in several studies to be more 
efficient at detecting mutations in smaller fragments of DNA ideally of 
approximately 200-400bp in size. The majority of HGPRT  exons were 
amplified in fragment sizes exceeding these parameters and heteroduplex 
detection on hydrolink gels has been shown to be able to detect mutations in 
fragments up to 1.3 kb in size which allows direct analysis of all exons 
analysed in this study without the need for restriction enzyme digestion. Due 
to the small number of exons in the gene and the comparitively low number 
of affected families the limitation of loading of only 10 samples per gel did 
not hamper this analysis, but it was apparent that with genes with a large 
number of exons and many samples to be analysed this could be a rate 
limiting step.
For detection of pathologies in cases where the mutation had not 
been identified, the DNA was extracted where required, though only a 
limited quantity of poor quality DNA was obtained from most samples. The 
strategy used for detection of mutations in the HGPRT gene, is outlined in 
figure 3.11. For the HGPRT gene, the individual exons with the exception of
exon 1 which could not be amplified, were amplified using PCR to identify 
the presence of large length mutations. Any bands of larger or smaller than 
expected size were then attempted to be sequenced to identify the exact 
nature of the insertion or deletion. Lack of amplification of an exon indicated 
the deletion of a whole exon or part of an exon of the gene which are 
reasonably common in Lesch-Nyhan syndrome.
The majority of mutations in Lesch-Nyhan syndrome result from a 
heterogeneous collection of point and small length mutations, (Davidson et 
al., 1988,1989, 1991; Gibbs et al., 1989; Gibbs et al., 1990; Marcus et al., 
1992; Yamada et al., 1992; Steingrimsdottir et al., 1992; Sege-Peterson et 
al., 1992; Tarle et al., 1992, Fujimori et al., 1991). Over 100 mutations have 
been described which cause Lesch Nyhan syndrome and H G P R T  
associated gout. A notable feature of the list is the great variety of mutations 
that can cause Lesch-Nyhan syndrome with mutations being present along 
the entire length of the gene. Many of these mutations have been 
documented in the computer databases. 61 such mutations were 
documented in The Mendelian Inheritance in Man’ and these appear to be 
representative of the types of pathologies found in this gene for HGPRT 
deficiency diseases. Of these mutations described 65.5% of the mutations 
were single base substitutions which lead to single amino acid substitutions 
or the introduction of premature stop codons which results in the production 
of a truncated protein. Approximately 8% of the mutations were the result of 
base insertions into the HGPRT gene and 23% were due to deletions of 
variable sizes including some of 1bp leading to frameshifts and premature 
stop codons and some of whole exons or indeed the entire HGPRT gene. 
The remainder of the mutations were complex gene rearangements 
involving insertions, and deletions which altered the entire structure of the 
coding sequence and hence the protein. Many of the pathologies resulted 
in abberant splicing of the HGPRT gene and while many of these were 
discovered as a result of examination of the cDNA from patients, these 
changes should also be apparent if the intronic sequences adja-cent to the 
exons are examined in cases where no RNA is available.
Due to the wide range of mutation types found in this gene and the 
presence of pathologies reported along the length of the gene and in the 
intronic sequences, a strategy was required to screen for large and small 
DNA changes. After PCR analysis had excluded large aberrations, the
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exons were screened for the presence of small changes. This was done 
primarily by heteroduplex detection on hydrolink gels, with each sample 
being analysed several times by using at least two different PCR reactions 
with at least two different control samples used. The samples were run at 
different voltages on different lengths of gel with the guidelines learned from 
the optimisation of the protocol using known mutations in the different exons 
used . However, despite the apparent success of heteroduplex detection on 
hydrolink gels in this study, extensive optimisation was required for each 
mutation and due to the lack of information from other groups as to the 
percentage of mutations detected, it has to be presumed that some changes 
may have been missed by this protocol due to failure of the PCR to amplify 
both alleles or due to the failure of the gel matrix to separate the different 
duplexes. For this gene therefore all the exons from the 13 families were 
also examined for base changes by CCM analysis using both 
hydroxylamine and osmium tetroxide to modify all potential bases before 
cleavage with piperidine. Once more information is available as to the 
eneuiveness of the hydrolink protocol only the exons deemed suspicious by 
ihis protocol would be screened by CCM analysis.
Due to the nature of the CCM protocol, a certain degree of probe 
degradation occurs and this often potentially obscured the identification of 
cleavage products. While CCM is a potentially ideal method for the 
theoretical detection of 100% of mutations there are many technical 
difficulties as was described, which can cause difficulties in the interpretation 
of results. Also due to the complex nature of this time consuming, 
hazardous, multi-stage protocol, human and technical errors involving such 
factors as fluctuations in temperatures of water baths or the preferential 
formation of homoduplexes, or even deficient labelling of probes, failure of 
the protocol cannot be excluded and some mutations may be missed. Once 
again, the time consuming nature of the protocol and the limitation in the 
number of samples which can be handled at one time, limits the value of this 
protocol for large genes, where many samples need to be analysed.
Using the strategy outlined for detection of mutations in the HGPRT 
gene, four mutations were definitively found in the families studied. Three of 
these could be sequenced the first of which being a G-A substitution in exon 
2 in the index case from pedigree Gla 7292. This mutation resulted in an 
amino acid substitution of lysine for arginine at amino acid 45 and as the
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mutation occuned in the last coding bases of exon 2 , may interfere with the 
splicing of the gene. No RNA was available to confirm this finding. This type 
of substitution mutation is the most common found in the HGPRT gene and 
this mutation is fairly representative of the type of mutations most commonly 
found. The second mutation , a T deletion in exon 6 of the index case from 
the pedigree Gla 7291 results in a frameshift mutation leading to the 
production of a truncated protein. Deletions of one base to entire portions of 
the gene are common in Lesch-Nyhan syndrome and again this type of 
mutation is fairly representative of the type of mutations which would be 
expected to be found. The third mutation discovered however, was more 
unique, a 60 bp insertion in the cDNA of the index case from the 
pedigreel 0427. The DNA from this index case could not be sequenced as it 
was difficult to obtain an amplification product from this region of the DNA. 
After sequencing the cDNA, the sequence was compared to a sequence 
database and an Alu sequence had been inserted into the cDNA between 
exons 6 and 7. There have been no previous reports of the insertion of only 
an Alu sequence into the HGPRT gene, but there has been one report of the 
duplication of a region of the gene which arose through unequal 
homologous recombination betwee two Alu sequences and involves a much 
larger duplication of some 1.8kb (Marcus et al.,1993). The origin of the Alu 
sequence and the exact point of theinsertion could not be further 
characterised as the DNA could not be sequenced. The fourth mutation, a 
large insertion in exon 4 of the index case from the pedigree 7293, could 
not be sequenced but the presence of the insert could be clearly identified in 
family members. DNA was not available from other family members from two 
of the pedigrees but if these are provided in the future the mutations can be 
clearly identified by the methods described.
Over 70% of the pathologies in the DMD gene were large deletions of 
one or more of the exons of the gene. The index cases with DMD in this 
study had previously been screened for deletions and the remaining index 
cases where no deletions were detected were screened for the presence of 
smaller changes such as small insertions, deletions and substitutions. The 
majority of the small changes previously reported in the gene caused the 
production of truncated proteins and the ideal scenario would have been to 
carry out protein truncation analysis on cDNA from the index cases. 
However no RNA was available for any of the index cases and as many had 
died, the only material available for analysis was DNA. Due to the
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increased number of exons in the DMD gene, it would have been too 
expensive and time consuming to analyse all the exons where PCR primers 
were available (21 in total) from every individual with both hydrolink and 
CCM strategies. Therefore only the exons which yielded suspicious results 
after heteroduplex detection were analysed using CCM.
The ideal protocol would result in the sequencing of suspicious exons 
to identify the exact nature of the mutations. This stage of the strategy was 
the weakest link in the chain as the manual sequencing strategies were 
problematic for both genes as was described. At this stage access was not 
availible to an automated sequencer. Small amounts of poor sequence 
was obtained and even after extensive optimisation it was very difficult to 
obtain adequate sequence information for many of the potential mutations. 
Added to this is the potential hazard of introduction of base changes by the 
PCR protocol itself. Consequently although potential mutations were 
present in many of the families these could not be conclusively identified at 
this stage. Many of the DNA samples were finished or degraded by the 
advent of the automated sequencing strategy and in future mutations found 
in other genes would be sequenced in this manner.
Primer sets were available for 21 exons of the DMD gene and in 
some of the individuals, 9 of these exons had previously been analysed by 
SSCP analysis by Kataki, (1992) and no mutations had been found. Due to 
the fact that SSCP was found to detect only a percentage of known 
mutations analysed in this study and that many false positives were 
reported, these exons from these individuals as well as all the exons from 
individuals where no analysis had been carried out were screened using 
HDHG and CCM analysis in an attempt to find small mutations or 
polymorphisms which may have been present.
Primer sequences for the 21 exons were available (Chamberlain et 
al., 1988, Beggs et al., 1990, Abbs et al., 1990), and the conditions for the 
amplification of individual exons using primer sets a-i had been optimised by 
Kataki, (1992). The PCR reaction for the amplification of the remaining 
exons individually was easily optimised in this study and the PCR reactions 
for the majority of the DMD exons were very robust and few spurious bands 
were seen. The primers for amplification of exons a-i were however quite 
old and during the course of the study amplification failure occured but could
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usually be re-established either by increasing the quantity of the primer used 
in each reaction or by cleaning of the primer by precipitation.
HDHG was used as the initial screening strategy and as for the 
HGPRT gene, control DNA was added to the PCR reaction to create a 
potential heterozygote state. All the amplification fragments were of a small 
to medium size and the hydrolink gels run were 20cm in length. The HDHG 
protocol was straightforward and the robust nature of the PCR reaction 
provided a good quantity of clean DNA for heteroduplex analysis. However, 
in several exons in particular exons 43 and 50 the results were unclear as 
when the PCR product was run on a hydrolink gel a second band was 
consistently present above the first in all lanes which was not seen on 
agarose gels.
The exons which showed a positive or suspicious HDHG result were 
then analysed by CCM analysis using both hydroxylamine and osmium 
tetroxide . This appeared less problematic than for the HGPRT gene as the 
robust PCR allowed good labelling of the probes and less background on 
the autorads. There were however still some non-specific cleavage products 
for some exons which hindered the analysis of the results. Lack of DNA or 
primer sets hindered the analysis of the exons from some index cases. 
However the CCM analysis confirmed the HDHG results.
As with the HGPRT gene, the direct sequencing of the PCR products
from the asymmetric PCR proved to be problematic and single-stranded
products could not be obtained for many of the exons despite applying all
the optimisations previously described. Sequence could not therefore be
obtained by this methodology to confirm several of the changes found. The
changes found in this gene could have been polymorphisms and as these
have been reported within the DMD gene it could not be presumed that any
changes found were the molecular pathologies responsible for the disease.
Internal primers were not available for any of the exons due primarily to the genomic
lack ©^sequence information available at the time of analysis and to the 
quantity of exons being screened. Double-stranded sequencing was also 
applied to several exons but once again no sequence was obtained. 
Sequence was obtained for two of the particularly suspicious exons which 
showed both positive HDHG and CCM results , namely exon a from 
pedigree 6397 and exon b from pedigree 5117, but many stops and
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compressions were present and this may have led to any mutations which 
were present being masked. The results of the screening for pathologies in 
the DMD gene were very disappointing and the possibility remains that the 
large size of the gene is not suitible for analysis of the DNA exon by exon. 
Other strategies which look at larger portions of the gene at one time such as 
protein truncation studies, seem to have been succesfull and are probably a 
better way to look for mutations in this gene.
After the discovery of the BRCA1 gene by Miki et al., (1994), Many 
mutations were reported in the BRCA1 gene in families with early onset 
breast/ovarian cancer. (Castillla et al., 1994; Friedman et al., 1994; Simard 
et al., 1994; Shattuck-Eidens et al., 1995). These mutations are reported 
along the length of the gene with the only clustering of the mutations 
appearing to be in the RING finger motif, which while only encoding for 2.3 
% of the protein, contains 11% of the mutations so far described. Shattuck- 
Eidens et al., ((1994) published a collaborative study detailing the mutations 
found in the BRCA 1 gene by groups throught the world and from a study of 
these mutations coupled with other mutations subsequently described, it 
appears that the majority of BRCA 1 patholagies (79% in the Shattuck- 
Eidens study) are small frameshift or nonsense mutations resulting in 
truncated or unstable proteins. The possibily must however be considered, 
that these mutations may be the easiest to detect using the methods so far 
chosen to look for mutations and due to the autosomal nature of the gene , 
deletions of entire exons of the gene may be missed when DNA is analysed 
as the normal copy of the gene from the other chromosome can be amplified 
and mask the deletion. Several of the mutations described have been 
found in unrelated familes representing possible common mutations which 
can be screened for as a first step in any screening strategy. 38% of the 
original mdations found are recurrent and these mutations account for 
approximately 63% of the total mutations detected in the Shattuck- 
Eidens(Shattuck-Eidens et al., 1995) study and indeed a large proportion of 
the pathologoes more recently reported are due to one of these mutations.
Due to the large size of the BRCA1 gene and the fact the the gene 
was amplified in over 39 segments, coupled to number of samples for 
analysis(60 family member samples, 100 sporadic tumours and 50 ovarian 
tumours) it wasnotfeasible to analyse this gene using HDHG analysis. The 
primers for this gene were designed to produce products of less than 300bp,
so it was decided that SSCP analysis coupled with an automated 
sequencing strategy would be employed. Further, this was the method 
employed by the majority of groups looking for BRCA1 mutations. The 
exons were amplified and the gels run under two conditions, at room 
temperature and at 4°C, in order to obtain maximum efficiency of detection. 
Each gel could run with 48 samples and any shifts seen were sequenced. 
Many band shifts were observed and all were scanned for the presence of 
heteroduplex bands in the sequence chromatograms, keeping in mind the 
limitations previously discussed. The blood samples were analysed, where 
any changes would probably be in a heterozygous state, while in the tumour 
samples loss of heterozygosity would result in the loss of the normal allele. 
Many fragments exhibiting a band shift showed no obvious changes and it is 
uncertain if this is due to the high false positive rate of SSCP analysis or to 
the failure of the sequencing strategy to show these mutations. Substitutions 
were harder to identify than insertions or deletions and in cases where 
known mutations were being sought, it was easier to detect the changes >< 
when the location was known. However, this strategy seemed good for this 
gene and four mutations were discovered in seven families and three 
polymorphisms were identified. Not all areas of the gene could be analysed 
at this point, so the strategy aimed the detection to regions of the gene 
previously shown to contain mutations. This included exon 11 which was 
the first region to be analysed and exons 2, and 20 and intron 5, which 
were shown to contain common mutations. Two of the common mutations 
the C insertion in exon 20 and the AG deletion in exon 2 each resulting in 
the production of a truncated protein, were each found in one of our families 
and a third mutation, an AA deletion in exon 20 , which had been described 
by Friedman et al (1994) in one family, was found in four Scottish families 
possibly indicating a common Scottish mutation. This mutation resulted in a 
truncated protein and if it appears to be relatively common in the Scottish 
population , antibodies may be able to be made against the protein 
sequence after the frameshift and this mutation may be able to be found on 
the bases of antibody recognition. The fourth mutation was an A-G 
substitution in exon 2 resulting in an lie to Val amino acid substitution. While 
these amino acids are very similar, the position of the substitution, at the 
second base of the RING finger motif may reflect its pathological importance. 
This mutation highlights one of the problems associated with mutation 
detection and hence carrier detection in this gene. The function or slructure 
of the protein is not yet fully understood and it is very difficult to determine
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the importance of many of the mutations found. Many single base 
substitutions could be polymorphisms that track with the disease through a 
family and hence base substitutions found need to be looked for in the 
population. This mutation in our family was not present in any of the other 
BRCA1 families or in any control DNA analysed but untill the function and 
structure of the BRCA1 protein is further characterised no further information 
can be gathered about this mutation and many others reported by other 
groups. Richard and Beckmann(1995) reported a silent third base mutation 
in the calpain ger\e(CANP3 ), a gene associated with chromosome 15- 
linked limb girdle muscular dystrophy. This apparent neutral polymorphism 
led to the production of an abnormally sized transcription product. They 
demonstrated that this mutation was actually a gain of donor splice sbfce 
mutation. Computer programmes failed to predict the creation of this splice 
sight which could only be demonstrated by the analysis of illegitimate 
transcripts from the gene. Other such mutations have been reported and 
these pathologies highlight the potential for any base change found in 
affected families to be significant and that these changes may be further 
characterised by analysis of the gene trascripts. In the remainder of families 
a portion of the gene was still to be analysed, but it is uncertain whether 
many of these families are linked to the BRCA 1 gene, as clinics sent the 
DNA purely on the basis of a positive family history which could be due to 
the clustering of sporadic cases or to another familial gene. Further, linkage 
analysis was not possible in the majority of these families as DNA from key 
family members was not available. Even in families where linkage has been 
positively attributed, it is impossible to rule out the possibility that females 
within the families may have sporadic breast /ovarian cancer and that the 
index cases examined for mutations in these families may be such cases 
and hence no mutations will be found.
For the majority of the tumour DNA samples where no BRCA 1 
mutation has yet been identified, the mutation may be present in regulatory 
regions of the gene not yet analysed or these mutations may be present in 
other regulatory genes or other genes in the region not yet identified, which 
may be downstream in the BRCA1 regulatory pathway. The methodology 
used to detect the mutations may be missing a proportion of the changes 
and other strategies such as the protein truncation test (PTT) which was 
used by Hogervorst et al ., (1995) succesfully to find several novel BRCA1 
mutations may need to be employed in conjunction with other technologies.
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As the majority of breast cancers are thought to be sporadic it would 
be important to ascertain if BRCA1 has a role in the initiation or progression 
of sporadic cancers. Several other cancer predisposing genes , such as the 
Rb gene and the adenopolyposis coli gene, have been shown to be 
initiators of the tumourigenic process and in inherited disease the affected 
individual inherits one mutated copy of the gene through the germline and 
acquired the second mutation to the other copy. The observation that many 
sporadic breast and ovarian cancers also show loss of an allele in the 
BRCA1 region, support the potential role for the BRCA1 gene in these 
cancers (Futreal et al., 1992, Saito et al., 1993, ). Although Futreal et al., 
(1994), examined sporadic breast/ovarian tumours with LOH , only a small 
percentage contained mutations in the BRCA1 gene and these mutations 
appeared to arise in the germline. Recently, mutations have been reported 
in sporadic ovarian cancers (Merajver et al. 1995, Hosking et al. (1995). No 
mutations have as yet been identified in sporadic breast cancers indicating 
that BRCA1 mutations may have no role in the development of these 
cancers. In this study we were unable to look for mutations in the majority of 
the sporadic breast and ovarian cancer DNA’s. Most of our material was 
provided as blood samples from genetic clinics, and in sporadic tumours the 
mutation would not be present in the blood ,only in the tumour. However 
some of the cases detailed as sporadic could have been due to familial 
cancer cases and hence to mutations in the BRCA1 gene. These presumed 
sporadic breast and ovarian cancer blood samples were analysed by ASO 
hybridisation for the common mutations, but none were found in any of the 
samples.
4.3. The Application of Mutation Detection Strategies to the Detection of the 
Mutant Gene in Lesch-Nvhan Familes.
DNA was available from several female family members of index 
cases with Lesch-Nyhan syndrom^but for females, clinical evaluation is not 
a reliable form of carrier determination and the biochemical analysis of 
female carriers is problematic. Carrier detection is most reliable where DNA 
analysis is diagnostic, and this can be done using linkage analysis or by 
direct detection of the mutation.
Linkage analysis has been used for many years to track the path of a 
disease carrying chromosome or gene within a pedigree. This can be done
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using conventional RFLP analysis or if a tandemly reiterated sequence 
which is highly polymorphic is available at a close proximity to the gene 
being traced, this can be a valuable and stable marker. One such 
hypervariable short tandem repeat (STR) reported within the HGPRT gene 
(Edwards et al. 1991), contains a tandem AGAT tetranucleotide repeat motif 
present in 9-16 copies. It is stably inherited and can be easily amplified by 
PCR using flanking primer sequences (Edwards et al. 1991).
This STR was used in this study to attempt to crudely determine the 
carrier status of female relatives of boys with Lesch-Nyhan syndrome. The 
PCR-STR approach was used in nine families where DNA was available 
from a sufficient number of key family members. In six of these families the 
alleles were informative and carrier status could be assigned as is shown in 
figure 3.23. In three of the families however the STR was uninformative due 
to the maternal alleles being non-informative or to the lack of DNA from key 
family relatives.
This PCR based strategy was very robust and has several 
advantages over conventional RFLP, Southern blotting, in the analysis of 
this disease. Often very small quantities of partially degraded DNA was 
available and amplification of the DNA by PCR negated the need for larger 
quantities of DNA that would be required for Southern Blotting after 
restriction enzyme digestion. The PCR-STR approach also provided results 
more quickly than Southern blotting and the position of the STR within the 
HGPRT coding sequence also reduced the likelihood of false results due to 
recombination between the gene and the marker.
There are several limitations however to this form of indirect carrier 
detection. As with conventional RFLP linkage analysis, DNA has to be 
available from key family members and this DNA is not always readily 
available. In many cases the alleles from the missing people can be 
determined by looking at the alleles present in the other family members, 
particularly the children as was the case with family 10185 (figure 3.23.e). In 
this pedigree the grandmaternal and grandpaternal alleles needed to be 
determined to see whether the aunt of the index case had inherited the 
chromosome which tracked with the affected allele. However this is not 
always possible and the absence of DNA from key family members hindered 
the application of this methodology in many of the families . Non-paternity is
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also a problem in this and conventional linkage analysis. In one pedigree 
10195 , where the maternal allele is not informative, the allele sizes clearly 
show that one daughter has not inherited one of her alleles from either 
parent . This suggests non-paternity and puts a question mark on the 
paternity of the other family members. In this case the allele which was not 
inherited from the father was clearly visible but in other cases where 
paternal DNA is not available or the paternal alleles cosegregates
with ihe maternal allele, the entire diagnosis could be
jeopardised. Varying figures have been quoted for rates of non-paternity , 
with levels quoted as high as 10%. This is therefor a potential pitfall of this 
type of carrier detection .
Following the segregation of alleles in a family can determine clearly 
which female family members are not carriers, barring the possibilities of 
recombination and non-paternity already discussed. However if a female is 
shown to have inherited the same allele and hence the same chromosome 
as an affected index case, it cannot be definitely concluded that she is a 
carrier. This is due to the 1/3 rate of new mutations in affected index cases . 
Only 2/3 of mothers of affected boys will theoretically carry the mutation 
which may be a new mutation in her germline cells or in her parents. The 
exact origin of a mutation in a pedigree can never be determined by linkage 
analysis so a percentage of female relatives will be falsely assigned as 
carriers. Some of the aunts of affected boys in this study could have their 
carrier status clarified by looking at the grandparental alleles to identify 
whether the mother has inherited the grandpaternal or grandmaternal allele. 
If she has inherited the grandpaternal allele, then as he only has one X 
chromosome and is not affected by the disease, it suggests that the new 
mutation is in the mothers germ line and could not be present in any of her 
sisters barring the possibility of gonadal mosaicism.
Even after all of the disadvantages of this system have been 
considered, it it clear that in this gene, linkage analysis using this marker has 
been very successful as a first step in the determination of carriers. This 
technology could therfore be applied to genetic counselling in families which 
were informative, but a more satisfactory result could be given when this was 
coupled to direct mutation detection and the actual pathology shown to be 
present or absent.
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Consequently, direct mutation detection strategies were employed in 
families where DNA was available and HDHG , CCM and sequencing 
analysis were applied to each family. Ideally both protocols should have 
provided information in each family and a definite carrier assignment made.
However, due to some of the deficiencies outlined previously, this 
was not the case and in many families definitive results could not be 
obtained for some of the protocols . In only four of the families were both 
strategies informative and both CCM and HDHG results indicated carrier 
status in all female relatives available. In a further family CCM and HDHG 
were not needed as a large insertion in exon 4 of this family allowed carriers 
to be directly assigned by running the PCR product on an agarose gel. In the 
pedigree 10427 the presence of a 60bp insertion in the cDNA could also be 
indicative of carrier status in female family members, which were not 
provided to us. In the two families analysed where the molecular pathology 
was in exon 7, one mutation was clearly identified by CCM and the other 
was not. Unfortunately the mutation was identified in two brothers with gout 
who had the mutation HGPRT Marlow and as they had the disease, it was 
already clear that any daughters would be carriers, therefore negating the 
need for carrier detection. In the other family with the mutation HGPRT North 
Mymms, the mutation could not be detected by CCM, probably due to the 
presence of the non-specific cleavage product which was masking the true 
cleavage product. This mutation could however, clearly be identified in the 
index case by HDHG analysis, and appeared to be absent in the DNA from 
female family members indicating that it was a new mutation in the index 
case. The sequencing results from the automated sequencer support the 
HDHG results, although no more DNA was available from the index case. 
So despite one sister(3, figure 3.26) appearing to have the same maternal 
chromosome as the index case in the linkage analysis, it appears that 
neither she nor the mother is a carrier
CCM also failed to detect the mutation in exon 2 from the pedigree 
10197 (HGPRT Mashad), while HDHG and sequencing results, indicated 
that all the sisters were not carriers. HDHG also clearly allowed carrier 
assignment to the mother and aunt of the index case from the pedigree 
10199(HGPRT Runcorn) though a limited amount of DNA was available for 
this family and neither linkage analysis or CCM could be carried out to 
confirm this data.
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For the pedigree 10198 (HGPRT Codicote), linkage analysis was 
uninformative, and insufficient maternal DNA was available for direct 
mutation detection protocols. The mother was however an obligate carrier, 
due to the detection of HGPRT deficiency in a second male fetus which had 
been terminated. The DNA from the sister and aunt showed no 
heteroduplex band or cleavage product and although no DNA was available 
for sequencing of the index case , no T insertion appeared to be present in 
these two individuals. These results taken together indicate that these 
females are not cariers and other female family members could easily be 
screened when DNA samples become available.
In pedigree 10186, the mutation,a G to C substitution in exon 3 , 
caused an alteration in a restriction enzyme sight and no mutation detection 
strategies were required as the carriers could be assigned by presence or 
absence of the cut at the restriction enzyme site (S. Laughlan, personal 
communication). This was the ideal situation as mutations which alter 
restriction sights can be easily identified without the need to undertake other 
time consuming protocols.
The results of the direct mutation analysis on these families was 
disappointing . In some of the families no further information could be given 
beyond linkage analysis as the mutations were previously unknown and 
could not be fully characterised due to lack of sequence information. In 
other families CCM proved problematic due to insufficient probe labelling or 
high background signal due to probe degradation. While HDHG proved 
very reliable when definite mutations were being sought in index cases, the 
interpretation became more complex when the presence of the mutation was 
uncertain . This would be satisfactory if CCM and sequence information 
confirmed the data, but carrier assignment would not be given on the 
strength of this alone. If the direct sequencing protocol could have been 
optimised this would have provided the definitive carrier designation and the 
way forward for more comprehensive carrier designation would be to find a 
suitable strategy for obtaining consistant sequence for all exons. The 
automated sequencing protocol did however provide further information in 
five families. This coupled to the fact that the sequence information agreed 
with the HDHG and CCM data, made the data reliable and carrier status 
could be further confirmed.
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As no mutations were identified in the DMD gene no carrier detection 
could be carried out on female family members.The large size of this gene 
may indicate that the strategies examined here are not suitable for such a 
large gene and that possibly examination of the cDNA to reveal abnormal 
transcripts or the use of strategies to analyse the protein such as protein 
truncation studies may be more suitable. At this stage it was not feasable to 
do carrier detection for mutations found in the BRCA1 gene. Most detection 
of the pathologies in Scotland at this stage were carried out in a research 
envicnment and no defin ite plan for screening family members has yet been 
implemented until many of the problems associated with screening in this 
disease have been dispelled.
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APPENDIX 1
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SOLUTIONS
/\ii solutions were prepared with distilled water and are listed alphabetically.
2X annealing buffer(CCivi; ;i2mfvr "i ns-nCi pH 7./, f.2M NaCi, Mmfvi 
MgCI2. The solution was autoclaved and stored at room temperature.
5X annelaing buffer(sequenase 2. kit USB): 200mM Tris-HCI pH 7.5, 100mfvi 
MgCl2, 250mM NaCI. Stored at -20°C.
Chorion buffer : 50mM Tris pH7.5, 100mM NaCI, 1mM EDTA,.
Denhardt’s solution : 2%(w/v) BSA, 2%(w/v) Ficoll, 2%(w/v) 
polyvinylpyrolidone
dNTP mix(Boeringer): A stock solution of dNTP’s was made up by mixing 
5ml of each dNTP (dATP, dCTP, dGTP and dTTP), with 380ml of double 
distilled water. Stored at -20°C.
‘HOT’ stop solution : 0.3M sodium acetate pH 5.2, 0.1 mM EDTA, 25mg 
tRNA/ml. Solution autoclaved before addition of tRNA and stored at -20°C.
Hydroxylamine solution : 1.39g hydroxylamine in 1.6ml ddH20, adjusted to 
pH 6.0 by addition of diethylamine. Solution made up on day of use.
Kinase buffer : 0.5M Tris-CI pH 7.6, 0.1M MgCI2, 50mM DTT, 1mM 
spermidine, 1mM EDTA.
Loading mixl, for acrylamide gels and SSCP gels : 95% formamide, 20mM 
EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol.
Leading mix 2, for agarose gels. 0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 40%(W/V) sucrose in water.
Loading mix 3, for hydrolink gels: 5% sucrose, 0.06% orange G, in water.
Leading mix for automated sequencer gels : ipan ^2umM EDTA, 30mg blue 
dextran): 5 parts diionised formamide.
Lysis buffer : 0.32M sucrose, 10mM Tris-CI pH 7.4, 5mM MgCI2, 1% Triton X- 
100. The solution was autoclaved and stored at 4°C.
NEW solution(Geneclean Kit) : 0.5ml concentrated NEW solution (supplied 
with kit), 10ml ddH20, 11.1 ml 100% ethanol(filtered). Stored at -20°C.
Nuclei lysis buffer : 10mm Tris-CI, 0.44 M NaCI, 2mM EDTA pH 8.2. The 
solution was autoclaved and stored at room temperature.
Os04 buffer: 10mM Tris-HCI pH 7.7, 1mM EDTA, 1.5% pyridine. Solution 
stored in safety cabinet in a darkened container.
1.7?
0s04 solution : 0.5g/12.5ml ddH20 left to dissolve for 48hours before use.
Solution is stored in a safety cabinet in an airtight daikened container and is 
made up into a 1/5 dilution on day of use.
10X PCR reaction buffer(Boeringer).
Phenol/chloroform : 50% phenol, 50% chloroform, 0.1% 8-hydroxyquinoline 
equilibriated to pH 7.5 with T.E. buffer. Topped with buffer and stored in a 
dark bottle at 4°C.
10% piperidine : 100ml piperidine in 900 ml ddH20. Solution stored as 
i00% stock solution in a darkened bottle in a safety cabinet and is diluted 
on day of use.
Prehybridisation buffer for ASO dot blotts : 3.0M TMAC, 0.1 M NaP04 pH 
6.8, 1mM EDTA, 5X Denhardt’s solution, 0.6% SDS, 100|ig/ml yeast tRNA.
20X SSC : 3M NaCI, 0.3M sodium citrate.
Stop solution (Sequenase 2 kit, USB) : 95% formamide, 20mM EDTA,
0.05% bromophenol blue, 0.05% xylene cyano! F k  Stored at
10X TBE buffer (5 litres) : 540g Tris base, 275g boric acid, 200ml Q.5M 
EDTA pH 8.
T.E. buffer : 10mM Tris-CI pH 7.4, 1mM EDTA. Solution was autoclaved and 
stored at room temperature.
